to	O	O
supplement	O	O
traditional	O	O
therapies	O	O
for	O	O
advanced	D	D
lung	D	D
cancer	D	D

methods	O	O
:	O	O
the	O	O
author	O	O
reviews	O	O
the	O	O
use	O	O
of	O	O
several	O	O
endobronchial	T	O
treatment	T	T
modalities	T	O
that	T	O
can	T	O
augment	T	O
standard	T	O
antitumor	T	O
therapies	T	O
for	O	O
advanced	O	O
lung	D	D
cancer	D	D
,	O	O
including	O	O
rigid	O	O
and	O	O
flexible	O	O
bronchoscopy	O	O
,	O	O
laser	O	T
therapy	O	T
,	O	O
endobronchial	O	O
prosthesis	O	T
,	O	O
and	O	O
photodynamic	O	T
therapy	O	T

conclusions	O	O
:	O	O
endobronchial	T	O
interventions	T	O
are	O	O
important	O	O
adjuncts	O	O
in	O	O
the	O	O
multimodality	O	O
management	O	O
of	O	O
lung	D	D
cancer	D	D
and	O	O
should	O	O
become	O	O
standard	O	O
considerations	O	O
in	O	O
the	O	O
management	O	O
of	O	O
patients	O	O
with	O	O
advanced	O	D
lung	O	D
cancer	O	D

standard	O	O
operations	O	O
for	O	O
lung	D	D
cancer	D	D
patients	O	O
are	O	O
generally	O	O
accepted	O	O
as	O	O
performing	O	O
lobectomy	T	O
or	T	O
pneumonectomy	T	O
on	O	O
the	O	O
tumor	O	D
baring	O	D
lung	O	D
and	O	O
ipsilateral	O	O
hilar	O	O
and	O	O
mediastinal	O	D
lymphadenectomy	O	O
including	O	O
subcarinal	O	O
lymph	O	O
nodes	O	O

small	D	O
cell	D	D
lung	D	D
cancer	D	D
is	O	O
a	O	O
frequently	O	O
relapsing	O	D
tumor	O	D
despite	O	O
a	O	O
high	O	O
rate	O	O
of	O	O
response	O	O
after	O	O
first-line	O	O
chemotherapy	T	T

for	O	O
symptomatic	D	O
metastases	D	O
in	D	O
bone	D	O
or	D	O
brain	D	D
,	O	O
radiotherapy	T	O
usually	O	O
gives	O	O
temporary	O	O
palliation	O	O

for	O	O
intrathoracic	D	O
relapse	D	O
and	D	O
severe	D	O
obstruction	D	O
of	D	O
main	D	O
bronchus	D	O
and/or	D	O
superior	D	O
caval	D	O
vein	D	O
,	O	O
radiotherapy	T	O
is	O	O
a	O	O
possibility	O	O
if	O	O
not	O	O
given	O	O
as	O	O
part	O	O
of	O	O
first-line	O	O
treatment	O	T

tumor	T	D
vaccines	T	O
against	O	O
gangliosides	O	O
that	O	O
are	O	O
expressed	O	O
on	O	O
almost	O	O
all	O	O
human	O	O
sclc	D	O
cells	O	O
have	O	O
been	O	O
recently	O	O
developed	O	O

an	O	O
anti-idiotypic	T	O
monoclonal	T	O
antibody	T	O
against	O	O
the	O	O
gd3	O	O
ganglioside	O	O
,	O	O
bec-2	O	O
,	O	O
is	O	O
being	O	O
evaluated	O	O
after	O	O
chemotherapy	O	T
in	O	O
sclc	D	O
patients	O	O
in	O	O
a	O	O
european	O	O
study	O	O

the	O	O
matrix	T	O
metalloproteinase	T	O
inhibitors	T	O
marimastat	T	O
and	T	O
bms-275291	T	O
are	O	O
under	O	O
evaluation	O	O
in	O	O
sclc	D	O

we	O	O
attempted	O	O
a	O	O
new	O	O
regimen	O	O
of	O	O
intermittent	O	O
administration	O	O
of	O	O
5-fu	T	O
and	T	O
low-dose	T	T
isovorin	T	O
(	T	O
f.i	T	O
)	T	O
to	O	O
four	O	O
patients	O	O
with	O	O
advanced	O	O
and	O	O
recurrent	O	D
colon	D	D
cancer	D	D

purpose/objectives	O	O
:	O	O
to	O	O
describe	O	O
the	O	O
relationship	O	O
between	O	O
fatigue	O	O
and	O	O
nutritional	O	O
status	O	O
in	O	O
patients	O	O
receiving	O	O
radiation	T	T
therapy	T	T
for	O	O
lung	D	D
cancer	D	D

sample	O	O
:	O	O
45	O	O
adults	O	O
with	O	O
primary	O	D
cancer	D	D
of	D	O
the	D	O
lung	D	D
receiving	O	O
<	O	O
outpatient	O	O
primary	O	O
or	O	O
adjuvant	O	T
radiation	T	T
therapy	T	T

we	O	O
present	O	O
the	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
metastatic	D	D
transitional	D	D
cell	D	D
carcinoma	D	D
of	D	O
the	D	O
bladder	D	D
and	D	O
renal	D	D
failure	D	D
who	O	O
underwent	O	T
successful	O	O
systemic	T	D
chemotherapy	T	T
with	T	O
paclitaxel	T	O
and	T	O
carboplatin	T	O

background	O	O
:	O	O
the	O	O
objective	O	O
of	O	O
this	O	O
phase	O	O
ii	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
concept	O	O
of	O	O
sequential	T	O
chemotherapy	T	T
in	O	O
the	O	O
treatment	O	O
of	O	O
patients	O	O
with	O	O
advanced	D	D
nonsmall	D	D
cell	D	D
lung	D	D
carcinoma	D	D
(	D	O
nsclc	D	O
)	D	O
by	O	O
the	O	O
administration	O	O
of	O	O
carboplatin	T	O
plus	T	O
gemcitabine	T	O
followed	T	O
by	T	O
of	T	O
paclitaxel	T	O

conclusions	O	O
:	O	O
this	O	O
study	O	O
is	O	O
the	O	O
first	O	O
to	O	O
evaluate	O	O
planned	T	O
sequential	T	O
chemotherapy	T	T
in	O	O
patients	O	O
with	O	O
nsclc	D	O

patients	O	O
who	O	O
benefit	O	O
from	O	O
a	O	O
surgical	T	T
resection	T	O
for	O	O
non-small-cell	D	D
lung	D	D
cancer	D	D
with	O	O
aneuploid	O	O
dna	O	O
content	O	O
prove	O	O
to	O	O
have	O	O
a	O	O
higher	O	O
risk	O	O
of	O	O
death	O	O

purpose	O	O
:	O	O
this	O	O
randomized	O	O
trial	O	O
was	O	O
designed	O	O
to	O	O
determine	O	O
whether	O	O
paclitaxel	T	O
plus	T	O
carboplatin	T	O
(	T	O
pc	T	O
)	T	O
offered	O	O
a	O	O
survival	O	O
advantage	O	O
over	O	O
vinorelbine	T	O
plus	T	O
cisplatin	T	O
(	T	O
vc	T	O
)	T	O
for	O	O
patients	O	O
with	O	O
advanced	D	O
non	D	D
--	D	D
small-cell	D	D
lung	D	D
cancer	D	D

conclusion	O	O
:	O	O
pc	T	O
is	O	O
equally	O	O
efficacious	O	O
as	O	O
vc	T	O
for	O	O
the	O	O
treatment	O	O
of	O	O
advanced	D	O
non	D	D
--	D	D
small-cell	D	D
lung	D	D
cancer	D	D

purpose	O	O
:	O	O
a	O	O
prospective	O	O
randomized	O	O
trial	O	O
in	O	O
small-cell	O	D
lung	O	D
cancer	O	D
(	O	O
sclc	O	O
)	O	O
was	O	O
performed	O	O
to	O	O
determine	O	O
if	O	O
intensification	O	O
of	O	O
the	O	O
platinum	O	O
dose	O	O
by	O	O
giving	O	O
cisplatin	T	O
and	T	O
carboplatin	T	O
in	O	O
combination	O	O
to	O	O
patients	O	O
with	O	O
sclc	D	O
yields	O	O
higher	O	O
response	O	O
rates	O	O
and	O	O
survival	O	O
,	O	O
than	O	O
carboplatin	T	O
alone	T	O
in	T	O
a	T	O
combination	T	O
chemotherapy	T	T
regimen	T	O

conclusions	O	O
:	O	O
the	O	O
intensification	T	O
of	T	O
platinum	T	O
dose	T	O
(	T	O
cisplatin	T	O
plus	T	O
carboplatin	T	O
)	T	O
in	T	O
combination	T	O
chemotherapy	T	T
significantly	O	O
increased	O	O
the	O	O
complete	O	O
response	O	O
rate	O	O
,	O	O
overall	O	O
survival	O	O
and	O	O
number	O	O
of	O	O
two-year	O	O
survivors	O	O
among	O	O
sclc	D	O
patients	O	O
with	O	O
limited	O	O
disease	O	D
compared	O	O
to	O	O
combination	T	O
therapy	T	T
with	T	O
carboplatin	T	O
alone	T	O
,	O	O
suggesting	O	O
that	O	O
a	O	O
more	O	O
aggressive	O	O
treatment	O	O
to	O	O
this	O	O
category	O	O
of	O	O
patients	O	O
is	O	O
worthwhile	O	O
,	O	O
while	O	O
no	O	O
difference	O	O
in	O	O
treatment	O	O
outcome	O	O
was	O	O
observed	O	O
for	O	O
patients	O	O
with	O	O
extensive	O	D
disease	O	D

the	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
relationships	O	O
among	O	O
technetium-99m	O	O
tetrofosmin	O	O
(	O	O
tc-tf	O	O
)	O	O
accumulation	O	O
in	O	O
untreated	O	O
small	O	O
cell	O	D
lung	O	D
cancer	O	D
(	O	O
sclc	O	O
)	O	O
,	O	O
the	O	O
expression	O	O
of	O	O
p-glycoprotein	O	O
(	O	O
pgp	O	O
)	O	O
and	O	O
multidrug	O	O
resistance	O	O
related	O	O
protein-1	O	O
(	O	O
mrp1	O	O
)	O	O
,	O	O
and	O	O
the	O	O
response	O	O
to	O	O
chemotherapy	T	T
in	O	O
patients	O	O
with	O	O
untreated	D	O
sclc	D	O

tc-tf	O	O
chest	O	O
scintigraphy	O	O
correlated	O	O
well	O	O
with	O	O
pgp	O	O
or	O	O
mrp1	O	O
expression	O	O
and	O	O
accurately	O	O
predicted	O	O
the	O	O
response	O	O
to	O	O
chemotherapy	T	T
in	O	O
patients	O	O
with	O	O
sclc	D	O

exploratory	T	O
interventions	T	O
,	T	O
partial	T	O
tumor	T	D
resections	T	D
and	T	O
lung	T	D
resections	T	O
for	O	O
metastasis	D	O
were	O	O
more	O	O
frequently	O	O
performed	O	O
in	O	O
young	O	O
patients	O	O
than	O	O
in	O	O
older	O	O
patients	O	O

in	O	O
the	O	O
present	O	O
report	O	O
,	O	O
we	O	O
reviewed	O	O
articles	O	O
on	O	O
pulmonary	T	D
angiography	T	D
for	O	O
patients	O	O
with	O	D
pulmonary	D	D
hypertension	D	D

prophylactic	T	O
cranial	T	O
irradiation	T	T
(	T	O
pci	T	O
)	T	O
has	O	O
been	O	O
demonstrated	O	O
to	O	O
significantly	O	O
reduce	O	O
the	O	O
incidence	O	O
of	O	O
brain	O	D
relapse	O	D
from	O	O
limited	D	O
disease	D	D
small-cell	D	D
lung	D	D
cancer	D	D
(	D	D
ld	D	D
sclc	D	O
)	D	O
,	O	O
but	O	O
concerns	O	O
about	O	O
neurologic	O	O
toxicity	O	O
remain	O	O

thus	O	O
,	O	O
twice-daily	O	O
pci	T	O
should	O	O
be	O	O
considered	O	O
for	O	O
patients	O	O
with	O	O
ld	D	O
sclc	D	O
who	O	O
achieve	O	O
a	O	O
complete	O	O
response	O	O
to	O	O
chemoirradiation	O	O

animal	O	O
studies	O	O
suggest	O	O
that	O	O
the	O	O
kidney	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
elimination	O	O
of	O	O
recombinant	T	O
human	T	O
granulocyte	T	O
colony-stimulating	T	O
factor	T	O
(	T	O
rhg-csf	T	O
)	T	O
,	O	O
which	O	O
is	O	O
used	O	O
for	O	O
patients	O	O
with	O	O
neutropenia	D	D
during	O	D
cancer	D	D
chemotherapy	T	T

amifostine	T	O
(	T	O
wr-2721	T	O
)	T	O
is	O	O
a	O	O
cytoprotective	O	O
agent	O	O
that	O	O
protects	O	O
a	O	O
broad	O	O
range	O	O
of	O	O
normal	O	O
tissues	O	O
from	O	O
the	O	O
toxic	D	O
effects	D	O
of	D	O
chemotherapy	D	T
and	D	O
radiotherapy	D	T
without	O	O
attenuating	O	O
tumour	O	O
response	O	O

in	O	O
a	O	O
pivotal	O	O
phase	O	O
iii	O	O
trial	O	O
,	O	O
242	O	O
patients	O	O
with	O	O
advanced	D	D
ovarian	D	D
cancer	D	D
were	O	O
randomised	O	O
to	O	O
receive	O	O
treatment	O	O
with	O	O
cisplatin	T	O
100	O	O
mg/m2	O	O
and	O	O
cyclophosphamide	T	O
1000	O	O
mg/m2	O	O
every	O	O
3	O	O
weeks	O	O
with	O	O
or	O	O
without	O	O
pretreatment	O	O
with	O	O
intravenous	O	O
amifostine	O	O
910	O	O
mg/m2	O	O

over	O	O
6	O	O
cycles	O	O
of	O	O
therapy	O	T
,	O	O
amifostine	T	O
significantly	O	O
reduced	O	O
haematological	D	O
,	D	O
renal	D	D
and	D	O
neurological	D	D
toxicities	D	D
:	O	O
treatment	O	T
delays	O	O
,	O	O
treatment	O	O
discontinuation	O	O
and	O	O
days	O	O
in	O	O
hospital	O	O
related	O	O
to	O	O
these	O	O
adverse	O	O
events	O	O
were	O	O
also	O	O
significantly	O	O
reduced	O	O
in	O	O
patients	O	O
receiving	O	O
amifostine	O	O
versus	O	O
patients	O	O
receiving	O	T
chemotherapy	O	T
alone	O	O

<	O	O
TO_SEE	O	O
>	O	O
in	O	O
another	O	O
randomised	O	O
phase	O	O
iii	O	O
trial	O	O
in	O	O
303	O	O
patients	O	O
with	O	O
head	D	O
and	D	O
neck	D	D
cancer	D	D
undergoing	O	T
irradiation	T	T
therapy	T	T
(	O	O
total	O	O
dose	O	O
50	O	O
to	O	O
70gy	O	O
)	O	O
,	O	O
pretreatment	O	O
with	O	O
intravenous	O	O
amifostine	T	O
200	O	O
mg/m2	O	O
significantly	O	O
reduced	O	O
the	O	O
incidence	O	O
of	O	O
acute	O	D
and	O	O
late	O	O
grade	O	O
>	O	O
or	O	O
=2	O	O
xerostomia	D	O

amifostine	T	O
(	O	O
340	O	O
mg/m2	O	O
)	O	O
also	O	O
provided	O	O
significant	O	O
protection	O	O
against	O	O
pneumonitis	D	O
and	D	O
oesophagitis	D	O
in	O	O
patients	O	O
with	O	O
lung	D	D
cancer	D	D
receiving	O	D
thoracic	T	D
irradiation	T	O
in	O	O
a	O	O
preliminary	O	O
report	O	O
from	O	O
a	O	O
phase	O	O
iii	O	O
trial	O	O
(	O	O
n	O	O
=	O	O
144	O	O
)	O	O

amifostine	T	O
has	O	O
also	O	O
been	O	O
shown	O	O
to	O	O
stimulate	O	O
haematopoietic	O	O
stem	O	O
cells	O	O
and	O	O
has	O	O
been	O	O
investigated	O	O
as	O	O
a	O	O
therapy	O	T
for	O	O
patients	O	O
with	O	O
myelodysplastic	D	D
syndrome	D	D
in	O	O
number	O	O
of	O	O
small	O	O
preliminary	O	O
studies	O	O

<	O	O
TO_SEE	O	O
>	O	O
conclusion	O	O
:	O	O
the	O	O
results	O	O
of	O	O
phase	O	O
iii	O	O
trials	O	O
have	O	O
confirmed	O	O
the	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
amifostine	T	O
as	O	O
a	O	O
cytoprotectant	O	O
to	O	O
ameliorate	O	O
cisplatin-induced	D	D
cumulative	D	D
renal	D	D
toxicity	D	O
,	O	O
for	O	O
which	O	O
it	O	O
is	O	O
the	O	O
only	O	O
agent	O	O
proven	O	O
to	O	O
be	O	O
effective	O	O
,	O	O
and	O	O
neutropenia	D	O
in	O	O
patients	O	O
with	O	O
advanced	O	D
ovarian	O	D
cancer	O	D
,	O	O
and	O	O
to	O	O
reduce	O	O
xerostomia	D	O
in	O	O
patients	O	O
with	O	O
head	D	O
and	D	O
neck	D	D
cancer	D	D
receiving	O	T
irradiation	T	T
therapy	T	T

depending	O	O
on	O	O
the	O	O
outcome	O	O
of	O	O
numerous	O	O
ongoing	O	O
clinical	O	O
trials	O	O
,	O	O
amifostine	T	O
may	O	O
eventually	O	O
find	O	O
broader	O	O
clinical	O	O
applications	O	O
,	O	O
both	O	O
as	O	O
a	O	O
cytoprotectant	O	O
and	O	O
as	O	O
a	O	O
potential	O	O
therapy	O	T
in	O	O
myelodysplastic	D	D
syndrome	D	D

to	O	O
perform	O	O
a	O	O
curative	O	O
operation	O	O
for	O	O
the	O	O
lung	D	D
cancer	D	D
without	O	D
myocardial	O	D
infarction	O	D
,	O	O
minimally	T	T
invasive	T	T
direct	T	T
coronary	T	T
artery	T	T
bypass	T	T
and	T	O
left	T	O
lower	T	O
lobectomy	T	O
with	T	O
video-endoscopic	T	O
assistance	T	O
were	O	O
performed	O	O
simultaneously	O	O

A	O	O
review	O	O
of	O	O
the	O	O
fetal-maternal	O	O
carboxyhemoglobin	O	O
relationships	O	O
and	O	O
the	O	O
differences	O	O
in	O	O
fetal	O	O
oxyhemoglobin	O	O
physiology	O	O
are	O	O
used	O	O
to	O	O
explain	O	O
the	O	O
recommendation	O	O
that	O	O
pregnant	O	O
women	O	O
with	O	O
carbon	D	O
monoxide	D	O
poisoning	D	O
should	O	O
receive	O	O
100	O	O
%	O	O
oxygen	T	O
therapy	T	T
for	O	O
up	O	O
to	O	O
five	O	O
times	O	O
longer	O	O
than	O	O
is	O	O
otherwise	O	O
necessary	O	O

The	O	O
authors	O	O
describe	O	O
the	O	O
case	O	O
of	O	O
a	O	O
child	O	O
with	O	O
status	D	O
epilepticus	D	O
in	O	O
whom	O	O
phenytoin	T	O
was	O	O
administered	O	O
via	O	O
the	O	O
intraosseous	O	O
route	O	O
,	O	O
and	O	O
seizure	O	O
resolution	O	O
and	O	O
therapeutic	O	O
serum	O	O
levels	O	O
were	O	O
achieved	O	O

A	O	O
patient	O	O
suffering	O	O
baclofen	D	D
overdose	D	D
successfully	O	D
treated	O	O
with	O	O
atropine	T	O
is	O	O
reported	O	O

Atropine	T	O
appears	O	O
to	O	O
be	O	O
useful	O	O
in	O	O
treating	O	O
cases	O	O
of	O	O
baclofen	D	O
overdose	D	O
complicated	O	O
by	O	O
bradycardia	O	O
and	O	O
hypotension	O	O

Therapeutic	O	O
effect	O	O
of	O	O
a	O	O
left	T	O
ventricular	T	O
assist	T	D
device	T	D
on	O	O
acute	D	D
myocardial	D	D
infarction	D	D
evaluated	O	O
by	O	O
magnetic	O	O
resonance	O	O
imaging	O	O

Continuous	T	O
arteriovenous	T	O
hemofiltration	T	O
for	O	O
the	O	O
treatment	O	O
of	O	O
anasarca	D	D
and	D	O
acute	D	D
renal	D	D
failure	D	D
in	O	O
severely	O	D
burned	O	D
patients	O	O

Continuous	T	O
renal	T	T
replacement	T	T
therapy	T	T
in	O	O
patients	O	O
with	O	O
acute	D	D
renal	D	D
dysfunction	D	D
undergoing	O	D
intraaortic	O	D
balloon	O	D
pump	O	O
and/or	O	O
left	O	O
ventricular	O	O
device	O	O
support	O	O

Continuous	T	O
arterio-venous	T	O
hemofiltration	T	O
in	O	O
a	O	O
wearable	O	O
device	O	O
to	O	O
treat	O	D
end-stage	D	D
renal	D	D
disease	D	D

The	O	O
effectiveness	O	O
of	O	O
neostigmine	T	O
0.07	T	O
mg	T	O
kg-1	T	O
and	T	O
edrophonium	T	O
0.8	O	O
mg	O	O
kg-1	O	O
as	O	O
antagonists	O	O
of	O	O
profound	D	O
neuromuscular	D	O
blockade	D	O
induced	O	O
by	O	O
vecuronium	O	O
0.1	O	O
mg	O	O
kg-1	O	O
or	O	O
atracurium	O	O
0.5	O	O
mg	O	O
kg-1	O	O
was	O	O
studied	O	O
in	O	O
59	O	O
healthy	O	O
patients	O	O

Antagonism	O	O
of	O	O
atracurium-induced	O	O
neuromuscular	D	O
blockade	D	O
by	O	O
neostigmine	T	O
or	T	O
edrophonium	T	O
has	O	O
been	O	O
studied	O	O
using	O	O
the	O	O
tetanic	O	O
(	O	O
50	O	O
Hz	O	O
)	O	O
and	O	O
train-of-four	O	O
(	O	O
2	O	O
Hz	O	O
)	O	O
or	O	O
single	O	O
twitch	O	O
responses	O	O
of	O	O
the	O	O
adductor	O	O
pollicis	O	O
muscle	O	O
in	O	O
22	O	O
anaesthetized	O	O
patients	O	O

Active	T	O
forms	T	O
of	T	O
vitamin	T	O
D3	T	O
,	T	O
1	T	O
alpha-hydroxyvitamin	T	O
D3	T	O
and	T	O
1	T	O
alpha	T	O
,	T	O
25-dihydroxyvitamin	T	O
D3	T	O
,	O	O
were	O	O
administered	O	O
in	O	O
an	O	O
open-design	O	O
study	O	O
to	O	O
40	O	O
patients	O	O
with	O	O
psoriasis	D	O
vulgaris	D	O
in	O	O
three	O	O
ways	O	O
:	O	O
to	O	O
17	O	O
patients	O	O
1	O	O
alpha-hydroxyvitamin	O	O
D3	O	O
was	O	O
given	O	O
orally	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
1.0	O	O
micrograms/day	O	O
for	O	O
6	O	O
months	O	O
,	O	O
to	O	O
four	O	O
patients	O	O
1	O	O
alpha	O	O
,	O	O
25-dihydroxyvitamin	O	O
D3	O	O
was	O	O
given	O	O
orally	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
0.5	O	O
microgram/day	O	O
for	O	O
6	O	O
months	O	O
,	O	O
and	O	O
19	O	O
patients	O	O
were	O	O
given	O	O
1	O	O
alpha	O	O
,	O	O
25-dihydroxyvitamin	O	O
D3	O	O
applied	O	O
topically	O	O
at	O	O
concentration	O	O
of	O	O
0.5	O	O
microgram/g	O	O
of	O	O
base	O	O
for	O	O
8	O	O
weeks	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
psoriasis	D	O
may	O	O
respond	O	O
to	O	O
active	T	O
metabolites	T	O
of	T	O
vitamin	T	O
D3	T	O
and	O	O
that	O	O
abnormalities	O	O
in	O	O
vitamin	O	O
D	O	O
metabolism	O	O
or	O	O
in	O	O
responsiveness	O	O
of	O	O
the	O	O
skin	O	O
cells	O	O
to	O	O
active	O	O
metabolites	O	O
of	O	O
vitamin	O	O
D	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
this	O	O
skin	O	D
disease	O	D

Successful	O	O
treatment	O	O
of	O	O
psoriasis	D	O
with	O	O
topical	O	O
application	O	O
of	O	O
active	T	O
vitamin	T	O
D3	T	O
analogue	T	O
,	T	O
1	T	O
alpha	T	O
,	T	O
24-dihydroxycholecalciferol	T	O

We	O	O
suggest	O	O
that	O	O
1	T	O
alpha	T	O
,	T	O
24	T	O
(	T	O
OH	T	O
)	T	O
2D3	T	O
merits	O	O
further	O	O
investigation	O	O
as	O	O
a	O	O
potentially	O	O
useful	O	O
topical	O	T
therapy	O	T
for	O	O
psoriasis	D	O

When	O	O
indomethacin	T	O
was	O	O
applied	O	O
immediately	O	O
after	O	O
irradiation	O	O
,	O	O
UVR	O	O
(	O	O
ultraviolet	O	O
radiation	O	O
)	O	O
dose-dependent	O	O
suppression	O	O
of	O	O
erythema	D	O
was	O	O
demonstrated	O	O
for	O	O
both	O	O
wavelengths	O	O
until	O	O
36	O	O
h	O	O
after	O	O
irradiation	O	O
when	O	O
both	O	O
indomethacin	O	O
and	O	O
control	O	O
gel	O	O
base-treated	O	O
sites	O	O
were	O	O
equally	O	O
erythematous	O	O

Suppression	O	O
of	O	O
erythema	D	O
also	O	O
occurred	O	O
when	O	O
application	O	O
of	O	O
indomethacin	T	O
was	O	O
delayed	O	O
until	O	O
24	O	O
h	O	O
after	O	O
irradiation	O	O
,	O	O
showing	O	O
that	O	O
for	O	O
both	O	O
wavelengths	O	O
prostaglandin	O	O
synthesis	O	O
remains	O	O
increased	O	O
throughout	O	O
this	O	O
period	O	O

There	O	O
was	O	O
one	O	O
retinal	O	O
dialysis	O	O
,	O	O
and	O	O
one	O	O
lens	D	O
dislocation	D	O
requiring	O	O
extraction	T	O

Rates	O	O
of	O	O
superoxide	O	O
(	O	O
SA	O	O
)	O	O
generation	O	O
by	O	O
blood	O	O
monocytes	O	O
stimulated	O	O
ex	O	O
vivo	O	O
were	O	O
studied	O	O
before	O	O
and	O	O
during	O	O
corticosteroid	T	O
treatment	O	T
of	O	O
rheumatoid	D	D
arthritis	D	D
(	D	D
RA	D	D
)	D	O
patients	O	O
,	O	O
in	O	O
control	O	O
patients	O	O
and	O	O
in	O	O
healthy	O	O
controls	O	O

Significant	O	O
inhibition	O	O
of	O	O
monocyte	O	O
SA	O	O
output	O	O
stimulated	O	O
with	O	O
IgG-treated	O	O
zymosan	O	O
(	O	O
ITZ	O	O
)	O	O
and	O	O
fluoride	O	T
ion	O	O
(	O	O
F	O	O
)	O	O
,	O	O
but	O	O
not	O	O
serum-treated	O	O
zymosan	O	O
(	O	O
STZ	O	O
)	O	O
was	O	O
demonstrated	O	O
following	O	O
steroid	T	O
therapy	T	T
in	O	O
RA	D	O

Methotrexate	T	O
(	T	O
MTX	T	O
)	T	O
appears	O	O
to	O	O
be	O	O
useful	O	O
in	O	O
patients	O	O
with	O	O
rheumatoid	D	D
arthritis	D	D
(	D	D
RA	D	O
)	D	O
refractory	O	O
to	O	O
other	O	O
drugs	O	O
but	O	O
its	O	O
long-term	O	O
toxicity	O	O
and	O	O
efficacy	O	O
are	O	O
uncertain	O	O

MTX	T	O
in	O	O
a	O	O
low-dose	O	O
regimen	O	O
is	O	O
useful	O	O
in	O	O
refractory	D	O
RA	D	O
and	O	O
superior	O	O
to	O	O
low-dose	O	O
purine	O	O
analogues	O	O

Twelve	O	O
patients	O	O
with	O	O
intractable	D	D
rheumatoid	D	D
arthritis	D	D
were	O	O
treated	O	O
with	O	O
antilymphocyte	T	O
globulin	T	O
(	T	O
ALG	T	O
)	T	O
,	T	O
prednisolone	T	O
and	T	O
a	T	O
cytotoxic	T	O
agent	T	O
,	T	O
usually	T	O
azathioprine	T	O
,	O	O
and	O	O
were	O	O
followed	O	O
for	O	O
1	O	O
year	O	O

Rigid	T	O
ureteroscopy	T	O
for	O	O
the	O	O
treatment	O	O
of	O	O
ureteric	D	O
calculi	D	O
:	O	O
experience	O	O
in	O	O
120	O	O
cases	O	O

Over	O	O
a	O	O
1-year	O	O
period	O	O
,	O	O
rigid	T	O
ureteroscopy	T	O
has	O	O
been	O	O
used	O	O
to	O	O
retrieve	O	O
ureteric	D	O
calculi	D	O
in	O	O
120	O	O
patients	O	O

Eleven	O	O
patients	O	O
with	O	O
vesicoureteric	D	D
reflux	D	D
secondary	O	D
to	O	O
neuropathic	O	D
bladder	O	D
were	O	O
treated	O	O
by	O	O
endoscopic	T	O
injection	T	O
of	T	O
pyrolised	T	O
polytetrafluoroethylene	T	O
(	T	O
Polytef	T	O
)	T	O
paste	T	O

Two	O	O
hundred	O	O
and	O	O
seventy-seven	O	O
patients	O	O
with	O	O
advanced	D	D
prostatic	D	D
cancer	D	D
were	O	O
treated	O	O
by	O	O
either	O	O
orchiectomy	T	O
or	T	O
oestrogen	T	O

Use	O	O
of	O	O
scarred	O	O
flaps	O	O
and	O	O
secondary	O	O
flaps	O	O
for	O	O
reconstructive	T	O
surgery	T	T
of	O	O
extensive	D	O
burns	D	O

A	O	O
patient	O	O
with	O	O
a	O	O
vesico-enteric	D	O
fistula	D	O
was	O	O
successfully	O	O
treated	O	O
with	O	O
resection	T	O
of	T	O
the	T	O
small	T	O
intestine	T	O
and	T	O
dome	T	O
of	T	O
the	T	O
bladder	T	D
and	T	O
drainage	T	O
of	T	O
the	T	O
intervening	T	D
abscess	T	D

Supramaximal	T	O
horizontal	T	O
rectus	T	O
surgery	T	T
in	O	O
the	O	O
management	O	O
of	O	O
third	D	O
and	D	O
sixth	D	D
nerve	D	D
palsy	D	D

Supramaximal	T	O
medial	T	O
and	T	O
lateral	T	O
rectus	T	T
surgery	T	T
was	O	O
performed	O	O
to	O	O
correct	O	O
horizontal	D	O
deviations	D	O
in	D	O
seven	D	O
cases	D	O
of	D	O
sixth	D	D
nerve	D	D
palsy	D	D
and	D	O
three	D	O
cases	D	O
of	D	O
third	D	O
nerve	D	D
palsy	D	D
,	O	O
with	O	O
satisfactory	O	O
results	O	O
in	O	O
most	O	O
cases	O	O

Steroid	T	T
therapy	T	T
was	O	O
also	O	O
used	O	O
in	O	O
two	O	O
patients	O	O
with	O	O
NSAID-induced	D	O
proteinuria	D	O

Recombinant	T	O
leukocyte	T	O
A	T	O
interferon	T	O
(	T	O
rIFN-alpha	T	O
A	T	O
)	T	O
in	O	O
the	O	O
treatment	O	O
of	O	O
disseminated	D	D
malignant	D	D
melanoma	D	D

Ninety-six	O	O
patients	O	O
with	O	O
disseminated	D	D
malignant	D	D
melanoma	D	O
received	O	O
thrice	O	O
weekly	O	O
intramuscular	O	O
injections	O	O
of	O	O
leukocyte	T	O
A	T	O
recombinant	T	O
interferon	T	O
(	T	O
rIFN-alpha	T	O
A	T	O
,	T	O
Roferon-A	T	O
,	T	O
Hoffmann	T	O
La	T	O
Roche	T	O
)	T	O
at	O	O
doses	O	O
of	O	O
12	O	O
X	O	O
10	O	O
(	O	O
6	O	O
)	O	O
U/m2	O	O
or	O	O
50	O	O
X	O	O
10	O	O
(	O	O
6	O	O
)	O	O
U/m2	O	O
with	O	O
or	O	O
without	O	O
cimetidine	O	O
as	O	O
an	O	O
immunorestorative	O	O
agent	O	O

As	O	O
noted	O	O
previously	O	O
,	O	O
using	O	O
chemotherapy	O	T
,	O	O
a	O	O
small	O	O
proportion	O	O
of	O	O
patients	O	O
with	O	O
advanced	D	D
malignant	D	D
melanoma	D	D
,	O	O
despite	O	O
prior	O	O
therapy	O	T
,	O	O
may	O	O
achieve	O	O
prolonged	O	O
objective	O	O
regression	O	O
with	O	O
rIFN-alpha	T	O
A	T	O

Clinical	O	O
course	O	O
of	O	O
breast	O	D
cancer	O	D
patients	O	O
with	O	O
osseous	D	D
metastasis	D	D
treated	O	O
with	O	O
combination	T	T
chemotherapy	T	T

Between	O	O
July	O	O
1973	O	O
and	O	O
December	O	O
1979	O	O
,	O	O
1171	O	O
patients	O	O
with	O	O
metastatic	D	D
breast	D	D
cancer	D	D
were	O	O
treated	O	O
with	O	O
doxorubicin-containing	T	T
chemotherapy	T	T

Two	O	O
patients	O	O
with	O	O
metastatic	D	D
dysgerminoma	D	O
of	D	O
the	D	O
ovary	D	O
were	O	O
treated	O	O
with	O	O
a	T	O
combination	T	O
of	T	O
etoposide	T	O
,	T	O
bleomycin	T	O
,	T	O
and	T	O
cisplatin	T	O
at	O	O
The	O	O
University	O	O
of	O	O
Texas	O	O
M.D	O	O

Chemotherapy	T	T
may	O	O
be	O	O
an	O	O
alternative	O	O
to	O	O
radiotherapy	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
metastatic	D	D
dysgerminoma	D	O
and	O	O
should	O	O
also	O	O
be	O	O
considered	O	O
for	O	O
selected	O	O
patients	O	O
with	O	O
Stage	O	O
I	O	O
disease	O	D

Long-term	O	O
survival	O	O
and	O	O
morbidity	O	O
in	O	O
patients	O	O
with	O	O
metastatic	D	D
malignant	D	D
germ	D	D
cell	D	D
tumors	D	D
treated	O	O
with	O	O
cisplatin-based	T	T
combination	T	T
chemotherapy	T	T

Treatment	O	O
of	O	O
advanced	D	O
stage	D	O
mycosis	D	O
fungoides	D	O
with	O	O
bleomycin	T	O
,	T	O
doxorubicin	T	O
,	T	O
and	T	O
methotrexate	T	O
with	T	O
topical	T	O
nitrogen	T	O
mustard	T	O
(	T	O
BAM-M	T	O
)	T	O

Ten	O	O
patients	O	O
with	O	O
advanced	D	O
stage	D	O
(	D	O
TNM	D	O
IIB-IVB	D	O
)	D	O
mycosis	D	O
fungoides	D	O
were	O	O
treated	O	O
with	O	O
a	O	O
combination	T	O
chemotherapy	T	T
program	T	O
consisting	T	O
of	T	O
bleomycin	T	O
and	T	O
methotrexate	T	O
weekly	T	O
,	T	O
doxorubicin	T	O
every	T	O
3	T	O
weeks	T	O
,	T	O
and	T	O
topical	T	O
nitrogen	T	O
mustard	T	O
daily	T	O
(	T	O
BAM-M	T	O
)	T	O

Three	O	O
patients	O	O
in	O	O
whom	O	O
splenomegaly	D	O
was	O	O
detected	O	O
during	O	O
their	O	O
staging	O	O
evaluation	O	O
underwent	O	O
splenectomy	T	O

This	O	O
study	O	O
indicates	O	O
that	O	O
BAM-M	T	O
is	O	O
effective	O	O
therapy	O	T
for	O	O
advanced	D	O
stage	D	O
mycosis	D	O
fungoides	D	O
and	O	O
suggests	O	O
that	O	O
the	O	O
therapeutic	O	O
role	O	O
of	O	O
splenectomy	O	O
should	O	O
be	O	O
evaluated	O	O
further	O	O

Only	O	O
patients	O	O
whose	O	O
primary	D	O
head	D	O
and	D	O
neck	D	D
tumor	D	D
shows	O	O
a	O	O
response	O	O
to	O	O
systemic	O	O
therapy	O	T
undergo	O	O
Ommaya	T	O
placement	T	O

Additional	O	O
chemotherapy	T	T
may	O	O
thus	O	O
have	O	O
eradicated	O	O
these	O	O
micrometastases	D	O
in	O	O
the	O	O
older	O	O
children	O	O
,	O	O
since	O	O
the	O	O
age	O	O
influence	O	O
on	O	O
Stage	O	O
II	O	O
disease	O	D
disappeared	O	D
when	O	O
multimodal	O	O
treatment	O	O
was	O	O
given	O	O
in	O	O
this	O	O
study	O	O

Traditional	O	T
therapy	O	T
for	O	O
malignant	D	D
pleural	D	D
effusions	D	D
includes	O	O
thoracentesis	T	O
or	T	O
tube	T	O
drainage	T	O
with	O	O
instillation	O	O
of	O	O
irritants	O	O
to	O	O
achieve	O	O
pleurodesis	O	O

We	O	O
feel	O	O
that	O	O
pleuroperitoneal	T	O
shunting	T	O
is	O	O
a	O	O
valid	O	O
new	O	O
method	O	O
for	O	O
treatment	O	O
of	O	O
malignant	D	D
pleural	D	D
effusions	D	D
which	O	O
can	O	O
effectively	O	D
palliate	O	D
respiratory	O	D
symptoms	O	D
with	O	O
low	O	O
morbidity	O	D

When	O	O
right	D	O
ventricular	D	D
failure	D	D
prohibits	O	O
separation	O	O
from	O	O
cardiopulmonary	O	O
bypass	O	T
,	O	O
standard	T	O
methods	T	O
of	T	O
increasing	T	O
pulmonary	T	D
blood	T	O
flow	T	O
should	O	O
be	O	O
employed	O	O
,	O	O
including	O	O
correction	O	O
of	O	O
hypoxia	O	O
and	O	O
acidosis	O	O
,	O	O
volume	O	O
loading	O	O
,	O	O
and	O	O
inotropic	O	O
support	O	O
of	O	O
the	O	O
right	O	O
ventricle	O	O

For	O	O
refractory	D	O
right	D	O
ventricular	D	D
failure	D	D
following	O	O
the	O	O
surgical	O	T
repair	O	O
of	O	O
congenital	O	D
cardiac	O	D
defects	O	D
in	O	O
which	O	O
the	O	O
placement	O	O
of	O	O
right	O	O
atrial	O	D
and	O	O
pulmonary	O	D
artery	O	D
cannulae	O	O
is	O	O
not	O	O
technically	O	O
feasible	O	O
,	O	O
use	T	O
of	T	O
high-frequency	T	O
high-volume	T	O
ventilation	T	O
appears	O	O
to	O	O
be	O	O
quite	O	O
promising	O	O

Current	O	O
results	O	O
suggest	O	O
that	O	O
RHBP	T	O
remains	O	O
the	O	O
gold	O	O
standard	O	O
for	O	O
severe	D	D
RV	D	D
failure	D	D
,	O	O
but	O	O
further	O	O
clinical	O	O
experience	O	O
with	O	O
PABC	O	O
may	O	O
more	O	O
clearly	O	O
define	O	O
its	O	O
role	O	O
in	O	O
the	O	O
management	O	O
of	O	O
RV	O	D
failure	O	D

Guiding	O	T
surgical	T	T
therapy	T	T
of	O	O
ventricular	D	O
tachycardia	D	O
by	O	O
preoperative	O	O
endocardial	O	O
catheter	O	O
mapping	O	O
necessitates	O	O
improvement	O	O
of	O	O
the	O	O
accuracy	O	O
of	O	O
localization	O	O
of	O	O
the	O	O
arrhythmogenic	O	O
site	O	O

However	O	O
,	O	O
the	O	O
results	O	O
of	O	O
this	O	O
study	O	O
indicate	O	O
that	O	O
procainamide	T	O
may	O	O
be	O	O
effective	O	O
in	O	O
suppressing	O	O
the	O	O
induction	O	O
of	O	O
sustained	O	O
ventricular	D	O
tachycardia	D	O
at	O	O
a	O	O
relatively	O	O
low	O	O
plasma	O	O
concentration	O	O
,	O	O
but	O	O
not	O	O
at	O	O
a	O	O
higher	O	O
plasma	O	O
concentration	O	O

Coronary	T	O
angioplasty	T	O
for	O	O
early	D	O
postinfarction	D	D
unstable	D	D
angina	D	D

Coronary	T	O
angioplasty	T	O
was	O	O
performed	O	O
in	O	O
53	O	O
patients	O	O
in	O	O
whom	O	O
unstable	D	D
angina	D	D
had	O	O
reoccurred	O	O
after	O	O
48	O	O
hr	O	O
and	O	O
within	O	O
30	O	O
days	O	O
after	O	O
sustained	O	D
myocardial	O	D
infarction	O	D

At	O	O
6	O	O
months	O	O
follow-up	O	O
26	O	O
%	O	O
(	O	O
14/53	O	O
)	O	O
of	O	O
all	O	O
the	O	O
patients	O	O
who	O	O
underwent	O	O
angioplasty	T	O
had	O	O
recurrence	O	O
of	O	O
angina	D	D
,	O	O
which	O	O
was	O	O
successfully	O	O
treated	O	O
with	O	O
repeat	T	O
angioplasty	T	T
,	T	O
bypass	T	T
surgery	T	T
,	T	O
or	T	O
medical	T	O
therapy	T	T

Coronary	D	O
dissection	D	O
and	D	O
total	D	O
coronary	D	O
occlusion	D	O
leading	O	O
to	O	O
emergency	T	O
coronary	T	T
surgery	T	T
are	O	O
the	O	O
most	O	O
frequent	O	O
complications	O	O
of	O	O
percutaneous	O	D
transluminal	O	D
coronary	O	D
angioplasty	O	O
(	O	O
PTCA	O	O
)	O	O
and	O	O
their	O	O
occurrence	O	O
usually	O	O
is	O	O
unpredictable	O	O

Effect	O	O
of	O	O
zanamivir	T	O
on	O	O
duration	O	O
and	O	O
resolution	O	O
of	O	O
influenza	D	D
symptoms	O	D

A	O	O
comparison	O	O
of	O	O
a	O	O
five-day	O	O
regimen	O	O
of	O	O
cefdinir	T	O
with	O	O
a	O	O
seven-day	O	O
regimen	O	O
of	O	O
loracarbef	T	O
for	O	O
the	O	O
treatment	O	O
of	O	O
acute	O	D
exacerbations	O	D
of	O	D
chronic	D	D
bronchitis	D	D

Initial	O	O
empiric	O	O
therapy	O	T
for	O	O
community-acquired	O	O
bacterial	D	O
meningitis	D	O
should	O	O
be	O	O
based	O	O
on	O	O
the	O	O
possibility	O	O
that	O	O
penicillin-resistant	O	O
pneumococci	O	O
may	O	O
be	O	O
the	O	O
etiologic	O	O
organisms	O	O
and	O	O
,	O	O
hence	O	O
,	O	O
should	O	O
include	O	O
a	O	O
combination	O	O
of	O	O
third-generation	O	O
cephalosporin	T	O
(	T	O
cefotaxime	T	O
or	T	O
ceftriaxone	T	O
)	T	O
and	T	O
vancomycin	T	O

Ampicillin	T	O
should	O	O
be	O	O
included	O	O
if	O	O
the	O	O
patient	O	O
has	O	O
predisposing	O	O
factors	O	O
that	O	O
are	O	O
associated	O	O
with	O	O
a	O	O
risk	O	O
for	O	O
infection	D	D
with	D	O
Listeria	D	D
monocytogenes	D	D

Results	O	O
of	O	O
clinical	O	O
trials	O	O
and	O	O
meta-analysis	O	O
suggest	O	O
that	O	O
dexamethasone	T	T
therapy	T	T
improves	O	O
the	O	O
outcome	O	O
for	O	O
patients	O	O
with	O	O
bacterial	D	D
meningitis	D	D

Placebo-controlled	O	O
trials	O	O
have	O	O
shown	O	O
that	O	O
vitamin	T	O
C	T	O
supplementation	O	O
decreases	O	O
the	O	O
duration	O	O
and	O	O
severity	O	O
of	O	O
common	D	D
cold	D	D
infections	D	D

Since	O	O
few	O	O
trials	O	O
have	O	O
examined	O	O
the	O	O
effects	O	O
of	O	O
therapeutic	O	O
supplementation	O	O
and	O	O
their	O	O
results	O	O
have	O	O
been	O	O
variable	O	O
,	O	O
further	O	O
therapeutic	O	O
trials	O	O
are	O	O
required	O	O
to	O	O
examine	O	O
the	O	O
role	O	O
of	O	O
vitamin	T	O
C	T	O
in	O	O
the	O	O
treatment	O	O
of	O	O
colds	D	O

<	O	O
TO_SEE	O	O
>	O	O
Progressive	D	O
multifocal	D	O
leukoencephalopathy	D	O
following	O	O
oral	T	T
fludarabine	T	T
treatment	O	T
of	O	O
chronic	D	D
lymphocytic	D	D
leukemia	D	D

<	O	O
TO_SEE	O	O
>	O	O
PURPOSE	O	O
:	O	O
To	O	O
review	O	O
reported	O	O
inflammatory	D	D
reactions	D	O
occurring	O	O
after	O	O
initiation	O	O
of	O	O
highly	O	O
active	O	O
antiretroviral	T	T
therapy	T	T
(	T	O
HAART	T	O
)	T	O
in	O	O
persons	O	O
infected	O	O
with	O	O
HIV-1	D	O
and	O	O
to	O	O
explore	O	O
the	O	O
mechanisms	O	O
leading	O	O
to	O	O
these	O	O
reactions	O	O

Levofloxacin	T	O
versus	T	O
intravenous	T	O
ceftriaxone	T	O
and	T	O
amoxicillin/clavulanate	T	O
in	O	O
the	O	O
treatment	O	O
of	O	O
community-acquired	O	O
pneumonia	D	O
that	O	O
require	O	O
hospitalization	O	O

Overall	O	O
1	O	O
year	O	O
survival	O	O
(	O	O
operative	O	O
deaths	O	O
excluded	O	O
)	O	O
was	O	O
68	O	O
%	O	O
after	O	O
tumor	D	O
resection	T	O
compared	O	O
to	O	O
31	O	O
%	O	O
after	O	O
palliative	O	O
surgery	O	T
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O

The	O	O
results	O	O
of	O	O
this	O	O
study	O	O
show	O	O
that	O	O
resection	T	O
of	O	O
extrahepatic	D	D
bile	D	D
duct	D	D
carcinomas	D	D
,	O	O
particularly	O	O
in	O	O
an	O	O
upper-third	O	O
localization	O	O
,	O	O
is	O	O
often	O	O
associated	O	O
with	O	O
worthwhile	O	O
long-term	O	O
survival	O	O

Background	O	O
:	O	O
N-acetylcysteine	T	O
(	T	O
NAC	T	O
)	T	O
and	T	O
ambroxol	T	O
(	T	O
AMB	T	O
)	T	O
have	O	O
recently	O	O
been	O	O
proposed	O	O
as	O	O
possible	O	O
therapeutic	O	O
agents	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
pulmonary	D	D
disorders	D	D

<	O	O
TO_SEE	O	O
>	O	O
Postoperative	O	O
alkaline	D	O
reflux	D	O
after	O	O
total	T	O
gastrectomy	T	O
for	O	O
stomach	D	D
cancer	D	D

Antimicrobial	T	T
therapy	T	T
for	O	O
respiratory	D	D
disease	D	D

Corticosteroids	T	O
for	O	O
the	O	O
treatment	O	O
of	O	O
croup	D	O

<	O	O
TO_SEE	O	O
>	O	O
BACKGROUND	O	O
:	O	O
In	O	O
the	O	O
present	O	O
study	O	O
we	O	O
investigated	O	O
the	O	O
efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
i.m	T	O
.	T	O
octreotide	T	O
acetate	T	O
(	T	O
octreotide	T	O
LAR	T	O
)	T	O
in	O	O
patients	O	O
with	O	O
metastatic	D	D
neuroendocrine	D	D
tumors	D	D
(	D	D
NETs	D	D
)	D	O
previously	O	O
treated	O	O
and	O	O
failed	O	O
on	O	O
i.m	T	O
.	T	O
lanreotide	T	O

The	O	O
PR	O	O
was	O	O
observed	O	O
in	O	O
one	O	O
patient	O	O
with	O	O
non-functioning	D	D
endocrine	D	D
pancreatic	D	D
tumor	D	D
with	D	O
progressive	D	D
liver	D	D
and	D	O
lymph	D	D
node	D	O
metastases	D	O
after	O	O
16	O	O
months	O	O
of	O	O
i.m	T	O
.	T	O
lanreotide	T	T
therapy	T	T

CONCLUSIONS	O	O
:	O	O
Octreotide	T	O
LAR	T	O
20	O	O
mg	O	O
shows	O	O
significant	O	O
efficacy	O	O
in	O	O
terms	O	O
of	O	O
objective	O	O
response	O	O
rate	O	O
(	O	O
PR	O	O
+	O	O
SD	O	O
)	O	O
,	O	O
biochemical	O	O
and	O	O
symptomatic	O	O
control	O	O
in	O	O
patients	O	O
with	O	O
metastatic	D	D
NETs	D	O
of	O	O
the	O	O
GEP	O	O
system	O	O
pretreated	O	O
and	O	O
progressing	O	O
on	O	O
slow	O	O
release	O	O
lanreotide	O	O

Inchinko-to	T	O
(	T	O
TJ-135	T	O
)	T	O
is	O	O
a	O	O
herbal	O	O
medicine	O	O
consisting	O	O
of	O	O
three	O	O
kinds	O	O
of	O	O
crude	O	O
drugs	O	O
,	O	O
and	O	O
in	O	O
Japan	O	O
it	O	O
is	O	O
administered	O	O
mainly	O	O
to	O	O
patients	O	O
with	O	O
cholestasis	D	O

The	O	O
present	O	O
study	O	O
evaluated	O	O
the	O	O
effects	O	O
of	O	O
TJ-135	T	O
on	O	O
concanavalin	D	O
A	D	O
(	D	O
con	D	O
A	D	O
)	D	O
-induced	D	O
hepatitis	D	D
in	O	O
mice	O	O
in	O	O
vivo	O	O
and	O	O
con	O	O
A-induced	O	O
cytokine	O	O
production	O	O
in	O	O
vitro	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
con	D	D
A-induced	D	D
hepatitis	D	D
was	O	O
ameliorated	O	O
by	O	O
pretreatment	O	O
with	O	O
TJ-135	T	O

Therefore	O	O
administration	O	O
of	O	O
TJ-135	T	O
may	O	O
be	O	O
useful	O	O
in	O	O
patients	O	O
with	O	O
severe	O	D
acute	O	D
hepatitis	D	D
accompanying	D	D
cholestasis	D	D
or	O	O
in	O	O
those	O	O
with	O	O
autoimmune	D	D
hepatitis	D	D

Zinc	T	O
lozenges	T	O
--	O	O
a	O	O
cure	O	O
for	O	O
common	D	O
colds	D	O
?	O	O

T-helper	T	O
type	T	O
2	T	O
cell-directed	T	T
therapy	T	T
for	O	O
asthma	D	D

Effects	O	O
of	O	O
the	O	O
Japanese	T	O
herbal	T	O
medicine	T	O
'Inchinko-to	T	O
'	T	O
(	T	O
TJ-135	T	O
)	T	O
on	O	O
concanavalin	D	O
A-induced	D	D
hepatitis	D	D
in	O	O
mice	O	O

Presumed	O	O
cavernomas	O	O
have	O	O
been	O	O
documented	O	O
following	O	O
radiation	T	O
for	O	O
malignancy	D	O
(	O	O
5-6	O	O
)	O	O
,	O	O
and	O	O
sterotactic	O	O
cerebral	O	D
biopsy	O	T
(	O	O
7	O	O
)	O	O

Surgical	T	T
management	T	O
of	O	O
syringomyelia	D	D
associated	D	O
with	D	O
spinal	D	D
adhesive	D	D
arachnoiditis	D	D

Discontinuation	O	O
of	O	O
secondary	O	O
prophylaxis	O	T
for	O	O
cryptococcal	D	O
meningitis	D	O
in	O	O
HIV-infected	O	O
patients	O	O
responding	O	O
to	O	O
highly	O	O
active	O	O
antiretroviral	T	T
therapy	T	T

Hepatectomy	T	O
for	O	O
cholangiocarcinoma	D	O
complicated	O	O
with	O	O
right	O	O
umbilical	O	O
portion	O	O
:	O	O
anomalous	O	O
configuration	O	O
of	O	O
the	O	O
intrahepatic	O	O
biliary	O	D
tree	O	D

Traditionally	O	O
,	O	O
the	O	O
therapy	O	O
of	O	O
symptomatic	D	O
bronchiectasis	D	O
is	O	O
based	O	O
on	O	O
antibiotics	T	T
,	T	O
antibronchoobstructive	T	O
medication	T	O
,	T	O
and	T	O
chest	T	O
physical	T	O
therapy	T	T

Bilateral	T	D
lung	T	D
transplantation	T	T
should	O	O
be	O	O
considered	O	O
in	O	O
younger	O	O
patients	O	O
with	O	O
severe	O	D
,	O	O
generalized	O	D
bronchiectasis	D	D
and	D	O
respiratory	D	D
failure	D	D

Prospective	O	O
,	O	O
randomized	O	O
,	O	O
largescale	O	O
trials	O	O
supporting	O	O
any	O	O
of	O	O
the	O	O
different	O	O
treatment	O	O
strategies	O	O
are	O	O
not	O	O
available	O	O
,	O	O
but	O	O
antibiotics	T	T
and	T	O
surgery	T	T
probably	O	O
have	O	O
improved	O	O
the	O	O
long-term	O	O
outcome	O	O
of	O	O
many	O	O
patients	O	O
with	O	O
bronchiectasis	D	O

OBJECTIVES	O	O
:	O	O
Interest	O	O
in	O	O
zinc	T	O
as	O	O
a	O	O
treatment	O	O
for	O	O
the	O	O
common	D	O
cold	D	O
has	O	O
grown	O	O
following	O	O
the	O	O
recent	O	O
publication	O	O
of	O	O
several	O	O
controlled	O	O
trials	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
review	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
effects	O	O
of	O	O
zinc	T	O
lozenges	T	O
for	O	O
cold	D	D
symptoms	D	D

Results	O	O
from	O	O
two	O	O
trials	O	O
(	O	O
04	O	O
-	O	O
Mossad	O	O
;	O	O
08	O	O
-	O	O
Smith	O	O
)	O	O
suggested	O	O
zinc	T	O
lozenges	T	O
reduced	O	O
the	O	O
severity	O	O
and	O	O
duration	O	O
of	O	O
cold	D	D
symptoms	D	D

Given	O	O
the	O	O
potential	O	O
for	O	O
treatment	O	O
to	O	O
produce	O	O
side	O	O
effects	O	O
,	O	O
the	O	O
use	O	O
of	O	O
zinc	T	O
lozenges	T	O
to	O	O
treat	O	D
cold	D	D
symptoms	D	D
deserves	O	O
further	O	O
study	O	O

Randomized	O	O
trial	O	O
of	O	O
interferon-alpha	T	O
plus	T	O
ursodeoxycholic	T	O
acid	T	O
versus	O	O
interferon	T	T
plus	T	T
placebo	T	O
in	O	O
patients	O	O
with	O	O
chronic	D	D
hepatitis	D	D
C	D	D
resistant	D	D
to	D	O
interferon	D	O

We	O	O
describe	O	O
a	O	O
rare	O	O
case	O	O
of	O	O
spontaneous	D	O
rupture	D	O
of	D	O
a	D	O
hepatic	D	D
metastasis	D	D
from	D	D
renal	D	D
cell	D	D
carcinoma	D	D
that	O	O
was	O	O
treated	O	O
successfully	O	O
by	O	O
hepatic	T	D
arterial	T	D
embolization	T	D

A	O	O
65-year-old	O	O
woman	O	O
,	O	O
who	O	O
had	O	O
been	O	O
undergoing	O	O
immunotherapy	T	O
for	O	O
inoperably	D	D
disseminated	D	D
renal	D	D
carcinoma	D	D
and	D	O
lung	D	D
metastases	D	D
,	O	O
presented	O	O
with	O	O
severe	O	D
abdominal	O	D
pain	O	D
in	O	O
a	O	O
state	O	O
of	O	O
hypovolemic	O	O
shock	O	D

Although	O	O
hepatic	O	D
rupture	O	D
due	O	O
to	O	O
metastatic	O	D
cancer	O	D
is	O	O
extremely	O	O
rare	O	O
,	O	O
transcatheter	T	D
arterial	T	D
embolization	T	O
(	T	O
TAE	T	O
)	T	O
is	O	O
an	O	O
appropriate	O	O
and	O	O
useful	O	O
treatment	O	O
for	O	O
massive	D	D
hemorrhage	D	D
caused	D	D
by	D	O
spontaneous	D	D
rupture	D	D
of	D	O
liver	D	D
metastasis	D	D

Patients	O	O
with	O	O
classical	O	D
symptoms	O	D
such	O	O
as	O	O
heartburn	D	O
and	D	O
regurgitation	D	O
may	O	O
be	O	O
treated	O	O
pharmaceutically	T	O
combined	T	O
with	T	O
life	T	O
style	T	O
counselling	T	O

Surgical	T	T
treatment	T	T
is	O	O
a	O	O
good	O	O
alternative	O	O
for	O	O
patients	O	O
with	O	O
persistent	D	D
severe	D	D
regurgitation	D	D
during	O	O
medical	O	O
therapy	O	T
and	O	O
for	O	O
young	O	O
patients	O	O
who	O	O
prefer	O	T
surgery	O	T
to	O	O
lifelong	O	O
medication	O	O

The	O	O
surgical	T	T
treatment	T	T
of	O	O
lung	D	D
lacerations	D	D
and	D	O
major	D	O
bronchial	D	D
disruptions	D	D
caused	O	D
by	O	O
blunt	O	D
thoracic	O	D
trauma	O	D

BACKGROUND	O	O
:	O	O
An	O	O
increasing	O	O
number	O	O
of	O	O
reports	O	O
indicate	O	O
symptomatic	O	O
relief	O	O
of	O	O
biliary	O	D
colic	O	D
symptoms	O	D
after	O	O
cholecystectomy	T	O
for	O	O
biliary	D	D
dyskinesia	D	D

Despite	O	O
this	O	O
,	O	O
cholecystectomy	T	O
as	O	O
a	O	O
treatment	O	O
for	O	O
biliary	D	D
dyskinesia	D	O
remains	O	O
controversial	O	O

Our	O	O
aim	O	O
was	O	O
to	O	O
determine	O	O
efficacy	O	O
of	O	O
cholecystectomy	T	O
in	O	O
alleviating	O	D
biliary	D	D
dyskinesia	D	D
symptoms	D	D
and	O	O
the	O	O
correlation	O	O
with	O	O
histologic	O	O
findings	O	O

CONCLUSIONS	O	O
:	O	O
Biliary	D	D
dyskinesia	D	D
patients	O	O
who	O	O
underwent	O	O
cholecystectomy	T	O
had	O	O
significantly	O	O
greater	O	O
symptom	O	O
improvement	O	O
compared	O	O
with	O	O
nonsurgical	O	O
patients	O	O

Cholecystectomy	T	O
should	O	O
be	O	O
a	O	O
first-line	O	O
therapy	O	T
for	O	O
biliary	D	D
dyskinesia	D	D
patients	O	O

Transbronchial	O	O
biopsy	O	O
revealed	O	O
inflammatory	D	D
nonspecific	D	D
alveolar	D	D
lesions	D	D
suggestive	D	O
of	D	O
bronchiolitis	D	O
obliterans	D	O
organizing	D	O
pneumonia	D	O
,	O	O
which	O	O
responded	O	O
well	O	O
clinically	O	O
and	O	O
radiologically	O	O
to	O	O
oral	T	O
corticosteroids	T	O

Novel	O	O
treatment	O	O
strategies	O	O
for	O	O
patients	O	O
with	O	O
advanced	D	O
NSCLC	D	O
may	O	O
involve	O	O
chemotherapy	T	T
combined	O	O
with	O	O
inhibition	O	O
of	O	O
NF-kappaB-dependent	O	O
cell-survival	O	O
pathways	O	O

Effectiveness	O	O
of	O	O
pseudoephedrine	T	O
plus	T	O
acetaminophen	T	O
for	O	O
treatment	O	O
of	O	O
symptoms	O	D
attributed	O	O
to	O	O
the	O	O
paranasal	O	O
sinuses	O	O
associated	O	O
with	O	O
the	O	O
common	D	O
cold	D	O

OBJECTIVE	O	O
:	O	O
This	O	O
retrospective	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
confirm	O	O
that	O	O
aggressive	T	O
pulmonary	T	D
resection	T	O
can	O	O
provide	O	O
effective	O	O
long-term	O	O
palliation	O	O
of	O	O
disease	O	D
for	O	O
patients	O	O
with	O	O
pulmonary	D	D
aspergilloma	D	D

METHODS	O	O
AND	O	O
RESULTS	O	O
:	O	O
From	O	O
1959	O	O
to	O	O
1998	O	O
,	O	O
84	O	O
patients	O	O
underwent	O	O
a	O	O
total	O	O
of	O	O
90	O	O
operations	T	O
for	O	O
treatment	O	O
of	O	O
pulmonary	D	D
aspergilloma	D	D
in	O	O
the	O	O
Marie-Lannelongue	O	O
Hospital	O	O

The	O	O
lesion	D	O
was	O	O
resected	O	O
by	O	O
video-assisted	T	O
thoracoscopic	T	T
surgery	T	T
because	O	O
it	O	O
was	O	O
suspected	O	O
of	O	O
being	O	O
a	O	O
lung	O	D
abscess	O	D
that	O	O
had	O	O
caused	O	O
repeated	O	O
episodes	O	O
of	O	O
inflammation	O	D

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
expression	O	O
and	O	O
therapeutic	O	O
potential	O	O
of	O	O
TRAIL	T	O
in	O	O
cholangiocarcinoma	D	O
,	O	O
one	O	O
of	O	O
the	O	O
most	O	O
devastating	O	O
human	O	O
hepatic	O	O
malignancies	O	O

Finally	O	O
,	O	O
in	O	O
vivo	O	O
administration	O	O
of	O	O
recombinant	O	O
TRAIL	T	O
substantially	O	O
inhibited	O	O
subcutaneous	O	O
tumor	O	O
growth	O	O
of	O	O
human	O	O
cholangiocarcinoma	D	O
cells	O	O

Induction	O	O
of	O	O
apoptosis	O	O
in	O	O
tumor	O	D
cells	O	O
is	O	O
possible	O	O
with	O	O
a	O	O
biologically	O	O
active	O	O
TRAIL	T	O
,	O	O
and	O	O
suggests	O	O
that	O	O
this	O	O
cytokine	O	O
is	O	O
a	O	O
promising	O	O
antitumor	O	O
agent	O	O
against	O	O
human	D	O
cholangiocarcinoma	D	O

Interferon	T	O
plays	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
the	O	O
host	O	O
's	O	O
natural	O	O
defense	O	O
against	O	O
viral	D	D
infections	D	D
and	O	O
in	O	O
their	O	O
treatment	O	O

This	O	O
study	O	O
investigated	O	O
whether	O	O
intensive	O	O
chemotherapy	T	T
might	O	O
have	O	O
a	O	O
positive	O	O
effect	O	O
on	O	O
asthma	D	D
in	O	O
these	O	O
special	O	O
cases	O	O
and	O	O
whether	O	O
asthma	O	D
generally	O	O
relapses	O	O
after	O	O
completion	O	O
of	O	O
chemotherapy	O	T

The	O	O
authors	O	O
monitored	O	O
clinical	O	O
outcome	O	O
and	O	O
lung	O	D
function	O	O
of	O	O
43	O	O
children	O	O
with	O	O
acute	D	D
lymphoblastic	D	D
leukemia	D	D
and	D	D
non-Hodgkin	D	D
lymphoma	D	D
who	O	O
received	O	O
chemotherapy	T	T
at	O	O
the	O	O
University	O	O
Children	O	O
's	O	O
Hospital	O	O
of	O	O
Greifswald	O	O
between	O	O
1993	O	O
and	O	O
1998	O	O

She	O	O
was	O	O
diagnosed	O	D
as	O	O
miliary	D	D
tuberculosis	D	D
and	O	O
treated	O	O
with	O	O
antituberculous	T	O
drugs	T	T

The	O	O
hemorrhage	D	D
was	O	O
successfully	O	O
stopped	O	O
by	O	O
microcoil	T	O
embolization	T	O

Immunomodulatory	O	O
effects	O	O
of	O	O
acupuncture	T	O
in	O	O
the	O	O
treatment	O	O
of	O	O
allergic	D	D
asthma	D	D
:	O	O
a	O	O
randomized	O	O
controlled	O	O
study	O	O

An	O	O
open-label	O	O
study	O	O
of	O	O
lamivudine	T	O
for	O	O
chronic	D	D
hepatitis	D	D
B	D	O
in	O	O
six	O	O
patients	O	O
with	O	O
chronic	O	D
renal	O	D
failure	O	D
before	O	O
and	O	O
after	O	O
kidney	O	D
transplantation	O	T

CONCLUSION	O	O
:	O	O
The	O	O
WDTA	O	O
is	O	O
an	O	O
intrinsically	O	O
motivating	O	O
educational	O	O
program	O	O
that	O	O
has	O	O
the	O	O
ability	O	O
to	O	O
effect	O	O
determinants	O	O
of	O	O
asthma	D	D
self-management	T	D
behavior	O	O
in	O	O
9-	O	O
to	O	O
13-year-old	O	O
children	O	O
with	O	O
asthma	O	D

Usefulness	O	O
of	O	O
percutaneous	T	D
transhepatic	T	D
biliary	T	D
drainage	T	D
in	O	O
patients	O	O
with	O	O
surgical	D	T
jaundice	D	O
--	O	O
a	O	O
prospective	O	O
randomised	O	O
study	O	O

Neutralization	O	O
of	O	O
hepatitis	D	D
A	D	O
virus	D	O
(	D	O
HAV	D	O
)	D	O
by	O	O
an	O	O
immunoadhesin	T	O
containing	T	O
the	T	O
cysteine-rich	T	O
region	T	O
of	T	O
HAV	T	O
cellular	T	O
receptor-1	T	O

To	O	O
ascertain	O	O
the	O	O
results	O	O
of	O	O
standard	T	O
ABVD	T	O
chemotherapy	T	T
(	T	O
doxorubicin	T	O
,	T	O
bleomycin	T	O
,	T	O
vinblastine	T	O
,	T	O
dacarbazine	T	O
)	T	O
in	O	O
HIV-infected	O	O
patients	O	O
with	O	O
newly	D	D
diagnosed	D	D
Hodgkin	D	D
's	D	D
disease	D	D
(	D	O
HD	D	O
)	D	O
,	O	O
a	O	O
nonrandomized	O	O
,	O	O
prospective	O	O
,	O	O
multiinstitutional	O	O
clinical	O	O
trial	O	O
was	O	O
conducted	O	O
by	O	O
the	O	O
AIDS	O	O
Clinical	O	O
Trials	O	O
Group	O	O
(	O	O
ACTG	O	O
)	O	O
,	O	O
in	O	O
HIV-infected	O	O
patients	O	O
with	O	O
Hodgkin	O	D
's	O	D
disease	O	D

The	O	O
effectiveness	O	O
of	O	O
glucocorticoids	T	O
in	O	O
treating	O	O
croup	D	O
:	O	O
meta-analysis	O	O
(	O	O
see	O	O
comments	O	O
)	O	O

PURPOSE	O	O
:	O	O
Inhaled	O	O
corticosteroids	T	O
have	O	O
beneficial	O	O
effects	O	O
on	O	O
pulmonary	O	D
function	O	O
and	O	O
inflammation	O	D
in	O	O
patients	O	O
with	O	O
asthma	D	D
,	O	O
but	O	O
they	O	O
also	O	O
cause	O	O
systemic	O	O
adverse	O	O
effects	O	O
,	O	O
such	O	O
as	O	O
adrenal	O	O
suppression	O	O

Second	O	O
,	O	O
children	O	O
in	O	O
the	O	O
first	O	O
year	O	O
of	O	O
life	O	O
are	O	O
at	O	O
highest	O	O
risk	O	O
of	O	O
progression	O	O
and	O	O
should	O	O
be	O	O
treated	O	O
with	O	O
trimethoprim-sulfamethoxazole	T	O
to	O	O
prevent	O	O
Pneumocystis	D	O
carinii	D	O
pneumonia	D	O
,	O	O
and	O	O
targeted	O	O
for	O	O
receiving	O	O
antiretrovirals	O	O

Effectiveness	O	O
of	O	O
casein	T	O
hydrolysate	T	O
feedings	O	O
in	O	O
infants	O	O
with	O	O
colic	D	O
(	O	O
see	O	O
comments	O	O
)	O	O

We	O	O
conclude	O	O
that	O	O
antimicrobial/	T	O
antituberculous	T	O
agents	T	O
have	O	O
only	O	O
a	O	O
minor	O	O
short-term	O	O
effect	O	O
in	O	O
long-lasting	O	O
CGM	D	O
of	O	O
undetermined	O	O
cause	O	O

The	O	O
patient	O	O
had	O	O
previously	O	O
been	O	O
immunized	O	O
with	O	O
two	O	O
doses	O	O
of	O	O
Hib	D	O
conjugate	O	O
vaccine	T	O
(	O	O
PRP-T	O	O
)	O	O

Thus	O	O
,	O	O
s-ECP	O	O
appears	O	O
to	O	O
be	O	O
a	O	O
useful	O	O
marker	O	O
for	O	O
determining	O	O
when	O	O
a	O	O
step-down	O	O
in	O	O
iBDP	T	O
therapy	T	T
is	O	O
indicated	O	O
,	O	O
and	O	O
thus	O	O
may	O	O
contribute	O	O
to	O	O
successful	O	O
long-term	O	O
management	O	O
of	O	O
chronic	D	D
asthma	D	D

Twinrix	T	O
(	O	O
SmithKline	O	O
Beecham	O	O
Biologicals	O	O
)	O	O
is	O	O
a	O	O
combined	O	O
hepatitis	D	D
A	D	O
and	D	O
B	D	O
vaccine	T	O
licensed	O	O
with	O	O
a	O	O
three-dose	O	O
schedule	O	O

A	O	O
two-dose	O	O
combined	O	O
hepatitis	D	D
A	D	O
and	D	O
B	D	O
vaccine	T	O
would	O	O
facilitate	O	O
immunisation	O	O
programs	O	O

Therefore	O	O
,	O	O
it	O	O
can	O	O
be	O	O
concluded	O	O
that	O	O
with	O	O
two	O	O
injections	O	O
of	O	O
the	O	O
high-dose	O	D
hepatitis	D	D
A	D	O
and	D	O
B	D	O
vaccine	T	O
,	O	O
6	O	O
months	O	O
apart	O	O
,	O	O
a	O	O
similar	O	O
immune	O	O
response	O	O
can	O	O
be	O	O
obtained	O	O
as	O	O
induced	O	O
with	O	O
three	O	O
doses	O	O
of	O	O
Twinrix	T	O
at	O	O
months	O	O
0	O	O
,	O	O
1	O	O
and	O	O
6	O	O

AIM	O	O
:	O	O
To	O	O
assess	O	O
the	O	O
impact	O	O
on	O	O
community-based	O	O
pediatricians	O	O
of	O	O
the	O	O
conclusions	O	O
of	O	O
the	O	O
10th	O	O
Conference	O	O
de	O	O
Consensus	O	O
en	O	O
Therapeutique	O	O
Anti-Infectieuse	O	O
(	O	O
CCTAI	O	O
)	O	O
on	O	O
the	O	O
antibiotic	T	T
treatment	T	T
in	O	O
acute	D	D
nasopharyngitis	D	D
(	D	O
ANP	D	O
)	D	O

CONCLUSIONS	O	O
:	O	O
These	O	O
data	O	O
,	O	O
the	O	O
first	O	O
evidence	O	O
that	O	O
chronic	O	D
stress	O	O
can	O	O
inhibit	O	O
the	O	O
stability	O	O
of	O	O
the	O	O
IgG	O	O
antibody	O	O
response	O	O
to	O	O
a	O	O
bacterial	T	O
vaccine	T	O
for	O	O
pneumonia	D	O
,	O	O
provide	O	O
additional	O	O
evidence	O	O
of	O	O
health	O	O
risks	O	O
associated	O	O
with	O	O
dementia	O	O
caregiving	O	O

We	O	O
assessed	O	O
the	O	O
prevalence	O	O
of	O	O
head	O	O
louse	O	O
infestation	O	O
and	O	O
the	O	O
effectiveness	O	O
of	O	O
1	T	O
%	T	O
permethrin	T	O
against	O	O
head	D	O
lice	D	O
in	O	O
Kosovar	O	O
refugees	O	O

Refugees	O	O
with	O	O
crawling	D	O
lice	D	O
were	O	O
treated	O	O
with	O	O
a	O	O
pediculicide	T	O
containing	T	O
1	T	O
%	T	O
permethrin	T	O

We	O	O
conclude	O	O
that	O	O
1	T	O
%	T	O
permethrin	T	O
treatment	T	O
was	O	O
effective	O	O
in	O	O
louse	D	O
control	O	O
in	O	O
this	O	O
refugee	O	O
population	O	O

Antibiotics	T	T
for	O	O
Salmonella	D	O
meningitis	D	O
in	O	O
children	O	O

Four	O	O
patients	O	O
developed	O	O
mild	O	D
pancreatitis	D	D
,	O	O
one	O	O
had	O	O
moderate	O	O
pancreatitis	D	D
and	O	O
one	O	O
had	O	O
leak	O	O
of	O	O
contrast	O	O
,	O	O
which	O	O
was	O	O
treated	O	O
by	O	O
administration	T	O
of	T	O
clear	T	O
fluids	T	O
orally	O	O
for	O	O
one	O	O
day	O	O

We	O	O
treated	O	O
two	O	O
children	O	O
with	O	O
influenza-associated	D	D
acute	D	D
encephalopathy	D	D
by	O	O
a	O	O
combination	T	O
of	T	O
mild	T	O
hypothermia	T	O
and	T	O
steroid	T	O
pulse	T	T
therapy	T	T

Successful	O	O
treatment	O	O
of	O	O
anaerobic	D	D
pleuropulmonary	D	D
infections	D	D
requires	O	O
a	O	O
combination	T	O
of	T	O
antibiotic	T	T
therapy	T	T
and	T	O
surgical	T	T
interventions	T	O

Treatment	O	O
of	O	O
spontaneous	D	D
carotid-cavernous	D	D
fistula	D	D
in	D	O
Ehlers-Danlos	D	D
syndrome	D	D
by	O	O
transvenous	T	O
occlusion	T	O
with	T	O
Guglielmi	T	O
detachable	T	O
coils	T	O

PURPOSE	O	O
:	O	O
Macrolide	T	O
antibiotics	T	T
are	O	O
frequently	O	O
prescribed	O	O
to	O	O
patients	O	O
with	O	O
symptoms	D	D
of	D	O
a	D	O
common	D	O
cold	D	O

Because	O	O
the	O	O
symptoms	O	O
of	O	O
rhinovirus	O	O
colds	O	O
are	O	O
attributed	O	O
to	O	O
the	O	O
inflammatory	O	D
response	O	O
to	O	O
infection	O	D
,	O	O
we	O	O
studied	O	O
the	O	O
effects	O	O
of	O	O
treatment	O	O
with	O	O
clarithromycin	T	O
on	O	O
the	O	O
symptomatic	O	O
and	O	O
inflammatory	O	O
response	O	O
to	O	O
nasal	O	O
inoculation	O	O
with	O	O
rhinovirus	D	O

Therapeutic	T	O
pneumothorax	T	O
(	T	O
TP	T	O
)	T	O
proved	O	O
its	O	O
efficacy	O	O
in	O	O
pre-antibiotic	O	O
era	O	O
,	O	O
so	O	O
one	O	O
can	O	O
assume	O	O
that	O	O
it	O	O
can	O	O
be	O	O
applied	O	O
with	O	O
the	O	O
same	O	O
success	O	O
in	O	O
multidrug	D	O
resistant	D	O
TB	D	O

In	O	O
conclusion	O	O
,	O	O
in	O	O
some	O	O
cases	O	O
of	O	O
MDR	D	O
TB	D	O
,	O	O
the	O	O
TP	T	O
(	O	O
if	O	O
there	O	O
are	O	O
no	O	O
pleural	O	O
adherences	O	O
)	O	O
may	O	O
lead	O	O
to	O	O
good	O	O
results	O	O

Acupuncture	T	O
treatment	O	O
of	O	O
common	D	O
cold	D	O

CONCLUSIONS	O	O
:	O	O
These	O	O
data	O	O
,	O	O
the	O	O
first	O	O
evidence	O	O
that	O	O
chronic	O	D
stress	O	O
can	O	O
inhibit	O	O
the	O	O
stability	O	O
of	O	O
the	O	O
IgG	O	O
antibody	O	O
response	O	O
to	O	O
a	O	O
bacterial	T	O
vaccine	T	O
for	O	O
pneumonia	D	O
,	O	O
provide	O	O
additional	O	O
evidence	O	O
of	O	O
health	O	O
risks	O	O
associated	O	O
with	O	O
dementia	O	O
caregiving	O	O

When	O	O
bleeding	D	D
is	O	O
stopped	O	O
via	O	O
surgical	T	T
or	T	O
radiological	T	O
methods	T	O
,	O	O
the	O	O
clinical	O	O
course	O	O
of	O	O
hemobilia-associated	O	D
pancreatitis	O	D
appears	O	O
to	O	O
be	O	O
benign	O	O

A	O	O
case	O	O
of	O	O
biliary	D	D
stenosis	D	D
in	O	O
polycystic	O	D
liver	O	D
improved	O	O
by	O	O
injection	T	O
of	T	O
minocycline	T	O
hydrochloride	T	O
to	O	O
a	O	O
hepatic	O	O
cyst	O	O

The	O	O
ruptured	D	O
horn	D	O
was	O	O
excised	O	O
by	O	O
laparotomy	T	O

Therapy	O	T
designed	O	O
to	O	O
control	O	O
the	O	O
efferent	D	O
phase	D	O
of	D	O
established	D	O
asthma	D	D
by	O	O
augmenting	T	O
down-regulatory	T	O
Th1	T	O
counterbalancing	T	O
mechanisms	T	O
should	O	O
be	O	O
effective	O	O

All	O	O
children	O	O
with	O	O
croup	D	D
symptoms	O	D
who	O	O
demonstrate	O	O
increased	O	O
work	O	O
of	O	O
breathing	O	O
in	O	O
the	O	O
clinics	O	O
or	O	O
emergency	O	O
departments	O	O
should	O	O
be	O	O
treated	O	O
with	O	O
glucocorticoids	T	O

Increasing	O	O
resistance	O	O
among	O	O
the	O	O
common	D	D
respiratory	D	D
pathogens	D	O
has	O	O
encouraged	O	O
assessment	O	O
of	O	O
alternative	O	O
agents	O	O
,	O	O
for	O	O
example	O	O
,	O	O
levofloxacin	T	O

Unlike	O	O
earlier	O	O
quinolones	O	O
,	O	O
levofloxacin	T	O
has	O	O
excellent	O	O
activity	O	O
against	O	O
Streptococcus	D	O
pneumoniae	D	O
,	O	O
including	O	O
strains	O	O
resistant	O	O
to	O	O
penicillin	O	T

Clinical	O	O
trials	O	O
show	O	O
levofloxacin	T	O
to	O	O
be	O	O
as	O	O
effective	O	O
as	O	O
cephalosporins	O	O
in	O	O
acute	O	D
exacerbation	O	D
of	O	O
chronic	D	D
bronchitis	D	D
and	O	O
as	O	O
effective	O	O
as	O	O
co-amoxiclav	O	O
,	O	O
cephalosporins	O	O
or	O	O
amoxycillin	O	O
in	O	O
community-acquired	D	O
pneumonia	D	O

Additionally	O	O
,	O	O
epidemiologic	O	O
evidence	O	O
of	O	O
a	O	O
marked	O	O
decline	O	O
in	O	O
new	O	O
KS	D	O
since	O	O
the	O	O
widespread	O	O
use	O	O
of	O	O
highly	T	O
active	T	O
antiretroviral	T	T
therapy	T	T
(	T	O
HAART	T	O
)	T	O
advocates	O	O
its	O	O
use	O	O

A	O	O
field	O	O
study	O	O
was	O	O
carried	O	O
out	O	O
to	O	O
evaluate	O	O
the	O	O
effect	O	O
of	O	O
vaccination	T	O
against	O	O
swine	D	O
enzootic	D	O
pneumonia	D	O
in	O	O
different	O	O
production	O	O
systems	O	O
(	O	O
closed	O	O
or	O	O
one-site	O	O
,	O	O
and	O	O
open	O	O
,	O	O
two-	O	O
or	O	O
three-site	O	O
,	O	O
systems	O	O
)	O	O

Humoral	O	O
immune	O	D
response	O	O
after	O	O
vaccination	T	O
against	O	O
influenza	D	O
in	O	O
patients	O	O
with	O	O
breast	O	D
cancer	O	D

Gingyo-san	T	O
and	O	O
its	O	O
components	O	O
were	O	O
administered	O	O
orally	O	O
to	O	O
mice	O	O
1	O	O
day	O	O
before	O	O
,	O	O
then	O	O
1	O	O
and	O	O
4	O	O
days	O	O
after	O	O
the	O	O
inhalation	O	O
of	O	O
a	O	O
mouse-adopted	D	O
strain	D	O
of	D	O
influenza	D	D
A2	D	D
(	D	O
H2N2	D	O
)	D	O
virus	D	O

From	O	O
these	O	O
results	O	O
Gingyo-san	T	O
was	O	O
shown	O	O
to	O	O
be	O	O
an	O	O
antiviral	O	O
agent	O	O
in	O	O
mice	O	O
infected	O	O
with	O	O
a	O	O
lethal	O	O
amount	O	O
of	O	O
a	O	O
mouse-adopted	D	O
strain	D	O
of	D	O
influenza	D	D
A2	D	D
virus	D	D

The	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
analyze	O	O
the	O	O
association	O	O
of	O	O
recurrent	O	D
abdominal	O	D
pain	O	D
and	O	O
H.	O	D
pylori	O	D
infection	O	D
in	O	O
children	O	O
and	O	O
to	O	O
evaluate	O	O
the	O	O
efficacy	O	O
of	O	O
antimicrobial	T	T
treatment	T	T
in	O	O
patients	O	O
with	O	O
evidence	O	O
of	O	O
infection	D	D

Patients	O	O
with	O	O
evidence	O	O
of	O	O
infection	D	D
with	D	O
H.	D	D
pylori	D	D
were	O	O
treated	O	O
with	O	O
a	O	O
combination	T	O
of	T	O
omeprazole	T	O
,	T	O
amoxicillin	T	O
,	T	O
and	T	O
clarithromycin	T	O

Treatment	O	O
with	O	O
omeprazole	T	O
,	T	O
amoxicillin	T	O
,	T	O
and	T	O
clarithromycin	T	O
resulted	O	O
in	O	O
eradication	O	O
of	O	O
the	O	O
infection	D	D
in	O	O
all	O	O
and	O	O
in	O	O
resolution	O	O
of	O	O
the	O	O
clinical	O	O
symptoms	O	O
in	O	O
15	O	O
(	O	O
80	O	O
%	O	O
)	O	O
of	O	O
19	O	O
patients	O	O
who	O	O
had	O	O
a	O	O
follow-up	O	O
examination	O	O

A	O	O
combined	T	O
therapy	T	T
results	O	O
in	O	O
eradication	O	O
of	O	O
the	O	O
bacterium	D	O
and	O	O
in	O	O
improvement	O	O
of	O	O
the	O	O
clinical	O	O
symptoms	O	D
in	O	O
a	O	O
significant	O	O
majority	O	O
of	O	O
the	O	O
patients	O	O

In	O	O
certain	O	O
clinical	O	O
settings	O	O
,	O	O
interventional	T	O
radiologic	T	O
procedures	T	O
have	O	O
become	O	O
an	O	O
important	O	O
alternative	O	O
to	O	O
surgery	O	T
in	O	O
the	O	O
treatment	O	O
of	O	O
gallstones	D	O
and	O	O
their	O	O
complications	O	O
;	O	O
techniques	O	O
include	O	O
percutaneous	T	O
cholecystostomy	T	O
and	T	O
gallstone	T	O
removal	T	O

BACKGROUND	O	O
:	O	O
The	O	O
administration	O	O
of	O	O
salbutamol	T	O
is	O	O
permitted	O	O
only	O	O
by	O	O
inhalation	O	O
by	O	O
the	O	O
International	O	O
Olympic	O	O
Committee	O	O
(	O	O
IOC	O	O
)	O	O
for	O	O
the	O	O
management	O	O
of	O	O
asthma	D	D
and	D	O
exercise-induced	D	D
asthma	D	D
in	O	O
athletes	O	O

Urine	O	O
was	O	O
also	O	O
obtained	O	O
from	O	O
subjects	O	O
who	O	O
had	O	O
received	O	O
the	O	O
maximum	O	O
dosage	O	O
of	O	O
inhaled	O	O
salbutamol	T	O
advisable	O	O
for	O	O
competing	O	O
athletes	O	O
to	O	O
provide	O	O
protection	O	O
from	O	O
exercise-induced	O	D
asthma	O	D
and	O	O
treatment	O	O
of	O	O
asthma	D	D
(	O	O
1600	O	O
microg	O	O
in	O	O
24	O	O
h	O	O
,	O	O
800	O	O
microg	O	O
being	O	O
in	O	O
the	O	O
last	O	O
4	O	O
h	O	O
)	O	O

Antimicrobials	T	O
were	O	O
prescribed	O	O
to	O	O
175	O	O
(	O	O
83.73	O	O
per	O	O
cent	O	O
)	O	O
patients	O	O
with	O	O
common	D	O
cold	D	O
and	O	O
78	O	O
(	O	O
82.11	O	O
per	O	O
cent	O	O
)	O	O
patients	O	O
with	O	O
diarrhea	D	O

OBJECTIVE	O	O
:	O	O
to	O	O
evaluate	O	O
the	O	O
possible	O	O
existence	O	O
of	O	O
the	O	O
so-called	O	O
<	O	O
Roux-en-Y	O	D
syndrome	O	D
>	O	O
in	O	O
a	O	O
group	O	O
of	O	O
21	O	O
patients	O	O
who	O	O
underwent	O	T
surgery	T	T
to	O	O
correct	O	O
postoperative	D	D
alkaline	D	D
reflux	D	D
gastritis	D	D

All	O	O
had	O	O
undergone	O	O
Billroth	T	O
II	T	O
subtotal	T	O
gastrectomy	T	O
(	O	O
20	O	O
for	O	O
ulcer	D	D
and	O	O
1	O	O
for	O	O
gastric	D	D
cancer	D	D
)	O	O

CONCLUSIONS	O	O
:	O	O
we	O	O
found	O	O
no	O	O
evidence	O	O
of	O	O
disturbances	O	O
in	O	O
gastric	O	O
remnant	O	O
emptying	O	O
after	O	O
Roux-en-Y	T	O
gastrojejunostomy	T	O
to	O	O
treat	O	D
postoperative	D	D
alkaline	D	D
gastric	D	D
reflux	D	D

BACKGROUND	O	O
:	O	O
Drainage	O	O
methods	O	O
for	O	O
the	O	O
gastric	O	O
conduit	O	O
after	O	O
esophagectomy	T	O
for	O	O
carcinoma	D	D
have	O	O
been	O	O
controversial	O	O

CONCLUSIONS	O	O
:	O	O
This	O	O
study	O	O
indicates	O	O
that	O	O
the	O	O
use	O	O
of	O	O
a	O	O
computerized	O	O
physician	O	O
reminder	O	O
and	O	O
a	O	O
mailed	O	O
patient	O	O
reminder	O	O
had	O	O
a	O	O
positive	O	O
impact	O	O
on	O	O
influenza	D	O
immunizations	T	O
for	O	O
older	O	O
adults	O	O
in	O	O
a	O	O
large	O	O
family	O	O
practice	O	O
office	O	O

Contemporary	O	D
asthma	O	D
management	O	O
guidelines	O	O
list	O	O
inhaled	T	O
corticosteroids	T	O
as	O	O
the	O	O
preferred	O	O
controller	O	O
medication	O	O
for	O	O
patients	O	O
with	O	O
persistent	D	D
asthma	D	D

Fluticasone	T	O
propionate	T	O
is	O	O
one	O	O
of	O	O
several	O	O
inhaled	O	O
corticosteroids	O	O
used	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
asthma	D	D

A	O	O
series	O	O
of	O	O
comparative	O	O
analyses	O	O
show	O	O
that	O	O
inhaled	T	O
fluticasone	T	O
propionate	T	O
is	O	O
more	O	O
cost	O	O
effective	O	O
than	O	O
oral	O	O
zafirlukast	O	O
and	O	O
triamcinolone	O	O
acetonide	O	O
and	O	O
slightly	O	O
more	O	O
cost	O	O
effective	O	O
than	O	O
flunisolide	O	O
in	O	O
adult	O	O
patients	O	O
with	O	O
asthma	D	D

Quality-of-life	O	O
assessments	O	O
in	O	O
patients	O	O
with	O	O
mild	O	D
to	O	O
moderate	O	D
disease	O	D
show	O	O
that	O	O
inhaled	T	O
fluticasone	T	O
propionate	T	O
achieved	O	O
improvements	O	O
which	O	O
were	O	O
deemed	O	O
to	O	O
be	O	O
clinically	O	O
meaningful	O	O
in	O	O
patients	O	O
with	O	O
mild	O	O
to	O	O
moderate	O	O
asthma	D	D
;	O	O
these	O	O
changes	O	O
were	O	O
significantly	O	O
greater	O	O
than	O	O
those	O	O
achieved	O	O
with	O	O
oral	O	O
zafirlukast	O	O
,	O	O
inhaled	O	O
triamcinolone	O	O
acetonide	O	O
or	O	O
placebo	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
addition	O	O
to	O	O
the	O	O
considerable	O	O
body	O	O
of	O	O
clinical	O	O
evidence	O	O
supporting	O	O
the	O	O
use	O	O
of	O	O
inhaled	T	O
fluticasone	T	O
propionate	T	O
in	O	O
patients	O	O
with	O	O
asthma	D	D
,	O	O
accumulating	O	O
short	O	O
term	O	O
cost-effectiveness	O	O
data	O	O
also	O	O
suggest	O	O
that	O	O
this	O	O
agent	O	O
can	O	O
be	O	O
administered	O	O
for	O	O
a	O	O
similar	O	O
or	O	O
lower	O	O
cost	O	O
per	O	O
outcome	O	O
than	O	O
other	O	O
inhaled	O	O
corticosteroids	O	O
or	O	O
oral	O	O
zafirlukast	O	O

Importantly	O	O
,	O	O
the	O	O
clinical	O	O
benefits	O	O
offered	O	O
by	O	O
fluticasone	T	O
propionate	T	O
in	O	O
patients	O	O
with	O	O
persistent	D	D
asthma	D	D
are	O	O
accompanied	O	O
by	O	O
clinically	O	O
significant	O	O
improvements	O	O
in	O	O
quality	O	O
of	O	O
life	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
describe	O	O
the	O	O
effect	O	O
of	O	O
influenza	D	O
vaccination	T	O
on	O	O
long-term	O	O
change	O	O
in	O	O
CD4	O	O
count	O	O
and	O	O
HIV	O	O
RNA	O	O
level	O	O
,	O	O
and	O	O
on	O	O
progression	O	O
to	O	O
AIDS	O	O
or	O	O
death	O	O

Combination	T	O
therapy	T	T
with	T	O
interferon-alpha	T	O
(	T	O
IFN	T	O
alpha	T	O
)	T	O
plus	T	O
Ribavirin	T	O
has	O	O
been	O	O
shown	O	O
to	O	O
improve	O	O
the	O	O
response	O	O
rate	O	O
in	O	O
patients	O	O
with	O	O
chronic	D	D
hepatitis	D	D
C	D	O
as	O	O
compared	O	O
to	O	O
IFN	O	O
alpha	O	O
alone	O	O

To	O	O
prove	O	O
,	O	O
whether	O	O
Ribavirin	T	O
has	O	O
any	O	O
additional	O	O
effect	O	O
on	O	O
the	O	O
decline	O	O
of	O	O
hepatitis	D	D
C	D	O
viremia	D	O
during	O	O
the	O	O
first	O	O
weeks	O	O
of	O	O
treatment	O	T
patients	O	O
with	O	O
and	O	O
without	O	O
combination	O	T
therapy	O	T
were	O	O
compared	O	O

In	O	O
patients	O	O
with	O	O
combination	T	T
therapy	T	T
,	O	O
a	O	O
further	O	O
reduction	O	O
of	O	O
viremia	D	O
level	O	O
could	O	O
be	O	O
observed	O	O
,	O	O
whereas	O	O
viremia	O	O
levels	O	O
in	O	O
patients	O	O
with	O	O
IFN	O	O
alpha	O	O
alone	O	O
slightly	O	O
increased	O	O

Ribavirin	T	O
in	T	O
combination	T	O
with	T	O
IFN	T	O
alpha	T	O
exerts	O	O
an	O	O
additional	O	O
anti-viral/immunmodulatory	O	O
effect	O	O
which	O	O
manifests	O	O
itself	O	O
in	O	O
phase	O	O
2	O	O
of	O	O
hepatitis	D	D
C	D	O
viremia	D	O
decline	O	O

Surgical	T	T
clearance	T	O
of	O	O
CBD	D	O
stones	D	O
was	O	O
achieved	O	O
in	O	O
58	O	O
patients	O	O
(	O	O
93.5	O	O
%	O	O
;	O	O
group	O	O
Ia	O	O
)	O	O

Use	O	O
of	O	O
ES	T	O
to	O	O
treat	O	O
CBD	D	O
stones	D	O
on	O	O
a	O	O
routine	O	O
basis	O	O
was	O	O
therefore	O	O
not	O	O
found	O	O
to	O	O
be	O	O
any	O	O
better	O	O
than	O	O
one-time	O	O
surgical	O	T
exploration	O	O

Effect	O	O
of	O	O
cholecystectomy	T	O
on	O	O
gastroesophageal	D	O
and	D	O
duodenogastric	D	O
reflux	D	O

It	O	O
is	O	O
suggested	O	O
that	O	O
damaged	D	O
mucosal	D	O
tissues	D	O
with	O	O
AHF	T	O
can	O	O
be	O	O
effectively	O	O
compensated	O	O
by	O	O
enhanced	O	O
regeneration	O	O
response	O	O
due	O	O
to	O	O
an	O	O
adequately	O	O
high	O	O
dose	O	O
intensity	O	O
,	O	O
suggesting	O	O
a	O	O
possible	O	O
tolerability	O	O
advantage	O	O
for	O	O
AHF	O	O

Minimally	O	O
invasive	O	O
treatment	O	O
of	O	O
abscesses	D	O
by	O	O
CT-controlled	T	O
drainage	T	O
with	T	O
a	T	O
basket	T	O
catheter	T	O
system	T	O

PL	T	O
granule	T	O
is	O	O
one	O	O
of	O	O
the	O	O
most	O	O
common	O	O
forms	O	O
of	O	O
composite	O	O
medicine	O	O
for	O	O
colds	D	O
in	O	O
Japan	O	O
,	O	O
including	O	O
acetaminophen	O	O

A	O	O
72-year	O	O
old	O	O
man	O	O
who	O	O
had	O	O
been	O	O
prescribed	O	O
amiodarone	T	O
for	O	O
more	O	O
than	O	O
one	O	O
year	O	O
before	O	O
for	O	O
arrhythmogenic	D	O
right	D	O
ventricular	D	O
dystrophy	D	O
,	O	O
repeatedly	O	O
took	O	O
PL	O	O
granules	O	O
at	O	O
one-week	O	O
intervals	O	O
because	O	O
of	O	O
sneezing	O	O
and	O	O
fever	O	D

He	O	O
needed	O	O
mechanical	T	O
ventilation	T	O
for	O	O
severe	D	D
hypoxemia	D	O
,	O	O
but	O	O
recovered	O	O
with	O	O
glucocorticoid	T	T
pulse	T	T
therapy	T	T

In	O	O
a	O	O
follow-up	O	O
study	O	O
operative	O	O
risk	O	O
,	O	O
postoperative	O	D
functional	O	D
disorders	O	D
and	O	O
incidence	O	O
of	O	O
anastomotic	O	D
(	O	D
recurrent	O	D
)	O	D
ulcer	O	D
after	O	O
partial	T	O
gastrectomy	T	O
with	T	O
Roux-en-Y	T	O
gastrojejunostomy	T	O
for	O	O
gastroduodenal	D	D
ulcer	D	D
were	O	O
evaluated	O	O
in	O	O
52	O	O
patients	O	O

<	O	O
TO_SEE	O	O
>	O	O
With	O	O
regard	O	O
to	O	O
the	O	O
high	O	O
rate	O	O
of	O	O
recurrent	D	D
ulcer	D	D
Roux-en-Y	T	D
reconstruction	T	D
after	O	O
partial	T	O
gastrectomy	T	O
for	O	O
primary	D	D
ulcer	D	D
surgery	D	T
should	O	O
be	O	O
avoided	O	O
and	O	O
reconstruction	O	O
procedures	O	O
preferred	O	O
,	O	O
which	O	O
guarantee	O	O
duodenogastric	O	O
reflux	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
aim	O	O
of	O	O
these	O	O
studies	O	O
was	O	O
to	O	O
compare	O	O
the	O	O
pharmacokinetics	O	O
of	O	O
inhaled	T	O
fluticasone	T	O
propionate	T	O
(	T	O
FP	T	O
)	T	O
after	O	O
repeated	O	O
administration	O	O
via	O	O
the	O	O
Diskus	O	O
or	O	O
Diskhaler	O	O
dry	O	O
powder	O	O
inhalers	O	O
(	O	O
DPIs	O	O
)	O	O
to	O	O
patients	O	O
with	O	O
mild-to-moderate	D	D
asthma	D	D

CONCLUSION	O	O
:	O	O
In	O	O
patients	O	O
with	O	O
asthma	D	D
receiving	O	T
repeated	T	O
inhaled	T	O
doses	T	O
of	T	O
FP	T	O
,	O	O
the	O	O
systemic	O	O
exposure	O	O
(	O	O
AUC	O	O
)	O	O
after	O	O
inhalation	O	O
from	O	O
the	O	O
Diskus	O	O
was	O	O
similar	O	O
to	O	O
that	O	O
from	O	O
the	O	O
Diskhaler	O	O
,	O	O
with	O	O
no	O	O
difference	O	O
between	O	O
the	O	O
DPIs	O	O
in	O	O
the	O	O
effects	O	O
on	O	O
cortisol	O	O
suppression	O	O

DATA	O	O
SYNTHESIS	O	O
:	O	O
Recently	O	O
,	O	O
an	O	O
expert	O	O
panel	O	O
of	O	O
the	O	O
Centers	O	O
for	O	O
Disease	O	D
Control	O	O
and	O	O
Prevention	O	O
recommended	O	O
use	O	O
of	O	O
only	O	O
three	O	O
of	O	O
16	O	O
systemic	T	D
antibiotics	T	T
approved	O	O
by	O	O
the	O	O
Food	O	O
and	O	O
Drug	O	O
Administration	O	O
for	O	O
treatment	O	O
of	O	O
AOM	D	O
:	O	O
amoxicillin	T	O
,	T	O
cefuroxime	T	O
axetil	T	O
,	T	O
and	T	O
ceftriaxone	T	O

A	O	O
three-step	O	O
treatment	O	O
algorithm	O	O
for	O	O
refractory	D	O
AOM	D	O
that	O	O
employs	O	O
amoxicillin	T	O
,	T	O
trimethoprim/sulfamethoxazole	T	O
(	T	O
TMP/SMX	T	O
)	T	O
,	T	O
or	T	O
high-dose	T	O
amoxicillin/clavulanate	T	O
(	T	O
depending	T	O
on	T	O
the	T	O
prior	T	O
dose	T	O
of	T	O
and	T	O
adherence	T	O
to	T	O
amoxicillin	T	T
therapy	T	T
)	T	O
,	T	O
and	T	O
ceftriaxone	T	O
or	T	O
tympanocentesis	T	O
at	O	O
steps	O	O
1	O	O
,	O	O
2	O	O
,	O	O
and	O	O
3	O	O
,	O	O
respectively	O	O
,	O	O
appears	O	O
rational	O	O
and	O	O
cost-effective	O	O

CONCLUSIONS	O	O
:	O	O
Amoxicillin	T	O
remains	O	O
the	O	O
antibiotic	O	O
of	O	O
choice	O	O
for	O	O
initial	O	O
empiric	O	O
treatment	O	O
of	O	O
AOM	D	O
,	O	O
although	O	O
the	O	O
traditional	O	O
dosage	O	O
should	O	O
be	O	O
increased	O	O
in	O	O
patients	O	O
at	O	O
risk	O	O
for	O	O
drug-resistant	O	O
S.	O	O
pneumoniae	O	O

We	O	O
support	O	O
the	O	O
use	O	O
of	O	O
conjugate	T	O
pneumococcal	T	O
vaccine	T	O
per	O	O
guidelines	O	O
for	O	O
prevention	O	O
of	O	O
Raom	D	O
from	O	O
the	O	O
Advisory	O	O
Committee	O	O
on	O	O
Immunization	O	O
Practice	O	O
of	O	O
the	O	O
Centers	O	O
for	O	O
Disease	O	D
Control	O	O
and	O	O
Prevention	O	O
,	O	O
with	O	O
consideration	O	O
given	O	O
to	O	O
influenza	D	O
vaccine	T	O
for	O	O
cases	O	O
of	O	O
rAOM	O	O
that	O	O
historically	O	O
worsen	O	O
during	O	O
the	O	O
flu	O	O
season	O	O

This	O	O
model	O	O
can	O	O
be	O	O
used	O	O
to	O	O
test	O	O
the	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
liver-assist	T	O
devices	T	O
aimed	O	O
at	O	O
temporizing	O	O
the	O	O
detoxification	O	O
functions	O	O
of	O	O
the	O	O
failing	D	O
liver	D	D

Recent	O	O
major	O	O
epidemiologic	O	O
trends	O	O
in	O	O
bacterial	O	O
meningitis	O	O
include	O	O
a	O	O
dramatic	O	O
decline	O	O
in	O	O
the	O	O
incidence	O	O
of	O	O
Haemophilus	D	O
influenzae	D	O
meningitis	D	O
since	O	O
the	O	O
introduction	O	O
of	O	O
the	O	O
protein-conjugated	T	O
H.	T	O
influenzae	T	O
vaccines	T	O
,	O	O
and	O	O
a	O	O
worldwide	O	O
increase	O	O
in	O	O
infections	O	D
with	O	O
antibiotic-resistant	O	D
strains	O	D
of	O	O
bacterial	O	D
pathogens	O	O

dverse	O	O
outcomes	O	O
and	O	O
opioid	T	T
analgesic	T	T
administration	T	O
in	O	O
acute	D	D
abdominal	D	D
pain	D	D

We	O	O
examined	O	O
the	O	O
remnant	O	O
stomach	O	O
for	O	O
H.	O	D
pylori	O	D
infection	O	D
after	O	O
gastrectomy	T	D
for	O	O
gastric	D	D
cancer	D	D
or	D	O
peptic	D	D
ulcer	D	D
between	O	O
October	O	O
1992	O	O
and	O	O
July	O	O
1997	O	O

The	O	O
recent	O	O
introduction	O	O
of	O	O
ribavirin	T	O
,	O	O
given	O	O
in	O	O
combination	O	O
,	O	O
has	O	O
led	O	O
to	O	O
a	O	O
re-appraisal	O	O
of	O	O
the	O	O
management	O	O
of	O	O
chronic	D	D
hepatitis	D	D
C	D	D

The	O	O
current	O	O
report	O	O
considers	O	O
the	O	O
additional	O	O
benefit	O	O
of	O	O
combination	T	T
therapy	T	T
(	T	O
interferon	T	T
alfa	T	O
and	T	O
ribavirin	T	O
)	T	O
compared	O	O
with	O	O
monotherapy	O	T
(	O	T
interferon	O	T
alfa	O	O
alone	O	O
)	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
patients	O	O
with	O	O
chronic	D	D
hepatitis	D	D
C	D	D

OBJECTIVE	O	O
:	O	O
To	O	O
review	O	O
the	O	O
clinical	O	O
effectiveness	O	O
and	O	O
cost-effectiveness	O	O
of	O	O
combination	T	T
therapy	T	T
with	T	O
interferon	T	T
alfa	T	T
and	T	O
ribavirin	T	O
in	O	O
patients	O	O
with	O	O
chronic	D	D
hepatitis	D	D
C	D	D

Sida	T	O
cordifolia	T	O
L.	T	O
(	T	O
Malvaceae	T	O
)	T	O
is	O	O
used	O	O
in	O	O
folk	O	O
medicine	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
inflammation	D	D
of	D	O
the	D	O
oral	D	O
mucosa	D	O
,	D	O
blenorrhea	D	O
,	D	O
asthmatic	D	O
bronchitis	D	O
and	D	O
nasal	D	O
congestion	D	O

Double-blind	O	O
placebo-controlled	O	O
trial	O	O
of	O	O
Mycobacterium	T	O
vaccae	T	D
immunotherapy	T	D
for	O	O
tuberculosis	D	D
in	O	O
KwaZulu	O	O
,	O	O
South	O	O
Africa	O	O
,	O	O
1991-97	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
efficacy	O	O
of	O	O
oral	T	T
tacrolimus	T	O
as	O	O
an	O	O
induction	O	O
agent	O	O
in	O	O
steroid-refractory	D	O
severe	D	D
colitis	D	O
.Study	O	O
design	O	O
:	O	O
Open-label	O	O
,	O	O
multicenter	O	O
trial	O	O
of	O	O
oral	O	T
tacrolimus	O	O
in	O	O
patients	O	O
with	O	O
severe	O	D
colitis	O	D

CONCLUSION	O	O
:	O	O
Although	O	O
tacrolimus	T	O
is	O	O
effective	O	O
induction	O	T
therapy	O	T
for	O	O
severe	D	D
ulcerative	D	D
or	D	O
Crohn	D	D
's	D	O
colitis	D	O
,	O	O
fewer	O	O
than	O	O
50	O	O
%	O	O
of	O	O
patients	O	O
treated	O	O
will	O	O
successfully	O	O
achieve	O	O
a	O	O
long-term	O	O
remission	O	O

Cytomegalovirus	D	O
(	D	O
CMV	D	D
)	D	D
infection	D	D
was	O	O
one	O	O
of	O	O
the	O	O
most	O	O
common	O	O
opportunistic	O	D
infections	O	D
in	O	O
AIDS	O	D
patients	O	O
,	O	O
leading	O	O
to	O	O
blindness	O	O
or	O	O
life-threatening	O	D
disease	O	D
in	O	O
about	O	O
40	O	O
%	O	O
of	O	O
patients	O	O
in	O	O
the	O	O
later	O	O
stages	O	O
of	O	O
AIDS	O	D
before	O	O
highly	T	O
active	T	O
antiretroviral	T	T
therapy	T	T
(	T	O
HAART	T	O
)	T	O

New	T	O
vaccines	T	O
are	O	O
under	O	O
study	O	O
to	O	O
further	O	O
control	O	O
bacterial	D	O
meningitis	D	O

The	O	O
study	O	O
involved	O	O
117	O	O
infants	O	O
(	O	O
mean	O	O
age	O	O
2.6	O	O
months	O	O
)	O	O
,	O	O
who	O	O
needed	O	O
hospital	T	O
treatment	T	O
because	O	O
of	O	O
RSV	D	O
bronchiolitis	D	O

According	O	O
to	O	O
the	O	O
present	O	O
study	O	O
it	O	O
seems	O	O
that	O	O
inhaled	T	O
corticosteroid	T	T
treatment	T	T
during	O	O
and	O	O
after	O	O
the	O	O
acute	O	O
phase	O	O
of	O	O
infant	D	O
RSV	D	O
bronchiolitis	D	O
may	O	O
have	O	O
a	O	O
beneficial	O	O
effect	O	O
on	O	O
subsequent	O	O
bronchial	O	O
wheezing	O	O
tendency	O	O

OBJECTIVE	O	O
:	O	O
This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
evaluate	O	O
the	O	O
safety	O	O
and	O	O
estimate	O	O
the	O	O
efficacy	O	O
of	O	O
oral	T	T
budesonide	T	O
in	O	O
patients	O	O
with	O	O
primary	D	O
sclerosing	D	O
cholangitis	D	O
(	D	O
PSC	D	O
)	D	O

Combined	T	O
interferon	T	T
and	T	O
lamivudine	T	T
therapy	T	T
:	O	O
is	O	O
this	O	O
the	O	O
treatment	O	O
of	O	O
choice	O	O
for	O	O
patients	O	O
with	O	O
chronic	D	D
hepatitis	D	D
B	D	D
virus	D	D
infection	D	D
?	O	O

She	O	O
had	O	O
been	O	O
taking	O	O
amitriptyline	T	O
75	O	O
mg	O	O
at	O	O
night	O	O
for	O	O
depression	D	O
for	O	O
four	O	O
months	O	O
before	O	O
her	O	O
admission	O	O

Side	O	O
effects	O	O
from	O	O
influenza	D	O
vaccination	T	O
:	O	O
differences	O	O
between	O	O
returned	O	O
and	O	O
random	O	O
surveys	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
study	O	O
the	O	O
relationship	O	O
between	O	O
interleukin-2	O	O
(	O	O
IL-2	O	O
)	O	O
,	O	O
soluble	O	O
interleukin-2	O	O
receptor	O	O
(	O	O
sIL-2R	O	O
)	O	O
and	O	O
the	O	O
non-and-hypo-responsiveness	O	O
to	O	O
hepatitis	D	D
B	D	O
vaccine	T	O

We	O	O
assessed	O	O
the	O	O
effects	O	O
of	O	O
early	T	O
replacement	T	T
therapy	T	T
with	T	O
protein-C	T	O
concentrate	T	O
together	T	O
with	T	O
continuous	T	O
veno-venous	T	O
haemodiafiltration	T	O
and	O	O
conventional	O	O
treatment	O	O
in	O	O
meningococcaemia	D	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
if	O	O
topical	T	O
DL-alpha-tocopherol	T	O
(	T	O
vitamin	T	O
E	T	O
)	T	O
could	O	O
reduce	O	O
ultraviolet-induced	D	O
damage	D	O
to	D	O
the	D	O
epidermis	D	O

We	O	O
observed	O	O
the	O	O
effects	O	O
of	O	O
cisapride	T	O
in	O	O
the	O	O
management	O	O
of	O	O
idiopathic	D	O
constipation	D	O
in	O	O
children	O	O

METHODS	O	O
:	O	O
Thirty-seven	O	O
children	O	O
with	O	O
a	O	O
history	O	O
of	O	O
constipation	D	O
(	O	O
i.e	O	O
.	O	O
,	O	O
pain	O	O
and	O	O
difficulty	O	O
or	O	O
delay	O	O
in	O	O
defecation	O	O
for	O	O
>	O	O
3	O	O
months	O	O
)	O	O
were	O	O
recruited	O	O
and	O	O
randomly	O	O
assigned	O	O
to	O	O
8	O	O
weeks	O	O
of	O	O
treatment	O	O
with	O	O
either	O	O
cisapride	T	O
,	O	O
0.2	O	O
mg/kg	O	O
three	O	O
times	O	O
daily	O	O
,	O	O
or	O	O
matching	O	O
placebo	O	O
after	O	O
a	O	O
2-week	O	O
run-in	O	O
period	O	O
in	O	O
a	O	O
double-blind	O	O
,	O	O
parallel-group	O	O
study	O	O
design	O	O

Patient	O	O
1	O	O
demonstrated	O	O
dramatic	O	O
clearing	O	O
of	O	O
his	O	O
MCV	D	D
lesions	D	D
when	O	O
intravenous	T	O
cidofovir	T	T
therapy	T	T
was	O	O
started	O	O
for	O	O
his	O	O
treatment-resistant	D	O
bilateral	D	O
CMV	D	O
retinitis	D	O
and	O	O
because	O	O
of	O	O
cidofovir	T	O
's	T	O
possible	O	O
activity	O	O
against	O	O
MCV	D	O

In	O	O
case	O	O
2	O	O
,	O	O
cidofovir	T	O
was	O	O
compounded	O	O
as	O	O
a	O	O
3	O	O
%	O	O
cream	O	O
in	O	O
a	O	O
combination	O	O
vehicle	O	O
(	O	O
Dermovan	O	O
)	O	O
for	O	O
extensive	O	O
facial	O	O
involvement	O	O
,	O	O
and	O	O
complete	O	O
resolution	O	O
of	O	O
MCV	D	O
was	O	O
seen	O	O
after	O	O
1	O	O
month	O	O
of	O	O
therapy	O	T

In	O	O
case	O	O
3	O	O
,	O	O
intravenous	T	O
cidofovir	T	T
therapy	T	T
was	O	O
started	O	O
both	O	O
for	O	O
CMV	D	O
retinitis	D	O
and	O	O
in	O	O
an	O	O
attempt	O	O
to	O	O
clear	O	O
90	O	O
%	O	O
facial	O	O
MCV	D	O
involvement	O	O
;	O	O
after	O	O
1	O	O
month	O	O
of	O	O
treatment	O	O
,	O	O
all	O	O
clinical	O	O
evidence	O	O
of	O	O
MCV	D	O
had	O	O
resolved	O	O

CONCLUSIONS	O	O
:	O	O
Cidofovir	T	O
,	O	O
a	O	O
nucleotide	O	O
analog	O	O
of	O	O
deoxycytidine	O	O
monophosphate	O	O
,	O	O
appears	O	O
to	O	O
have	O	O
contributed	O	O
to	O	O
clearing	O	O
of	O	O
advanced	D	O
MCV	D	D
lesions	D	D
in	O	O
these	O	O
3	O	O
patients	O	O
,	O	O
thus	O	O
providing	O	O
suggestive	O	O
evidence	O	O
of	O	O
clinical	O	O
activity	O	O
against	O	O
MCV	D	O

Controlled	O	O
trials	O	O
of	O	O
cidofovir	T	T
therapy	T	T
for	O	O
MCV	D	O
in	O	O
persons	O	O
infected	O	O
with	O	O
human	O	O
immunodeficiency	O	D
virus	O	D
are	O	O
warranted	O	O

OBJECTIVE	O	O
:	O	O
This	O	O
study	O	O
aimed	O	O
to	O	O
determine	O	O
the	O	O
effect	O	O
of	O	O
external	T	O
beam	T	O
radiation	T	O
therapy	T	T
on	O	O
choroidal	D	O
neovascularization	D	O
(	D	O
CNV	D	O
)	D	O
secondary	O	O
to	O	O
age-related	D	O
macular	D	O
degeneration	D	O
(	D	O
AMD	D	O
)	D	O

Thrombolytic	T	T
therapy	T	T
has	O	O
been	O	O
accepted	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
acute	D	D
myocardial	D	D
infarction	D	D

A	O	O
bolus	O	O
infusion	O	O
of	O	O
tissue	T	O
plasminogen	T	T
activator	T	T
was	O	O
administered	O	O
during	O	O
CPR	T	O
in	O	O
refractory	D	O
ventricular	D	O
fibrillation	D	O
(	O	O
two	O	O
cases	O	O
)	O	O
and	O	O
pulseless	D	O
ventricular	D	O
tachycardia	D	O
(	O	O
one	O	O
case	O	O
)	O	O

We	O	O
conclude	O	O
that	O	O
bolus	T	T
thrombolytic	T	T
infusions	T	O
during	O	O
CPR	D	O
may	O	O
facilitate	O	O
spontaneous	O	O
return	O	O
of	O	O
circulation	O	O
in	O	O
select	O	O
patients	O	O
with	O	O
confirmed	D	D
acute	D	D
myocardial	D	D
infarction	D	D
,	O	D
witnessed	O	D
cardiac	D	D
arrest	D	O
in	O	O
the	O	O
ED	O	O
,	O	O
and	O	O
refractory	D	O
ventricular	D	O
fibrillation	D	O
or	O	O
tachycardia	D	O

<	O	O
TO_SEE	O	O
>	O	O
CASE	O	O
SUMMARY	O	O
:	O	O
A	O	O
92-year	O	O
old	O	O
white	O	O
woman	O	O
who	O	O
was	O	O
receiving	O	O
venlafaxine	T	O
for	O	O
management	O	O
of	O	O
depression	D	D
was	O	O
found	O	O
to	O	O
have	O	O
hyponatremia	O	O

Touch	O	O
sensibility	O	O
was	O	O
assessed	O	O
with	O	O
von	O	O
Frey	O	O
's	O	O
monofilaments	O	O
in	O	O
the	O	O
breasts	O	O
of	O	O
10	O	O
healthy	O	O
women	O	O
(	O	O
controls	O	O
)	O	O
and	O	O
of	O	O
80	O	O
women	O	O
with	O	O
breast	D	D
cancer	D	D
who	O	O
at	O	O
least	O	O
1	O	O
year	O	O
previously	O	O
had	O	O
undergone	O	O
subcutaneous	T	O
mastectomy	T	O
and	O	O
immediate	O	O
reconstruction	O	O
with	O	O
a	O	O
prosthesis	O	O

Although	O	O
improved	O	O
glycemic	T	O
control	T	O
,	O	O
maintenance	O	O
of	O	O
normal	O	O
blood	O	O
pressure	O	O
,	O	O
and	O	O
use	O	O
of	O	O
angiotensin-converting	T	O
enzyme	T	O
inhibitors	T	O
are	O	O
important	O	O
strategies	O	O
to	O	O
avoid	O	O
developing	O	O
microalbuminuria	D	O
,	O	O
dietary	O	O
macronutrient	O	O
intake	O	O
may	O	O
also	O	O
play	O	O
a	O	O
role	O	O

Local	O	O
injection	O	O
of	O	O
corticosteroids	T	O
into	O	O
refractory	O	O
esophageal	O	O
strictures	O	O
to	O	O
decrease	O	O
the	O	O
restenosis	D	O
rate	O	O
has	O	O
been	O	O
reported	O	O

We	O	O
systematically	O	O
reviewed	O	O
the	O	O
evidence	O	O
concerning	O	O
the	O	O
ability	O	O
of	O	O
five	O	O
systemic	T	O
treatments	T	O
to	O	O
induce	O	O
remission	O	O
in	O	O
patients	O	O
with	O	O
severe	D	D
psoriasis	D	O
:	O	O
ultraviolet	T	O
B	T	O
(	T	O
UVB	T	O
)	T	O
,	O	O
photochemotherapy	T	O
(	T	O
PUVA	T	O
)	T	O
,	O	O
methotrexate	T	O
(	T	O
MTX	T	O
)	T	O
,	O	O
retinoids	T	O
(	T	O
RET	T	O
)	T	O
and	O	O
cyclosporin	T	O
A	T	O
(	T	O
CYA	T	O
)	T	O

Consequently	O	O
,	O	O
parenteral	T	O
nutrition	T	O
(	T	O
PN	T	O
)	T	O
solutions	T	O
used	O	O
to	O	O
treat	O	O
malnourished	O	D
patients	O	O
with	O	O
chronic	D	D
renal	D	D
failure	D	D
usually	O	O
are	O	O
prepared	O	O
with	O	O
little	O	O
supplementation	O	O
of	O	O
these	O	O
cations	O	O

<	O	O
TO_SEE	O	O
>	O	O
CONCLUSIONS	O	O
:	O	O
Malnourished	O	O
patients	O	O
with	O	O
chronic	D	D
renal	D	D
failure	D	D
receiving	O	O
PN	T	O
are	O	O
at	O	O
risk	O	O
of	O	O
developing	O	O
electrolyte	D	D
abnormalities	D	O
,	O	O
particularly	O	O
hypophosphatemia	D	O

PURPOSE	O	O
:	O	O
We	O	O
report	O	O
a	O	O
multicenter	O	O
experience	O	O
using	O	O
tubularized	T	O
incised	T	O
plate	T	O
urethroplastym	T	O
for	O	O
proximal	D	O
hypospadias	D	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
From	O	O
August	O	O
1993	O	O
to	O	O
December	O	O
1996	O	O
tubularized	T	O
incised	T	O
plate	T	O
urethroplasty	T	O
was	O	O
performed	O	O
in	O	O
27	O	O
boys	O	O
6	O	O
months	O	O
to	O	O
3	O	O
years	O	O
old	O	O
with	O	O
mid	D	O
shaft	D	O
and	D	O
penoscrotal	D	O
hypospadias	D	O

RESULTS	O	O
:	O	O
Tubularized	T	O
incised	T	O
plate	T	O
surgery	T	T
created	O	O
a	O	O
functional	O	O
neourethra	O	O
even	O	O
in	O	O
penoscrotal	D	O
hypospadias	D	O

CONCLUSIONS	O	O
:	O	O
Tubularized	T	O
incised	T	O
plate	T	O
urethroplasty	T	O
is	O	O
a	O	O
versatile	O	O
operation	O	O
that	O	O
corrects	O	O
proximal	D	D
hypospadias	D	D
defects	D	D
with	O	O
few	O	O
complications	O	O
and	O	O
superior	O	O
cosmetic	O	O
results	O	O

Aortocoronary	T	O
bypass	T	T
grafting	T	T
is	O	O
an	O	O
accepted	O	O
procedure	O	O
for	O	O
ischemic	D	D
heart	D	D
disease	D	D

Immunotherapy	T	O
of	O	O
mice	O	O
with	O	O
preexisting	O	D
cancers	D	D
with	O	O
heat	T	O
shock	T	O
protein	T	O
preparations	T	O
derived	T	O
from	T	O
autologous	T	D
cancer	T	D
resulted	O	O
in	O	O
retarded	O	O
progression	O	O
of	O	O
the	O	O
primary	O	D
cancer	D	D
,	O	O
a	O	O
reduced	O	O
metastatic	O	D
load	O	O
,	O	O
and	O	O
prolongation	O	O
of	O	O
life-span	O	O

<	O	O
TO_SEE	O	O
>	O	O
Intrapleural	T	O
injection	T	O
of	T	O
irradiated	T	O
LLC-IL2	T	D
cured	O	D
pre-existing	D	D
lung	D	D
LLC	D	D
tumors	D	D
and	O	O
extended	O	O
the	O	O
survival	O	O
of	O	O
the	O	O
mice	O	O
but	O	O
did	O	O
not	O	O
affect	O	O
survival	O	O
of	O	O
mice	O	O
with	O	O
pre-existing	O	D
peritoneal	D	D
tumors	D	D
nor	O	O
did	O	O
it	O	O
affect	O	O
the	O	O
growth	O	O
of	O	O
s.c.	D	D
tumors	D	D

<	O	O
TO_SEE	O	O
>	O	O
Intraperitoneal	T	O
injection	T	O
of	T	O
irradiated	T	O
LLC-IL2	T	O
cured	O	D
pre-existing	D	D
LLC	D	D
peritoneal	D	D
tumors	D	D
and	O	O
extended	O	O
the	O	O
survival	O	O
of	O	O
the	O	O
mice	O	O
but	O	O
did	O	O
not	O	O
affect	O	O
survival	O	O
of	O	O
mice	O	D
bearing	O	D
lung	D	D
tumors	D	D
nor	O	O
did	O	O
it	O	O
affect	O	O
the	O	O
growth	O	O
of	O	O
s.c.	D	D
tumors	D	D

Subcutaneous	T	O
injection	T	O
of	T	O
irradiated	T	O
LLC-IL2	T	O
did	O	O
not	O	O
affect	O	O
the	O	O
growth	O	O
of	O	O
preexisting	O	D
s.c.	D	D
tumors	D	D
and	O	O
also	O	O
did	O	O
not	O	O
improve	O	O
survival	O	O
of	O	O
mice	O	O
bearing	O	O
the	O	O
lung	D	D
or	D	O
peritoneal	D	D
tumors	D	D

We	O	O
describe	O	O
such	O	O
an	O	O
event	O	O
in	O	O
a	O	O
man	O	O
who	O	O
underwent	O	O
allogeneic	T	O
BMT	T	O
for	O	O
APL	D	O
in	O	O
second	O	O
relapse	O	O
and	O	O
4	O	O
years	O	O
later	O	O
presented	O	O
with	O	O
testicular	O	D
relapse	O	D

Olanzapine	T	O
is	O	O
an	O	O
atypical	O	O
antipsychotic	O	O
effective	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
schizophrenic	D	D
patients	D	O

After	O	O
a	O	O
2-	O	O
to	O	O
9-day	O	O
placebo	O	O
lead-in	O	O
,	O	O
79	O	O
inpatients	O	O
with	O	O
schizophrenia	D	D
according	O	O
to	O	O
DSM-III-R	O	O
criteria	O	O
were	O	O
placed	O	O
on	O	O
an	O	O
olanzapine	T	O
dosage	O	O
of	O	O
10	O	O
mg/day	O	O
or	O	O
1	O	O
mg/day	O	O
for	O	O
up	O	O
to	O	O
6	O	O
weeks	O	O

Fludarabine	T	O
and	O	O
ara-C	T	O
successfully	O	D
eradicated	O	D
bone	D	D
marrow	D	D
disease	D	D
in	O	O
16	O	O
of	O	O
27	O	O
patients	O	O
(	O	O
59	O	O
%	O	O
)	O	O
,	O	O
23	O	O
patients	O	O
of	O	O
which	O	O
had	O	O
been	O	O
treated	O	O
previously	O	O
with	O	O
high-dose	O	O
ara-C	T	O

These	O	O
results	O	O
verified	O	O
the	O	O
synergistic	O	O
effect	O	O
fludarabine	T	O
exhibited	O	O
in	O	O
augmenting	O	O
ara-CTP	T	O
concentrations	O	O
in	O	O
patients	O	O
'	O	O
leukemic	O	O
blasts	O	O
,	O	O
thus	O	O
improving	O	O
the	O	O
clinical	O	O
response	O	O
in	O	O
relapsed	D	O
pediatric	D	O
leukemias	D	O

BACKGROUND	O	O
:	O	O
The	O	O
growing	O	O
use	O	O
of	O	O
heparin	T	T
in	O	O
acute	D	D
thrombotic	D	D
disorders	D	D
,	O	O
coupled	O	O
with	O	O
the	O	O
availability	O	O
of	O	O
many	O	O
new	O	O
antithrombotic	T	O
agents	T	O
,	O	O
emphasizes	O	O
the	O	O
need	O	O
for	O	O
adequate	O	O
characterization	O	O
of	O	O
the	O	O
platelet	O	O
effects	O	O
of	O	O
the	O	O
various	O	O
anticoagulants	T	O

METHODS	O	O
AND	O	O
RESULTS	O	O
:	O	O
Platelet	O	O
P-selectin	O	O
(	O	O
CD62	O	O
)	O	O
and	O	O
activated	O	O
GP	O	O
IIb/IIIa	O	O
(	O	O
PAC-1	O	O
)	O	O
expression	O	O
on	O	O
platelet	O	O
membrane	O	O
was	O	O
quantified	O	O
in	O	O
whole	O	O
blood	O	O
as	O	O
well	O	O
as	O	O
platelet	O	O
aggregation	O	O
in	O	O
platelet-rich	O	O
plasma	O	O
in	O	O
43	O	O
patients	O	O
with	O	O
unstable	D	D
angina	D	D
before	O	O
and	O	O
during	O	O
treatment	O	O
with	O	O
UFH	T	O
or	O	O
enoxaparin	T	O

PURPOSE	O	O
:	O	O
We	O	O
review	O	O
our	O	O
initial	O	O
experience	O	O
with	O	O
direct	T	O
percutaneous	T	O
transluminal	T	O
angioplasty	T	O
(	T	O
PTA	T	O
)	T	O
as	O	O
a	O	O
reperfusion	T	O
treatment	T	T
for	O	O
acute	D	D
occlusion	D	D
of	D	O
the	D	O
middle	D	D
cerebral	D	D
artery	D	D

<	O	O
TO_SEE	O	O
>	O	O
CONCLUSION	O	O
:	O	O
Direct	O	O
PTA	O	O
may	O	O
be	O	O
performed	O	O
safely	O	O
as	O	O
an	O	O
alternative	O	O
to	O	O
thrombolytic	O	T
therapy	O	T
in	O	O
patients	O	O
with	O	O
acute	O	D
occlusion	O	D
of	O	O
the	O	O
middle	O	D
cerebral	O	D
artery	O	D
when	O	O
early	O	O
CT	O	O
findings	O	O
and/or	O	O
lenticulostriate	O	O
artery	O	O
involvement	O	O
are	O	O
present	O	O
or	O	O
when	O	O
superselective	O	O
local	O	O
angiography	O	O
shows	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
large	O	O
embolus	O	O
or	O	O
high-grade	O	O
stenosis	O	O

Women	O	O
randomised	O	O
to	O	O
screen-and-treat	O	O
received	O	O
appropriate	O	O
antibiotics	T	T
only	O	O
if	O	O
screening	O	O
proved	O	O
positive	O	O
for	O	O
one	O	O
or	O	O
more	O	O
infection	D	D

<	O	O
TO_SEE	O	O
>	O	O
A	O	O
71-year-old	O	O
woman	O	O
with	O	O
autoimmune	O	D
hemolytic	O	D
anemia	O	D
underwent	O	T
an	O	O
emergency	O	O
endocardial	T	O
patch	T	T
repair	T	T
for	O	O
ventricular	D	D
septal	D	D
perforation	D	D
after	O	D
acute	O	D
myocardial	O	D
infarction	O	D

Use	O	O
of	O	O
washed	T	O
red	T	O
blood	T	O
cells	T	O
was	O	O
effective	O	O
in	O	O
averting	O	O
hemolytic	D	O
crisis	D	O
throughout	O	O
perioperative	O	O
period	O	O

Therefore	O	O
,	O	O
prudent	O	O
management	O	O
and	O	O
use	O	O
of	O	O
washed	T	O
red	T	O
blood	T	O
cells	T	O
transfusion	T	O
would	O	O
prevent	O	O
hemolytic	D	O
aggravation	D	O
even	O	O
in	O	O
open	O	O
heart	O	D
surgery	O	T

<	O	O
TO_SEE	O	O
>	O	O
We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
a	O	O
29-year-old	O	O
male	O	O
chronic	O	D
HBV	O	D
carrier	O	D
who	O	O
developed	O	O
fulminant	D	D
reactivated	D	D
HBV	D	D
infection	D	D
following	O	O
intensive	O	T
chemotherapy	T	T
for	O	O
stage	D	O
IVB	D	O
large	D	O
cell	D	D
B-cell	D	D
non-Hodgkin	D	D
's	D	D
lymphoma	D	D
associated	O	O
with	O	O
extensive	O	O
central	O	O
nervous	O	O
system	O	O
and	O	O
bone	O	O
marrow	O	O
involvement	O	O

We	O	O
advise	O	O
that	O	O
lamivudine	T	O
should	O	O
be	O	O
considered	O	O
during	O	O
intensive	O	O
chemotherapy	T	T
treatment	T	T
of	O	O
chronic	O	D
carriers	O	O
of	O	O
HBV	D	O

OBJECTIVES	O	O
:	O	O
The	O	O
purpose	O	O
of	O	O
this	O	O
analysis	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
influence	O	O
of	O	O
an	O	O
additional	O	O
treatment	O	O
delay	O	O
inherent	O	O
in	O	O
transfer	O	O
to	O	O
an	O	O
angioplasty	O	O
center	O	O
for	O	O
primary	T	O
angioplasty	T	O
of	O	O
patients	O	O
with	O	D
acute	D	D
myocardial	D	D
infarction	D	D
who	O	O
are	O	O
first	O	O
admitted	O	O
to	O	O
hospitals	O	O
without	O	O
angioplasty	O	O
facilities	O	O

BACKGROUND	O	O
:	O	O
Several	O	O
randomized	O	O
trials	O	O
have	O	O
demonstrated	O	O
the	O	O
benefits	O	O
of	O	O
primary	T	D
angioplasty	T	D
in	O	O
acute	D	D
myocardial	D	D
infarction	D	D

We	O	O
report	O	O
the	O	O
first	O	O
case	O	O
(	O	O
to	O	O
our	O	O
knowledge	O	O
)	O	O
of	O	O
an	O	O
endoscopic	T	O
removal	T	O
of	O	O
a	O	O
forehead	D	O
soft	D	O
tissue	D	O
mass	D	O

As	O	O
the	O	O
overview	O	O
shows	O	O
,	O	O
both	O	O
groups	O	O
of	O	O
substances	O	O
are	O	O
useful	O	O
for	O	O
individualized	O	O
treatment	O	O
of	O	O
benign	D	O
prostatic	D	D
hyperplasia	D	D
(	D	O
BPH	D	O
)	D	O
,	O	O
provided	O	O
that	O	O
conservative	O	O
pharmacological	T	O
treatment	T	O
of	O	O
BPH	D	O
is	O	O
basically	O	O
accepted	O	O
and	O	O
that	O	O
the	O	O
patients	O	O
'	O	O
quality	O	O
of	O	O
life	O	O
is	O	O
also	O	O
considered	O	O

The	O	O
results	O	O
of	O	O
several	O	O
clinical	O	O
investigations	O	O
showed	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
artichoke	T	O
extracts	T	O
(	T	O
Cynara	T	O
scolymus	T	O
L.	T	O
)	T	O
in	O	O
the	O	O
treatment	O	O
of	O	O
hepato-biliary	D	D
dysfunction	D	D
and	D	O
digestive	D	O
complaints	D	O
,	O	O
such	O	O
as	O	O
sensation	O	O
of	O	O
fullness	O	O
,	O	O
loss	D	O
of	D	O
appetite	D	O
,	O	O
nausea	D	O
and	O	O
abdominal	D	D
pain	D	D

Besides	O	O
the	O	O
well-known	O	O
nonsteroidal	T	O
antiinflammatory	T	O
drugs	T	T
(	T	O
NSAID	T	O
)	T	O
for	O	O
the	O	O
treatment	O	O
of	O	O
rheumatic	D	D
pain	D	D
herbal	T	O
medicine	T	O
can	O	O
also	O	O
be	O	O
applied	O	O
successfully	O	O

Extracts	O	O
of	O	O
the	O	O
secondary	O	O
tubers	O	O
of	O	O
Devil	T	O
's	T	O
Claw	T	O
(	T	O
Harpagophytum	T	O
procumbens	T	O
)	T	O
are	O	O
recommended	O	O
for	O	O
the	O	O
supportive	O	O
treatment	O	O
of	O	O
degenerative	D	O
painful	D	O
rheumatism	D	O

High-dose	T	O
intravenous	T	O
immunoglobulin	T	O
(	T	O
hdIVIg	T	O
)	T	O
is	O	O
increasingly	O	O
used	O	O
to	O	O
treat	O	O
a	O	O
range	O	O
of	O	O
inflammatory	D	D
and	D	D
autoimmune	D	D
diseases	D	D

The	O	O
current	O	O
dermatological	O	O
uses	O	O
of	O	O
hdIVIg	T	O
include	O	O
the	O	O
treatment	O	O
of	O	O
dermatomyositis	D	O
and	O	O
the	O	O
autoimmune	D	D
bullous	D	D
disorders	D	D
,	O	O
epidermolysis	D	O
bullosa	D	O
acquisita	D	O
,	O	O
pemphigoid	D	O
,	O	O
and	O	O
pemphigus	D	O

Unfortunately	O	O
,	O	O
current	O	O
dermatological	O	O
uses	O	O
of	O	O
hdIVIg	O	O
have	O	O
been	O	O
limited	O	O
to	O	O
either	O	O
uncontrolled	O	O
trials	O	O
or	O	O
anecdotal	O	O
case	O	O
reports	O	O
,	O	O
except	O	O
for	O	O
a	O	O
single	O	O
controlled	O	O
trial	O	O
of	O	O
hdIVIg	T	O
as	O	O
adjunctive	O	T
therapy	O	T
in	O	O
patients	O	O
with	O	O
dermatomyositis	D	O
,	O	O
which	O	O
documented	O	O
a	O	O
significant	O	O
benefit	O	O

We	O	O
describe	O	O
a	O	O
technique	O	O
that	O	O
enables	O	O
the	O	O
autologous	T	O
repair	T	O
of	O	O
large	D	O
midline	D	O
incisional	D	O
hernias	D	O
by	O	O
restoring	O	O
the	O	O
functional	O	O
musculoaponeurotic	O	O
support	O	O
of	O	O
the	O	O
abdominal	O	D
wall	O	O

OBJECTIVE	O	O
AND	O	O
IMPORTANCE	O	O
:	O	O
The	O	O
use	O	O
of	O	O
chronic	T	D
intrathecal	T	D
morphine	T	O
for	O	O
the	O	O
treatment	O	O
of	O	O
intractable	D	O
,	D	O
nonmalignant	D	D
pain	D	D
is	O	O
becoming	O	O
more	O	O
prevalent	O	O

METHODS	O	O
:	O	O
During	O	O
a	O	O
19-month	O	O
period	O	O
,	O	O
seven	O	O
children	O	O
with	O	O
empyema	D	O
underwent	O	O
thoracoscopy	T	O

<	O	O
TO_SEE	O	O
>	O	O
We	O	O
describe	O	O
a	O	O
patient	O	O
with	O	O
left	D	O
cardiac	D	O
herniation	D	O
presenting	O	O
after	O	O
intrapericardial	T	O
pulmonectomy	T	O
for	O	O
primary	D	D
lung	D	D
cancer	D	D

The	O	O
growing	O	O
use	O	O
of	O	O
automated	T	O
night-time	T	O
dialysis	T	O
(	T	O
APD	T	O
)	T	O
in	O	O
peritoneal	D	O
dialysis	D	O
over	O	O
the	O	O
last	O	O
few	O	O
years	O	O
shows	O	O
that	O	O
this	O	O
method	O	O
represents	O	O
a	O	O
valid	O	O
alternative	O	O
to	O	O
continuous	T	O
ambulatory	T	O
peritoneal	T	O
dialysis	T	O
(	T	O
CAPD	T	O
)	T	O

La	O	O
Serna	O	O
et	O	O
al	O	O
.	O	O
(	O	O
Lancet	O	O
1987	O	O
;	O	O
26	O	O
:	O	O
1517	O	O
)	O	O
were	O	O
the	O	O
first	O	O
to	O	O
treat	O	O
adults	O	O
with	O	O
recurrent	D	D
pericarditis	D	O
with	O	O
colchicine	T	O
,	O	O
and	O	O
were	O	O
followed	O	O
by	O	O
other	O	O
authors	O	O

While	O	O
these	O	O
findings	O	O
are	O	O
observed	O	O
for	O	O
all	O	O
classes	O	O
of	O	O
oral	O	T
drugs	O	T
,	O	O
the	O	O
issue	O	O
is	O	O
especially	O	O
critical	O	O
for	O	O
cancer	D	D
chemotherapy	T	T
,	O	O
in	O	O
which	O	O
a	O	O
narrow	O	O
therapeutic	O	O
index	O	O
is	O	O
frequently	O	O
observed	O	O

Treatment	O	O
for	O	O
low-grade	D	O
NHL	D	O
during	O	O
the	O	O
past	O	O
30	O	O
yr	O	O
has	O	O
consisted	O	O
of	O	O
high-dose	T	O
radiation	T	O
and	O	O
cytotoxic	T	O
agents	T	O
,	O	O
administered	O	O
alone	O	O
or	O	O
in	O	O
combination	O	O
,	O	O
and	O	O
high-dose	T	O
therapy	T	T
with	T	O
stem	T	O
cell	T	O
transplant	T	O

However	O	O
,	O	O
recent	O	O
clinical	O	O
use	O	O
of	O	O
monoclonal	T	O
antibodies	T	O
(	T	O
mAbs	T	O
)	T	O
in	O	O
patients	O	O
with	O	O
low-grade	D	O
or	D	O
transformed	D	O
low-grade	D	O
NHL	D	O
has	O	O
resulted	O	O
in	O	O
less	O	O
toxicity	O	O
than	O	O
conventional	O	O
treatments	O	O
,	O	O
as	O	O
well	O	O
as	O	O
response	O	O
rates	O	O
that	O	O
are	O	O
comparable	O	O
or	O	O
superior	O	O
to	O	O
those	O	O
achieved	O	O
with	O	O
chemotherapy	T	T

Therefore	O	O
,	O	O
interest	O	O
is	O	O
growing	O	O
in	O	O
mAbs	T	O
as	O	O
therapeutic	O	O
alternatives	O	O
for	O	O
patients	O	O
with	O	O
low-grade	D	O
NHL	D	O
and	O	O
those	O	O
with	O	O
transformed	O	O
histology	O	O

CONCLUSION	O	O
:	O	O
The	O	O
treatment	O	O
paradigm	O	O
for	O	O
NHL	D	O
is	O	O
expected	O	O
to	O	O
change	O	O
over	O	O
the	O	O
next	O	O
few	O	O
years	O	O
to	O	O
include	O	O
radiolabeled	T	O
mAbs	T	O
,	O	O
administered	O	O
alone	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
cytotoxic	T	O
agents	T	O

RESULTS	O	O
:	O	O
Clinical	O	O
trials	O	O
of	O	O
UFT	T	O
published	O	O
in	O	O
the	O	O
Western	O	O
world	O	O
have	O	O
included	O	O
581	O	O
patients	O	O
with	O	O
colorectal	D	D
cancer	D	D

The	O	O
activity	O	O
of	O	O
oral	T	O
UFT	T	O
in	O	O
large-bowel	D	D
cancer	D	D
when	O	O
administered	O	O
with	O	O
oral	T	T
LV	T	O
(	O	O
approximately	O	O
50	O	O
mg/dose	O	O
)	O	O
has	O	O
resulted	O	O
in	O	O
objective	O	O
response	O	O
rates	O	O
of	O	O
approximately	O	O
40	O	O
%	O	O

CONCLUSION	O	O
:	O	O
UFT	T	O
is	O	O
a	O	O
fluoropyrimidine	T	O
active	O	O
in	O	O
colorectal	D	D
cancer	D	D

BACKGROUND	O	O
:	O	O
Adrenalectomy	T	O
is	O	O
the	O	O
current	O	O
treatment	O	O
for	O	O
phaeochromocytoma	D	O

CONCLUSION	O	O
:	O	O
Adrenal-sparing	T	O
surgery	T	T
is	O	O
safe	O	O
and	O	O
effective	O	O
,	O	O
and	O	O
may	O	O
become	O	O
the	O	O
treatment	O	O
of	O	O
choice	O	O
in	O	O
patients	O	O
with	O	O
hereditary	D	D
phaeochromocytoma	D	D

<	O	O
TO_SEE	O	O
>	O	O
PURPOSE	O	O
:	O	O
The	O	O
purposes	O	O
of	O	O
this	O	O
descriptive	O	O
,	O	O
longitudinal	O	O
study	O	O
were	O	O
to	O	O
evaluate	O	O
the	O	O
MacDibbs	O	O
Mouth	O	O
Assessment	O	O
instrument	O	O
for	O	O
the	O	O
assessment	O	O
of	O	O
mucositis	O	O
in	O	O
the	O	O
radiation	T	O
therapy	T	T
patient	O	O
being	O	O
treated	O	O
for	O	O
head	D	O
and	D	O
neck	D	D
cancer	D	D
and	O	O
to	O	O
describe	O	O
the	O	O
course	O	O
of	O	O
radiation-induced	D	O
mucositis	D	O
in	O	O
these	O	O
patients	O	O

<	O	O
TO_SEE	O	O
>	O	O
As	O	O
concomitant	D	O
thrombocytosis	D	O
persisted	O	O
despite	O	O
treatment	O	T
with	O	O
hydroxyurea	T	O
,	O	O
the	O	O
new	O	O
megakaryocyte	T	O
inhibitor	T	O
anagrelide	T	O
(	T	O
Agrelin	T	O
)	T	O
was	O	O
administered	O	O
and	O	O
led	O	O
to	O	O
normalization	O	O
of	O	O
the	O	O
platelet	O	O
count	O	O
within	O	O
11	O	O
days	O	O

Background	O	O
:	O	O
Troglitazone	T	O
is	O	O
a	O	O
new	O	O
drug	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
type	D	O
2	D	O
diabetes	D	D

<	O	O
TO_SEE	O	O
>	O	O
For	O	O
a	O	O
subset	O	O
of	O	O
patients	O	O
with	O	O
Kaposi	D	D
's	D	D
sarcoma	D	D
who	O	O
were	O	O
treated	O	O
with	O	O
recombinant	T	T
interferon	T	T
alfa-2a	T	O
,	O	O
the	O	O
disease	O	D
is	O	O
in	O	O
complete	O	O
remission	O	O
,	O	O
without	O	O
opportunistic	D	D
infection	D	D
,	O	O
and	O	O
they	O	O
appear	O	O
to	O	O
be	O	O
culture-negative	O	O
for	O	O
the	O	O
etiologic	O	O
retrovirus	O	O
that	O	O
causes	O	O
their	O	O
immune	D	D
deficiency	D	D

Interferon	T	O
alfa-2a	T	O
appears	O	O
to	O	O
have	O	O
antineoplastic	O	O
efficacy	O	O
,	O	O
(	O	O
and	O	O
may	O	O
have	O	O
antiretroviral	O	O
efficacy	O	O
as	O	O
well	O	O
)	O	O
in	O	O
this	O	O
epidemic	O	O
neoplasm	D	O

In	O	O
three	O	O
consecutive	O	O
Phase	O	O
II	O	O
trials	O	O
of	O	O
recombinant	T	O
interferon	T	T
alfa-2a	T	O
(	O	O
rIFN	O	O
alfa-2a	O	O
;	O	O
Roferon-A	O	O
Hoffmann-La	O	O
Roche	O	O
,	O	O
Nutley	O	O
,	O	O
NJ	O	O
)	O	O
involving	O	O
96	O	O
patients	O	O
with	O	O
advanced	D	O
malignant	D	D
melanoma	D	O
,	O	O
an	O	O
overall	O	O
response	O	O
rate	O	O
of	O	O
22	O	O
%	O	O
was	O	O
observed	O	O

As	O	O
single	O	O
agent	O	O
therapy	O	T
in	O	O
malignant	D	D
melanoma	D	O
,	O	O
interferon	T	T
alfa-2a	T	O
was	O	O
only	O	O
marginally	O	O
useful	O	O
in	O	O
most	O	O
patients	O	O

Studies	O	O
with	O	O
various	O	O
interferon	T	O
alpha	T	O
preparations	T	O
,	O	O
including	O	O
interferons	T	O
induced	O	O
in	O	O
human	O	O
leukocytes	O	O
,	O	O
interferon	T	O
alfa-N1	T	O
,	O	O
interferon	T	O
alfa-2a	T	O
,	O	O
and	O	O
interferon	T	O
alfa-2b	T	O
,	O	O
have	O	O
all	O	O
provided	O	O
evidence	O	O
for	O	O
modest	O	O
but	O	O
reproducible	O	O
antitumor	O	O
activity	O	O
in	O	O
advanced	D	O
renal	D	D
cell	D	D
carcinoma	D	D

Preliminary	O	O
evidence	O	O
suggests	O	O
that	O	O
interferons	T	O
beta	T	O
and	T	O
gamma	T	O
may	O	O
also	O	O
induce	O	O
regression	O	O
of	O	O
metastatic	D	D
renal	D	D
cell	D	D
carcinoma	D	D

The	O	O
rationale	O	O
for	O	O
antileukemic	T	O
therapy	T	T
in	O	O
hairy	D	D
cell	D	D
leukemia	D	D
is	O	O
to	O	O
reduce	O	O
the	O	O
significant	O	O
risk	O	O
of	O	O
infection	O	D
and	O	O
other	O	O
potential	O	O
serious	O	O
complications	O	D

Splenectomy	T	O
presumably	O	O
alleviates	O	O
the	O	O
pancytopenic	O	O
effect	O	O
of	O	O
hypersplenism	D	O
by	O	O
removing	O	O
the	O	O
preferred	O	O
site	O	O
of	O	O
leukemic	O	O
cell	O	O
proliferation	O	O

Recombinant	O	O
and	O	O
natural	O	O
forms	O	O
of	O	O
interferon	T	O
alpha	T	O
have	O	O
been	O	O
shown	O	O
to	O	O
bring	O	O
about	O	O
tumor	O	D
regressions	O	O
in	O	O
patients	O	O
with	O	O
low-grade	D	D
non-Hodgkin	D	D
's	D	D
lymphoma	D	D

Current	O	O
studies	O	O
using	O	O
interferon	T	O
in	O	O
patients	O	O
with	O	O
low-grade	D	D
non-Hodgkin	D	D
's	D	D
lymphomas	D	D
are	O	O
evaluating	O	O
lower	O	O
,	O	O
and	O	O
perhaps	O	O
better	O	O
tolerated	O	O
doses	O	O
of	O	O
interferon	T	T

This	O	O
approach	O	O
is	O	O
being	O	O
extended	O	O
to	O	O
the	O	O
clinic	O	O
,	O	O
and	O	O
trials	O	O
are	O	O
now	O	O
underway	O	O
evaluating	O	O
combinations	O	O
of	O	O
interferon	T	T
and	O	O
various	O	O
cytotoxic	T	O
drugs	T	O
known	O	O
from	O	O
previous	O	O
studies	O	O
to	O	O
be	O	O
active	O	O
in	O	O
patients	O	O
with	O	O
low-grade	D	D
non-Hodgkin	D	D
's	D	D
lymphomas	D	D

While	O	O
the	O	O
demonstrated	O	O
antiviral	O	O
,	O	O
antiproliferative	O	O
,	O	O
and	O	O
immunomodulatory	O	O
properties	O	O
of	O	O
interferons	T	O
have	O	O
led	O	O
to	O	O
a	O	O
number	O	O
of	O	O
theories	O	O
regarding	O	O
their	O	O
potential	O	O
use	O	O
in	O	O
treating	O	O
individuals	O	O
with	O	O
chronic	D	D
myelogenous	D	D
leukemia	D	D
(	D	D
CML	D	D
)	D	O
,	O	O
their	O	O
limited	O	O
availability	O	O
has	O	O
prevented	O	O
thorough	O	O
clinical	O	O
investigation	O	O

The	O	O
data	O	O
resulting	O	O
from	O	O
these	O	O
clinical	O	O
trials	O	O
indicate	O	O
that	O	O
interferon	T	O
alfa-2a	T	O
is	O	O
effective	O	O
in	O	O
inducing	O	O
hematologic	O	O
remissions	O	O
in	O	O
the	O	O
majority	O	O
of	O	O
minimally	O	O
treated	O	O
,	O	O
benign-phase	D	D
CML	D	D
,	O	O
Ph1-positive	O	O
patients	O	O

More	O	O
than	O	O
1600	O	O
patients	O	O
with	O	O
neoplastic	D	D
disorders	D	D
have	O	O
received	O	O
recombinant	T	O
human	T	O
interferon	T	O
alfa-2a	T	O
(	T	O
Roferon-A	T	O
,	T	O
Hoffmann-La	T	O
Roche	T	O
,	T	O
Nutley	T	O
,	T	O
NJ	T	O
)	T	O
as	O	O
part	O	O
of	O	O
ongoing	O	O
or	O	O
completed	O	O
clinical	O	O
trials	O	O

PURPOSE	O	O
:	O	O
A	O	O
phase	O	O
I/II	O	O
trial	O	O
of	O	O
docetaxel	T	O
,	O	O
cisplatin	T	O
,	O	O
fluorouracil	T	O
(	T	O
5-FU	T	O
)	T	O
,	O	O
and	O	O
leucovorin	T	O
(	T	O
TPFL5	T	O
)	T	O
induction	T	O
chemotherapy	T	T
for	O	O
patients	O	O
with	O	O
locally	D	O
advanced	D	O
squamous	D	D
cell	D	D
carcinoma	D	D
of	D	O
the	D	O
head	D	O
and	D	O
neck	D	O
(	D	O
SCCHN	D	O
)	D	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
Twenty-three	O	O
previously	O	O
untreated	O	O
patients	O	O
with	O	O
stage	D	O
III	D	O
or	D	O
IV	D	O
SCCHN	D	O
and	O	O
Eastern	O	O
Cooperative	O	O
Oncology	O	O
Group	O	O
functional	O	O
status	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
2	O	O
were	O	O
treated	O	O
with	O	O
TPFL5	T	O

Intrathecal	T	O
sufentanil	T	O
provides	O	O
approximately	O	O
2	O	O
h	O	O
of	O	O
excellent	O	O
labor	D	O
analgesia	O	O
with	O	O
minimal	O	O
motor	O	O
blockade	O	O

OBJECTIVE	O	O
:	O	O
We	O	O
report	O	O
the	O	O
results	O	O
of	O	O
a	O	O
double-blind	O	O
,	O	O
double-dummy	O	O
,	O	O
active-control	O	O
study	O	O
designed	O	O
to	O	O
evaluate	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
lamotrigine	T	O
(	T	O
LTG	T	O
)	T	O
administered	O	O
as	O	O
monotherapy	O	O
to	O	O
adult	O	O
outpatients	O	O
with	O	O
partial	D	D
seizures	D	D

BACKGROUND	O	O
:	O	O
The	O	O
effectiveness	O	O
of	O	O
LTG	T	O
as	O	O
add-on	O	T
therapy	O	T
for	O	O
partial	D	O
seizures	D	D
in	O	O
adults	O	O
has	O	O
previously	O	O
been	O	O
established	O	O

CONCLUSIONS	O	O
:	O	O
We	O	O
conclude	O	O
that	O	O
LTG	T	O
is	O	O
effective	O	O
and	O	O
well	O	O
tolerated	O	O
when	O	O
administered	O	O
as	O	O
monotherapy	O	T
in	O	O
adult	O	O
patients	O	O
with	O	O
partial	D	D
seizures	D	D

BACKGROUND	O	O
:	O	O
Omega3	O	O
fatty	O	O
acids	O	O
may	O	O
inhibit	O	O
neuronal	O	O
signal	O	O
transduction	O	O
pathways	O	O
in	O	O
a	O	O
manner	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
lithium	T	O
carbonate	T	O
and	O	O
valproate	T	O
,	O	O
2	O	O
effective	O	O
treatments	O	O
for	O	O
bipolar	D	D
disorder	D	D

The	O	O
present	O	O
study	O	O
was	O	O
performed	O	O
to	O	O
examine	O	O
whether	O	O
omega3	T	O
fatty	T	O
acids	T	O
also	O	O
exhibit	O	O
mood-stabilizing	O	O
properties	O	O
in	O	O
bipolar	D	O
disorder	D	D

CONCLUSION	O	O
:	O	O
Omega3	T	O
fatty	T	O
acids	T	O
were	O	O
well	O	O
tolerated	O	O
and	O	O
improved	O	O
the	O	O
short-term	O	O
course	O	O
of	O	O
illness	O	D
in	O	O
this	O	O
preliminary	O	O
study	O	O
of	O	O
patients	O	O
with	O	O
bipolar	D	D
disorder	D	D

Several	O	O
large-scale	O	O
trials	O	O
have	O	O
firmly	O	O
established	O	O
the	O	O
effectiveness	O	O
of	O	O
thrombolytic	T	T
therapy	T	T
,	O	O
beta	T	O
blockers	T	O
,	O	O
and	O	O
aspirin	T	T
in	O	O
the	O	O
treatment	O	O
of	O	O
AMI	D	O

<	O	O
TO_SEE	O	O
>	O	O
While	O	O
diastolic	D	O
left	D	O
ventricular	D	O
(	D	O
LV	D	O
)	D	O
dysfunction	D	D
is	O	O
frequent	O	O
and	O	O
associated	O	O
with	O	O
cardiovascular	D	D
complications	D	D
in	O	D
end-stage	D	D
renal	D	D
disease	D	D
treated	O	D
with	O	O
dialysis	T	O
,	O	O
controversial	O	O
information	O	O
exists	O	O
on	O	O
diastolic	O	O
LV	O	O
function	O	O
after	O	O
renal	O	D
transplantation	O	O

METHODS	O	O
:	O	O
Fluvastatin	T	O
40	O	O
mg	O	O
daily	O	O
was	O	O
administered	O	O
to	O	O
25	O	O
patients	O	O
with	O	O
hypercholesterolaemia	D	O
for	O	O
up	O	O
to	O	O
24	O	O
weeks	O	O

The	O	O
inhibitory	O	O
effect	O	O
of	O	O
n-3	T	O
polyunsaturated	T	O
fatty	T	O
acids	T	O
on	O	O
human	D	O
colorectal	D	D
cancer	D	D
has	O	O
been	O	O
speculated	O	O
on	O	O
from	O	O
epidemiological	O	O
data	O	O
and	O	O
animal	O	O
studies	O	O

We	O	O
conducted	O	O
a	O	O
long-term	O	O
trial	O	O
of	O	O
docosahexanoic	T	O
acid	T	O
(	T	O
DHA	T	O
)	T	O
-concentrated	T	O
fish	T	O
oil	T	O
capsules	T	O
for	O	O
patients	O	O
in	O	O
a	O	O
high-risk	O	O
group	O	O
for	O	O
colorectal	D	D
cancer	D	D

Three	O	O
patients	O	O
with	O	O
FAP	D	O
and	O	O
two	O	O
patients	O	O
with	O	O
multiple	O	O
(	O	O
more	O	O
than	O	O
30	O	O
)	O	O
colorectal	D	D
polyps	D	D
were	O	O
administered	O	O
DHA-concentrated	T	O
fish	T	O
oil	T	O
capsules_Hlk427554600	T	O
(	T	O
2.2	T	O
g	T	O
of	T	O
DHA	T	O
and	T	O
0.6	T	O
g	T	O
of	T	O
eicosapentanoic	T	O
acid	T	O
(	T	O
EPA	T	O
)	T	O
per	T	O
day	T	O
)	T	O
for	O	O
one	O	O
or	O	O
two	O	O
years	O	O

This	O	O
article	O	O
reviews	O	O
current	O	O
trends	O	O
in	O	O
management	O	O
of	O	O
esophageal	D	O
achalasia	D	O
,	O	O
highlighting	O	O
short-term	O	O
outcome	O	O
and	O	O
cost	O	O
comparisons	O	O
of	O	O
three	O	O
treatments	O	O
:	O	O
botulinum	T	O
toxin	T	O
injection	T	T
,	O	O
pneumatic	T	O
dilation	T	O
,	O	O
and	O	O
laparoscopic	T	O
myotomy	T	O

The	O	O
clinical	O	O
application	O	O
of	O	O
therapeutic	T	O
hysteroscopy	T	O
,	O	O
mainly	O	O
in	O	O
the	O	O
field	O	O
of	O	O
the	O	O
treatment	O	O
of	O	O
abnormal	D	D
uterine	D	D
bleeding	D	D
,	O	O
started	O	O
in	O	O
the	O	O
1980s	O	O

<	O	O
TO_SEE	O	O
>	O	O
In	O	O
this	O	O
article	O	O
,	O	O
evidence	O	O
of	O	O
effectiveness	O	O
and	O	O
cost-effectiveness	O	O
of	O	O
the	O	O
following	O	O
procedures	O	O
is	O	O
reviewed	O	O
:	O	O
(	O	O
1	O	O
)	O	O
laser	T	T
treatment	T	T
of	O	O
bladder	D	D
tumors	D	D
;	O	O
(	O	O
2	O	O
)	O	O
extracorporeal	O	T
shock-wave	O	O
lithotripsy	O	O
and	O	O
percutaneous	O	O
nephrolithotomy	O	O
;	O	O
(	O	O
3	O	O
)	O	O
laparoscopic	T	O
treatment	T	O
of	O	O
endometriosis	D	D
;	O	O
(	O	O
4	O	O
)	O	O
laparoscopic	T	O
removal	T	O
of	O	O
ovarian	D	D
cysts	D	O
;	O	O
(	O	O
5	O	O
)	O	O
laparoscopic	O	O
cholecystectomy	O	O
;	O	O
(	O	O
6	O	O
)	O	O
laparoscopic	O	O
appendectomy	O	O
;	O	O
(	O	O
7	O	O
)	O	O
catheter	T	T
treatment	T	T
of	O	O
coronary	D	D
artery	D	D
disease	D	D
;	O	O
(	O	O
8	O	O
)	O	O
palliation	O	O
of	O	O
colon	O	D
cancer	O	D
by	O	O
endoscopic	O	O
intervention	O	O
;	O	O
(	O	O
9	O	O
)	O	O
treatment	O	O
of	O	O
upper	D	D
gastrointestinal	D	D
(	D	D
UGI	D	D
)	D	D
bleeding	D	D
by	O	O
endoscopic	T	O
intervention	T	O
;	O	O
and	O	O
(	O	O
10	O	O
)	O	O
arthroscopic	O	O
knee	O	O
surgery	O	T

Gene	T	O
therapy	T	T
of	O	O
malignant	D	D
brain	D	D
tumors	D	D

Treatment	O	O
of	O	O
irritable	D	D
bowel	D	D
syndrome	D	D
with	O	O
Chinese	T	O
herbal	T	O
medicine	T	O
:	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O

Randomised	O	O
trial	O	O
of	O	O
interferon	T	O
alpha2b	T	O
plus	T	O
ribavirin	T	O
for	O	O
48	O	O
weeks	O	O
or	O	O
for	O	O
24	O	O
weeks	O	O
versus	O	O
interferon	T	T
alpha2b	T	T
plus	T	T
placebo	T	O
for	O	O
48	O	O
weeks	O	O
for	O	O
treatment	O	O
of	O	O
chronic	D	D
infection	D	D
with	D	D
hepatitis	D	D
C	D	D
virus	D	D

Low-molecular-weight	T	O
heparin	T	T
for	O	O
immediate	O	O
management	O	O
of	O	O
thromboembolic	D	D
disease	D	D
in	O	O
pregnancy	O	O

Tubularized	T	O
incised	T	O
plate	T	O
hypospadias	T	O
repair	T	O
for	O	O
proximal	D	O
hypospadias	D	O

Comparison	O	O
of	O	O
radical	T	O
prostatectomy	T	O
and	O	O
iodine	T	O
125	T	O
interstitial	T	T
radiotherapy	T	T
for	O	O
the	O	O
treatment	O	O
of	O	O
clinically	D	D
localized	D	D
prostate	D	D
cancer	D	D
:	O	O
a	O	O
7-year	O	O
biochemical	O	O
(	O	O
PSA	O	O
)	O	O
progression	O	O
analysis	O	O

The	O	O
effectiveness	O	O
of	O	O
acupuncture	T	D
in	O	O
treating	O	D
acute	D	D
dental	D	D
pain	D	D
:	O	O
a	O	O
systematic	O	O
review	O	O

Correction	O	O
of	O	O
cardiac	D	D
defects	D	D
through	O	O
a	O	O
right	T	O
thoracotomy	T	O
in	O	O
children	O	O

New	O	O
technique	O	O
for	O	O
mesh	T	O
repair	T	O
of	O	O
paracolostomy	D	O
hernias	D	O

Immunotherapy	T	O
of	O	O
tumors	D	D
with	O	O
autologous	T	O
tumor-derived	T	O
heat	T	O
shock	T	O
protein	T	O
preparations	T	O

Comprehensive	T	O
modified	T	O
diet	T	O
simplifies	O	O
nutrition	T	O
management	T	O
of	O	O
adults	O	O
with	O	O
short-bowel	D	D
syndrome	D	D

Extended	O	O
use	O	O
of	O	O
glatiramer	T	O
acetate	T	O
(	T	O
Copaxone	T	O
)	T	O
is	O	O
well	O	O
tolerated	O	O
and	O	O
maintains	O	O
its	O	O
clinical	O	O
effect	O	O
on	O	O
multiple	D	O
sclerosis	D	D
relapse	O	O
rate	O	O
and	O	O
degree	O	O
of	O	O
disability	O	O

European	O	O
register	O	O
of	O	O
patients	O	O
with	O	O
sickle	D	D
cell	D	D
disease	D	D
treated	O	O
with	O	O
hydroxyurea	T	O
is	O	O
being	O	O
set	O	O
up	O	O

Understanding	O	O
the	O	O
culture	O	O
of	O	O
prescribing	O	O
:	O	O
qualitative	O	O
study	O	O
of	O	O
general	O	O
practitioners	O	O
'	O	O
and	O	O
patients	O	O
'	O	O
perceptions	O	O
of	O	O
antibiotics	T	T
for	O	O
sore	D	D
throats	D	O

Steroid	T	O
delivery	T	O
in	O	O
croup	D	O

Haematoma	T	O
block	T	O
versus	O	O
intravenous	T	O
regional	T	O
anaesthesia	T	O
in	O	O
Colles	D	O
'	D	O
fractures	D	D

Direct	T	O
percutaneous	T	O
transluminal	T	D
angioplasty	T	D
for	O	O
acute	D	D
middle	D	D
cerebral	D	D
artery	D	D
occlusion	D	D

Magnesium	T	O
sulphate	T	O
for	O	O
the	O	O
control	O	O
of	O	O
spasms	D	O
in	D	O
severe	D	D
tetanus	D	D

Protective	O	O
effect	O	O
of	O	O
pralidoxime	T	O
on	O	O
muscle	D	O
fiber	D	D
necrosis	D	D
induced	O	O
by	O	O
organophosphate	O	O
compounds	O	O

Assessment	O	O
of	O	O
atrioventricular	T	O
junction	T	O
ablation	T	O
and	T	O
VVIR	T	O
pacemaker	T	O
versus	O	O
pharmacological	T	T
treatment	T	T
in	O	O
patients	O	O
with	O	O
heart	D	D
failure	D	D
and	D	O
chronic	D	D
atrial	D	D
fibrillation	D	O
:	O	O
a	O	O
randomized	O	O
,	O	O
controlled	O	O
study	O	O

Statins	T	T
for	O	O
prevention	O	O
of	O	O
stroke	D	D

Repair	O	O
of	O	O
ventral	D	O
hernias	D	O
with	O	O
expanded	T	O
polytetrafluoroethylene	T	O
patch	T	O

Spinal	T	D
manipulation	T	O
in	O	O
the	O	O
treatment	O	O
of	O	O
episodic	D	O
tension-type	D	O
headache	D	O
:	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O

Successful	O	O
treatment	O	T
with	O	O
lamivudine	T	O
for	O	O
fulminant	D	D
reactivated	D	D
hepatitis	D	D
B	D	D
infectioN	D	D
following	O	O
intensive	T	T
therapy	T	T
for	O	O
high-grade	D	D
non-Hodgkin	D	D
's	D	D
lymphoma	D	D

Influence	O	O
of	O	O
treatment	O	O
delay	O	O
on	O	O
infarct	O	O
size	O	O
and	O	O
clinical	O	O
outcome	O	O
in	O	O
patients	O	O
with	O	O
acute	D	D
myocardial	D	D
infarction	D	D
treated	O	D
with	O	O
primary	T	O
angioplasty	T	O

Should	O	O
patients	O	O
with	O	O
advanced	D	O
sarcomas	D	D
be	O	O
treated	O	O
with	O	O
chemotherapy	T	T
?	O	O

Plasma	T	O
exchange	T	O
and	T	O
tacrolimus-mycophenolate	T	O
rescue	T	O
for	O	O
acute	D	D
humoral	D	D
rejection	D	D
in	O	O
kidney	O	D
transplantation	O	O

Hyperbaric	T	O
oxygen	T	T
therapy	T	T
for	O	O
children	O	O
with	O	O
cerebral	D	D
palsy	D	D

Endoscopic	T	O
excision	T	O
of	O	O
a	D	O
forehead	D	O
mass	D	O

Effect	O	O
of	O	O
photodynamic	T	T
therapy	T	T
in	T	O
combination	T	O
with	T	O
mitomycin	T	O
C	T	O
on	O	O
a	O	O
mitomycin-resistant	D	D
bladder	D	D
cancer	D	D
cell	O	O
line	O	O

Is	O	O
conservative	T	O
surgery	T	T
for	O	O
tubal	D	O
pregnancy	D	O
preferable	O	O
to	O	O
salpingectomy	T	O
?	O	O
An	O	O
economic	O	O
analysis	O	O

Laparoscopic	T	O
cornuostomy	T	O
in	O	O
the	O	O
treatment	O	O
of	O	O
interstitial	D	D
pregnancy	D	O
with	O	O
subsequent	O	O
hysterosalpingography	O	O

Experimental	O	O
evaluation	O	O
of	O	O
the	O	O
use	O	O
of	O	O
recombinant	T	O
prourokinase	T	O
and	O	O
its	O	O
immobilized	O	O
forms	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
postoperative	D	D
fibrinoid	D	D
syndrome	D	D
in	O	O
ophthalmology	O	O

In	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
comparison	O	O
between	O	O
the	O	O
effects	O	O
of	O	O
treatment	O	O
with	O	O
adenosine	T	O
triphosphate	T	O
and	O	O
treatment	O	O
with	O	O
buthionine	T	O
sulfoximine	T	O
on	O	O
chemosensitization	O	O
and	O	O
tumour	O	O
growth	O	O
of	O	O
B16	D	O
melanoma	D	O

Effects	O	O
of	O	O
transpupillary	T	O
thermotherapy	T	O
on	O	O
immunological	O	O
parameters	O	O
and	O	O
apoptosis	O	O
in	O	O
a	O	O
case	O	O
of	O	O
primary	D	O
uveal	D	O
melanoma	D	O

Is	O	O
there	O	O
a	O	O
rational	O	O
therapy	O	T
for	O	O
symptomatic	O	T
treatment	O	T
of	O	O
benign	D	D
prostatic	D	D
hyperplasia	D	D
with	O	O
phytogenic	T	O
drugs	T	O
?	O	O
Illustrated	O	O
with	O	O
the	O	O
example	O	O
of	O	O
the	O	O
prostate	O	D
agent	O	O
from	O	O
Serenoa	O	O
repens	O	O
(	O	O
Sabal	O	O
fructus	O	O
)	O	O

Pharmacological	O	O
and	O	O
clinical	O	O
effectiveness	O	O
of	O	O
a	O	O
fixed	T	O
phytogenic	T	O
combination	T	O
trembling	T	O
poplar	T	O
(	T	O
Populus	T	O
tremula	T	O
)	T	O
,	T	O
true	T	O
goldenrod	T	O
(	T	O
Solidago	T	O
virgaurea	T	O
)	T	O
and	T	O
ash	T	O
(	T	O
Fraxinus	T	O
excelsior	T	O
)	T	O
in	O	O
mild	D	O
to	D	O
moderate	D	O
rheumatic	D	O
complaints	D	O

Therapy	O	T
of	O	O
degenerative	D	D
diseases	D	D
of	D	O
the	D	O
musculoskeletal	D	O
system	D	O
with	O	O
South	T	O
African	T	O
devil	T	O
's	T	O
claw	T	O
(	T	O
Harpagophytum	T	O
procumbens	T	O
DC	T	O
)	T	O

Treatment	O	O
strategy	O	O
for	O	O
mucin-producing	D	O
intrahepatic	D	O
cholangiocarcinoma	D	O
:	O	O
value	O	O
of	O	O
percutaneous	T	O
transhepatic	T	D
biliary	T	D
drainage	T	O
and	O	O
cholangioscopy	T	O

Strategy	O	O
for	O	O
surgical	T	T
management	T	O
of	O	O
ileocolonic	D	D
anastomotic	D	D
recurrence	D	D
in	D	O
Crohn	D	D
's	D	D
disease	D	D

Nerve-sparing	T	T
surgery	T	T
for	O	O
advanced	D	D
rectal	D	D
cancer	D	D
patients	O	O
:	O	O
special	O	O
reference	O	O
to	O	O
Dukes	O	O
C	O	O
patients	O	O

Prognostic	O	O
factors	O	O
in	O	O
patients	O	O
with	O	O
locally	O	D
advanced	O	D
rectal	D	D
adenocarcinoma	D	D
treated	O	O
with	O	O
preoperative	T	T
radiotherapy	T	T
and	O	O
surgery	T	T

Current	O	O
surgical	T	T
therapy	T	T
for	O	O
bronchiectasis	D	O

Thoracic	T	T
surgery	T	T
for	O	O
hydatid	D	D
disease	D	D

Surgical	T	T
treatment	T	O
of	O	O
postpneumonic	D	O
empyema	D	O

Thoracoscopic	T	D
surgery	T	T
for	O	D
pulmonary	D	D
tuberculosis	D	D

Thoracoscopic	T	O
surgery	T	T
for	O	O
spontaneous	D	O
pneumothorax	D	O

Surgery	T	T
for	O	O
chronic	D	D
thromboembolic	D	D
pulmonary	D	D
hypertension	D	D

Transabdominal	T	O
extensive	T	O
esophagogastric	T	O
devascularization	T	O
with	T	O
gastroesophageal	T	O
stapling	T	O
for	O	O
management	O	O
of	O	O
noncirrhotic	D	D
portal	D	D
hypertension	D	D
:	O	O
long-term	O	O
results	O	O

Surgical	T	T
treatment	T	T
for	O	O
lung	D	D
hydatid	D	D
disease	D	D

Sliding	T	O
door	T	O
technique	T	O
for	O	O
the	O	O
repair	O	O
of	O	O
midline	D	O
incisional	D	O
hernias	D	O

One-lung	T	O
ventilation	T	O
in	O	O
patients	O	O
with	O	O
difficult	D	O
airways	D	O

Thoracoscopy	T	O
for	O	O
empyema	D	O
in	O	O
children	O	O

Sex	O	O
differences	O	O
in	O	O
the	O	O
use	O	O
of	O	O
asthma	D	D
drugs	T	O
:	O	O
cross	O	O
sectional	O	O
study	O	O

Conventional	T	O
treatments	T	O
for	O	O
non-Hodgkin	D	D
's	D	D
lymphoma	D	D
:	O	O
the	O	O
need	O	O
for	O	O
new	O	O
therapies	O	O

Adrenal-sparing	T	O
surgery	T	T
for	O	O
phaeochromocytoma	D	O

Antiplatelet	T	T
therapy	T	T
in	O	O
acute	D	D
cerebral	D	D
ischemia	D	D

Laugier-Hunziker	D	D
syndrome	D	D
:	O	O
case	O	O
report	O	O
and	O	O
treatment	O	O
with	O	O
the	O	O
Q-switched	T	O
Nd-Yag	T	O
laser	T	T

Thoracoscopic	T	O
operation	T	O
for	O	O
secondary	D	O
pneumothorax	D	O
under	O	O
local	O	O
and	O	O
epidural	O	T
anesthesia	O	T
in	O	O
high-risk	O	O
patients	O	O

Troglitazone-induced	D	D
hepatic	D	D
failure	D	D
leading	O	O
to	O	O
liver	T	D
transplantation	T	O

A	O	O
modified	O	O
technique	O	O
of	O	O
tubeless	O	O
anaesthesia	O	O
for	O	O
microlaryngoscopy	T	O
and	T	O
bronchoscopy	T	O
in	O	O
young	O	O
children	O	O
with	O	O
stridor	D	O

A	O	O
randomized	O	O
trial	O	O
of	O	O
Lactobacillus	T	O
acidophilus	T	O
BG2FO4	T	O
to	O	O
treat	O	O
lactose	D	O
intolerance	D	O

Treatment	O	O
of	O	O
idiopathic	D	O
thrombopenic	D	O
purpura	D	O
in	O	O
adolescents	O	O
by	O	O
intravenous	T	O
immunoglobulin	T	O

Azithromycin	T	T
therapy	T	T
for	O	O
scrub	D	O
typhus	D	O
during	O	O
pregnancy	O	O

Excimer	T	O
laser	T	O
assisted	T	O
in	T	O
situ	T	O
keratomileusis	T	O
for	O	O
hyperopia	D	O

Three	O	O
consecutive	O	O
phase	O	O
II	O	O
studies	O	O
of	O	O
recombinant	T	O
interferon	T	T
alfa-2a	T	O
in	O	O
advanced	D	O
malignant	D	D
melanoma	D	D

Interferon	T	T
treatment	T	T
of	O	O
renal	D	D
cell	D	D
carcinoma	D	D

Current	O	O
and	O	O
future	O	O
uses	O	O
of	O	O
recombinant	T	O
interferon	T	T
alpha	T	O
in	O	O
the	O	O
treatment	O	O
of	O	O
low-grade	D	D
non-Hodgkin	D	D
's	D	D
lymphoma	D	D

Antimicrobial	T	O
treatment	T	O
options	O	O
in	O	O
the	O	O
management	O	O
of	O	O
odontogenic	D	D
infections	D	D

Recombinant	T	O
glycoprotein	T	O
vaccine	T	O
for	O	O
the	O	O
prevention	O	O
of	O	O
genital	D	D
HSV-2	D	D
infection	D	D
:	O	O
two	O	O
randomized	O	O
controlled	O	O
trials	O	O

Induction	T	O
chemotherapy	T	T
with	T	O
docetaxel	T	O
,	T	O
cisplatin	T	O
,	T	O
fluorouracil	T	O
,	T	O
and	T	O
leucovorin	T	O
for	O	O
squamous	D	D
cell	D	D
carcinoma	D	D
of	O	O
the	O	O
head	O	O
and	O	O
neck	O	O
:	O	O
a	O	O
phase	O	O
I/II	O	O
trial	O	O

Low-dose	T	T
steroids	T	T
reduce	O	O
flu-like	D	D
symptoms	D	D
at	O	O
the	O	O
initiation	O	O
of	O	O
IFNbeta-1b	O	O
in	O	O
relapsing-remitting	O	O
MS	O	O

Study	O	O
of	O	O
three	O	O
different	O	O
doses	O	O
of	O	O
epidural	T	T
neostigmine	T	T
coadministered	T	T
with	T	O
lidocaine	T	T
for	O	O
postoperative	D	T
analgesia	D	T

An	O	O
active-control	O	O
trial	O	O
of	O	O
lamotrigine	T	T
monotherapy	T	T
for	O	O
partial	D	D
seizures	D	D

<	O	O
TO_SEE	O	O
>	O	O
Safety	O	O
of	O	O
intrathecal	T	O
sodium	T	O
nitroprusside	T	O
for	O	O
the	O	O
treatment	O	O
and	O	O
prevention	O	O
of	O	O
refractory	D	D
cerebral	D	D
vasospasm	D	D
and	D	O
ischemia	D	O
in	O	O
humans	O	O

The	O	O
effect	O	O
of	O	O
heliox	T	D
in	O	O
acute	D	D
severe	D	D
asthma	D	D
:	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O
.	O	O

Long-term	O	O
survival	O	O
of	O	O
patients	O	O
with	O	O
unresectable	D	D
colorectal	D	D
cancer	D	D
liver	D	D
metastases	D	D
following	O	O
infusional	T	T
chemotherapy	T	T
with	T	O
5-fluorouracil	T	O
,	T	O
leucovorin	T	O
,	T	O
oxaliplatin	T	O
and	T	O
surgery	T	T

<	O	O
TO_SEE	O	O
>	O	O
Fatal	D	D
acute	D	D
haemolysis	D	D
in	O	O
an	O	O
AIDS	D	D
patient	O	O
treated	O	O
with	O	O
lindinavir	T	O

A	O	O
simplified	O	O
laparoscopic	T	O
technique	T	O
for	T	O
mesh	T	O
placement	T	O
in	O	O
ventral	D	O
hernia	D	D
repair	O	O

Pharmacological	T	O
management	T	O
of	O	O
acute	D	D
myocardial	D	D
infarction	D	D

Mesenteric	D	D
venous	D	D
thrombosis	D	D
:	O	O
successful	O	O
treatment	O	T
by	O	O
intraarterial	T	O
lytic	T	T
therapy	T	T

Gene	T	O
therapy	T	T
for	O	O
myocardial	D	D
angiogenesis	D	D

Dipyridamole	T	O
plus	T	D
aspirin	T	T
in	O	O
cerebrovascular	D	D
disease	D	D

What	O	O
is	O	O
the	O	O
real	O	O
role	O	O
of	O	O
CD40	O	O
in	O	O
cancer	D	D
immunotherapy	T	O
?	O	O

The	O	O
effects	O	O
of	O	O
oral	T	O
liarozole	T	O
on	O	O
epidermal	O	O
proliferation	O	O
and	O	O
differentiation	O	O
in	O	O
severe	D	O
plaque	D	O
psoriasis	D	O
are	O	O
comparable	O	O
with	O	O
those	O	O
of	O	O
acitretin	T	O
.	O	O

Safety	O	O
and	O	O
potential	O	O
effectiveness	O	O
of	O	O
daunorubicin-containing	T	O
liposomes	T	O
in	O	O
patients	O	O
with	O	O
advanced	D	D
recurrent	D	D
malignant	D	D
CNS	D	D
tumors	D	D

An	O	O
experimental	O	O
application	O	O
of	O	O
gene	T	O
therapy	T	T
for	O	O
human	D	O
retinoblastoma	D	D

Acid	T	O
suppression	T	O
therapy	T	T
in	O	O
Barrett	D	O
's	D	O
esophagus	D	O
:	O	O
the	O	O
importance	O	O
of	O	O
pH	O	O
monitoring	O	O

Surgical	T	T
approaches	T	O
to	O	O
pediatric	D	D
defecatory	D	D
disorders	D	D

Lutein	T	O
improves	O	O
visual	O	O
function	O	O
in	O	O
some	O	O
patients	O	O
with	O	O
retinal	D	O
degeneration	D	O
:	O	O
a	O	O
pilot	O	O
study	O	O
via	O	O
the	O	O
Internet	O	O

Drug	O	O
information	O	O
questions	O	O
and	O	O
answers	O	O
:	O	O
new	O	O
for	O	O
psoriasis	D	O
:	O	O
colchicine	T	O

IPPB	T	D
in	O	O
severe	D	D
pulmonary	D	D
emphysema	D	D
:	O	O
limited	O	O
applications	O	O

Long-term	O	O
mortality	O	O
in	O	O
patients	O	O
after	O	O
a	O	O
British	O	O
trial	O	O
of	O	O
anticoagulants	T	D
in	O	O
acute	D	D
myocardial	D	D
infarction	D	D

Our	O	O
results	O	O
in	O	O
the	O	O
surgical	T	T
treatment	T	O
of	O	O
habitual	D	O
shoulder	D	O
dislocation	D	O
with	O	O
special	O	O
reference	O	O
to	O	O
occupational	O	O
disability	O	O

Alkaline	O	O
phosphatase	O	O
in	O	O
neutrophil	O	O
leukocytes	O	O
of	O	O
patients	O	O
with	O	O
infectious	D	D
mononucleosis	D	O
and	O	O
the	O	O
effect	O	O
of	O	O
corticosteroid	T	T
therapy	T	T

Surgical	T	T
treatment	T	T
of	O	O
uterine	D	O
cervix	D	O
insufficiency	D	O
during	O	O
the	O	O
2d	O	O
trimester	O	O
of	O	O
pregnancy	O	O

Physiologic	T	O
treatment	T	O
of	O	O
depressive	D	O
reactions	D	O
:	O	O
a	O	O
pilot	O	O
study	O	O

The	O	O
use	O	O
of	O	O
quinidine	T	O
sulphate	T	O
for	O	O
the	O	O
treatment	O	O
of	O	O
atrial	D	O
fibrillation	D	O
in	O	O
twelve	O	O
horses	O	O

Synergism	O	O
in	O	O
the	O	O
chemotherapy	T	O
of	O	O
Eimeria	D	D
infections	D	D
of	O	O
chicks	O	O

Treatment	O	O
of	O	O
hydrocele	D	O
and	D	O
cysts	D	O
of	D	O
the	D	O
epididymis	D	O
with	O	O
sclerosing	T	O
injections	T	O
of	T	O
quinine	T	O
and	T	O
urea	T	O
chlorhydrolactate	T	O
in	O	O
a	O	O
30	O	O
per	O	O
cent	O	O
solution	O	O

The	O	O
single-place	T	O
caisson	T	O
in	O	O
the	O	O
treatment	O	O
of	O	O
decompression	D	D
accidents	D	D

Blood	O	O
volume	O	O
measurements	O	O
in	O	O
burn	D	O
therapy	T	T

Phenylbutazone	T	D
and	O	O
acute	D	D
leukemia	D	D
.	O	O

The	O	O
place	O	O
of	O	O
surgery	T	T
in	O	O
hypertrophic	D	D
obstructive	D	D
cardiomyopathy	D	O
(	D	O
idiopathic	D	O
hypertrophic	D	O
subaortic	D	O
stenosis	D	O
)	D	O

The	O	O
treatment	O	O
of	O	O
autoimmune	D	D
hemolytic	D	D
anemia	D	D
with	O	O
heparin	T	T

Effects	O	O
of	O	O
clomiphene	T	O
citrate	T	O
on	O	O
endometrial	D	O
hyperplasia	D	D
in	O	O
the	O	O
premenopausal	O	O
female	O	O

Prolonged	O	O
use	O	O
of	O	O
methyldopa	T	D
in	O	O
severe	D	D
hypertension	D	D
in	O	O
pregnancy	O	O

The	O	O
effects	O	O
of	O	O
social	O	O
class	O	O
and	O	O
friends	O	O
'	O	O
expectations	O	O
on	O	O
oral	O	O
polio	D	O
vaccination	T	O
participation	O	O

Glutathione	O	O
S-transferase	O	O
activity	O	O
in	O	O
epithelial	D	D
ovarian	D	D
cancer	D	D
:	O	O
association	O	O
with	O	O
response	O	O
to	O	O
chemotherapy	T	T
and	O	O
disease	O	D
outcome	O	O

Interferon-alpha-2b	T	O
in	O	O
the	O	O
management	O	O
of	O	O
patients	O	O
with	O	O
relapsed	O	D
and/or	O	O
refractory	O	D
Hodgkin	D	D
's	D	D
disease	D	D

<	O	O
TO_SEE	O	O
>	O	O
Frontal	D	O
dysfunction	D	D
blocks	O	O
the	O	O
therapeutic	O	O
effect	O	O
of	O	O
THA	T	O
on	O	O
attention	O	O
in	O	O
Alzheimer	D	D
's	D	D
disease	D	D

Effects	O	O
of	O	O
clomipramine	T	O
on	O	O
plasma	O	O
amino	O	O
acids	O	O
and	O	O
serotonergic	O	O
parameters	O	O
in	O	O
panic	D	D
disorder	D	D
and	D	O
depression	D	D
.	O	O

Thalidomide	T	T
for	O	O
aphthous	D	D
ulcers	D	D
in	O	O
HIV	D	D
infection	D	D

Aspirin	T	T
therapy	T	T
in	O	O
diabetes	D	D
mellitus	D	D

Combined	T	O
pancreas-/kidney	T	O
transplantation	T	O
as	O	O
a	O	O
standard	O	O
procedure	O	O
in	O	O
therapy	O	T
of	O	O
kidney	D	D
failure	D	D
in	D	O
type	D	O
I	D	O
diabetic	D	D
patients	D	O

Corticosteroid	T	O
injections	T	O
for	O	O
sciatica	D	O

Flutamide	T	O
plus	T	O
castration	T	O
in	O	O
patients	O	O
with	O	O
previously	O	O
untreated	O	D
prostate	D	D
cancer	D	D

The	O	O
immediate	O	O
effectiveness	O	O
of	O	O
electrical	T	O
nerve	T	O
stimulation	T	O
and	O	O
electrical	T	O
muscle	T	O
stimulation	T	O
on	O	O
myofascial	D	D
trigger	D	O
points	D	O

In	O	O
vitro	O	O
radiation-induced	O	O
apoptosis	O	O
and	O	O
tumour	O	O
response	O	O
to	O	O
radiotherapy	T	O
:	O	O
a	O	O
prospective	O	O
study	O	O
in	O	O
patients	O	O
with	O	O
non-Hodgkin	D	D
lymphomas	D	D
treated	O	O
by	O	O
low-dose	T	T
irradiation	T	T

Drug	T	T
therapy	T	T
for	O	O
coronary	D	D
heart	D	D
disease	D	D
:	O	O
the	O	O
Sheffield	O	O
table	O	O

Percutaneous	T	O
drainage	T	O
of	O	O
hydatid	D	O
cysts	D	O

Surgery	T	T
for	O	O
ectopia	D	O
lentis	D	O

<	O	O
TO_SEE	O	O
>	O	O
Antiplatelet	T	T
therapy	T	T
to	O	O
prevent	O	D
stroke	D	D
:	O	O
risk	O	O
of	O	O
brain	D	D
hemorrhage	D	D
and	O	O
efficacy	O	O
in	O	O
atrial	T	O
fibrillation	T	O

High-dose	T	T
chemotherapy	T	T
with	T	O
autologous	T	O
hematopoietic	T	O
stem-cell	T	O
support	T	O
for	O	O
breast	D	D
cancer	D	D
in	O	O
North	O	O
America	O	O

Is	O	O
concomitant	T	T
radiotherapy	T	T
and	T	O
chemotherapy	T	T
superior	O	O
to	O	O
optimal	O	O
radiotherapy	T	T
alone	O	O
in	O	O
anal	D	D
cancer	D	D
?	O	O

Standard	T	O
versus	T	O
high-dose	T	T
therapy	T	T
in	O	O
10+	O	D
breast	D	D
cancer	D	D

Anal	O	O
continence	O	O
after	O	O
surgery	T	T
for	O	O
rectal	D	D
prolapse	D	O

Aspirin	T	T
therapy	T	T
for	O	O
cardiovascular	D	D
disease	D	D

Dosing	O	O
of	O	O
amoxicillin/clavulanate	T	O
for	O	O
treatment	O	O
of	O	O
lower	D	D
respiratory	D	D
tract	D	D
infection	D	D

Pharmacoeconomic	O	O
analysis	O	O
of	O	O
ampicillin-sulbactam	T	O
versus	O	O
cefoxitin	T	O
in	O	O
the	O	O
treatment	O	O
of	O	O
intraabdominal	D	D
infections	D	D

New	T	O
therapies	T	O
for	O	O
severe	D	D
meningococcal	D	D
disease	D	D

Another	O	O
potential	O	O
use	O	O
of	O	O
troglitazone	T	O
in	O	O
noninsulin-dependent	D	D
diabetes	D	D
mellitus	D	D

<	O	O
TO_SEE	O	O
>	O	O
Jaw	D	O
clenching	D	O
following	O	O
Gamma	T	O
Knife	T	T
treatment	T	T
for	O	O
trigeminal	D	O
neuralgia	D	O

The	O	O
protective	O	O
effect	O	O
of	O	O
condoms	T	O
and	O	O
nonoxynol-9	T	O
against	O	O
HIV	D	D
infection	D	D

Evaluation	O	O
of	O	O
adjuvant	T	T
psychological	T	O
therapy	T	T
in	O	O
patients	O	O
with	O	O
testicular	D	D
cancer	D	D
:	O	O
randomised	O	O
controlled	O	O
trial	O	O

The	O	O
effect	O	O
of	O	O
an	O	O
endothelin-receptor	T	O
antagonist	T	O
,	T	O
bosentan	T	O
,	O	O
on	O	O
blood	O	O
pressure	O	O
in	O	O
patients	O	O
with	O	O
essential	D	D
hypertension	D	D
.	O	O

Guidelines	O	O
for	O	O
the	O	O
use	O	O
of	O	O
antiretroviral	T	O
agents	T	O
in	O	O
HIV	D	O
-infected	O	O
adults	O	O
and	O	O
adolescents	O	O

Long-term	O	O
therapy	O	T
with	O	O
long-acting	T	T
octreotide	T	O
(	T	O
Sandostatin-LAR	T	O
)	T	O
for	O	O
the	O	O
management	O	O
of	O	O
acromegaly	D	O

Are	O	O
ABVD	T	O
and	O	O
MOPP/ABV	T	O
truly	O	O
equivalent	O	O
for	O	O
treating	O	D
Hodgkin	D	D
's	D	D
disease	D	D
at	O	O
advanced	O	O
stages	O	O
?	O	O

Paclitaxel	T	O
for	O	O
the	O	O
treatment	O	O
of	O	O
lymphoma	D	D

Montelukast	T	O
,	T	O
a	T	O
leukotriene-receptor	T	O
antagonist	T	O
,	T	O
for	O	O
the	O	O
treatment	O	O
of	O	O
mild	D	D
asthma	D	D
and	D	O
exercise-induced	D	O
bronchoconstriction	D	O

Atypical	O	O
antipsychotic	T	O
agents	T	O
in	O	O
the	O	O
treatment	O	O
of	O	O
Schizophrenia	D	D
and	D	O
other	D	O
psychiatric	D	O
disorders	D	D

Percutaneous	T	O
transluminal	T	O
angioplasty	T	O
in	O	O
the	O	O
treatment	O	O
of	O	O
renovascular	D	D
hypertension	D	D
:	O	O
sequential	O	O
prospective	O	O
study	O	O

Esophageal	T	O
intubation	T	O
for	O	O
palliative	O	O
treatment	O	O
in	O	O
advanced	D	O
carcinoma	D	D
of	D	O
the	D	O
esophagus	D	O
and	D	O
cardia	D	O

Pathological	O	O
staging	O	O
and	O	O
biochemical	O	O
recurrence	O	O
after	O	O
neoadjuvant	T	O
androgen	T	T
deprivation	T	T
therapy	T	T
in	O	O
combination	O	O
with	O	O
radical	T	O
prostatectomy	T	O
in	O	O
clinically	O	O
localized	O	D
prostate	D	D
cancer	D	D

How	O	O
often	O	O
does	O	O
surgery	T	T
for	O	O
peptic	D	D
ulceration	D	D
eradicate	O	D
Helicobacter	O	D
pylori	O	D
?	O	O
Systematic	O	O
review	O	O
of	O	O
36	O	O
studies	O	O

A	O	O
comparison	O	O
of	O	O
noninvasive	T	O
positive-pressure	T	O
ventilation	T	O
and	O	O
conventional	T	O
mechanical	T	O
ventilation	T	D
in	O	O
patients	O	O
with	O	O
acute	D	D
respiratory	D	D
failure	D	D

Long-term	O	O
safety	O	O
and	O	O
effectiveness	O	O
of	O	O
iron-chelation	T	T
therapy	T	T
with	T	O
deferiprone	T	O
for	O	O
thalassemia	D	O
major	D	O

Positron	O	O
emission	O	O
tomography	O	O
in	O	O
assessing	O	O
response	O	O
to	O	O
neoadjuvant	T	O
chemotherapy	T	T
for	O	O
non-small-cell	D	D
lung	D	D
cancer	D	D

Reconstruction	O	O
of	O	O
thoracic	O	D
wall	O	D
defects	O	D
after	O	O
tumor	D	D
resection	T	O
using	O	O
a	O	O
polytetrafluoroethylene	O	O
soft	O	O
tissue	O	O
(	O	O
Gore-Tex	O	O
)	O	O
patch	O	O

A	O	O
comparison	O	O
of	O	O
rectal	T	T
diazepam	T	T
gel	T	T
and	O	O
placebo	O	O
for	O	O
acute	D	D
repetitive	D	D
seizures	D	D

Effect	O	O
of	O	O
long-term	O	O
salmeterol	T	O
treatment	T	T
on	O	O
exercise-induced	D	D
asthma	D	D

Randomized	O	O
trial	O	O
of	O	O
intensive	T	O
cyclophosphamide	T	O
,	T	O
epirubicin	T	O
,	T	O
and	T	O
fluorouracil	T	O
chemotherapy	T	T
compared	O	O
with	O	O
cyclophosphamide	T	O
,	T	O
methotrexate	T	O
,	T	O
and	T	O
fluorouracil	T	O
in	O	O
premenopausal	O	O
women	O	O
with	O	O
node-positive	D	D
breast	D	D
cancer	D	D

Acute	O	D
effect	O	O
of	O	O
lorazepam	T	D
on	O	O
respiratory	O	D
muscles	O	D
in	O	O
patients	O	O
with	O	D
chronic	D	D
obstructive	D	D
pulmonary	D	D
disease	D	D

Low-molecular-weight	T	O
heparins	T	O
in	O	O
the	O	O
treatment	O	O
of	O	O
venous	D	D
thromboembolism	D	D

5-year	O	O
outcome	O	O
of	O	O
surgical	T	T
resection	T	O
and	O	O
watchful	O	O
waiting	O	O
for	O	O
men	O	O
with	O	O
moderately	O	O
symptomatic	O	D
benign	D	D
prostatic	D	D
hyperplasia	D	D
:	O	O
a	O	O
Department	O	O
of	O	O
Veterans	O	O
Affairs	O	O
cooperative	O	O
study	O	O

For	O	O
how	O	O
long	O	O
should	O	O
antipsychotic	T	O
medication	T	O
be	O	O
continued	O	O
after	O	O
the	O	O
first	O	O
psychotic	D	O
episode	D	O
in	D	O
schizophrenics	D	O
?	O	O

IDA-FLAG	T	O
(	T	O
idarubicin	T	O
,	T	O
fludarabine	T	O
,	T	O
cytarabine	T	O
,	T	O
G-CSF	T	T
)	T	O
,	O	O
an	O	O
effective	O	O
remission-induction	T	T
therapy	T	T
for	O	O
poor-prognosis	D	O
AML	D	O
of	D	O
childhood	D	O
prior	O	O
to	O	O
allogeneic	O	O
or	O	O
autologous	O	O
bone	O	D
marrow	O	D
transplantation	O	O
:	O	O
experiences	O	O
of	O	O
a	O	O
phase	O	O
II	O	O
trial	O	O

<	O	O
TO_SEE	O	O
>	O	O
Effects	O	O
of	O	O
anal	T	T
invasive	T	T
treatment	T	T
and	O	O
incontinence	D	D
on	O	O
mental	O	O
health	O	O
and	O	O
psychosocial	O	O
functioning	O	O
of	O	O
adolescents	O	O
with	O	O
Hirshsprung	D	D
's	D	D
disease	D	D
and	O	O
low	O	O
anorectal	D	O
anomalies	D	O

Single	O	O
or	O	O
double	O	O
lung	T	D
transplantation	T	D
for	O	D
pulmonary	D	D
hypertension	D	D

Interferon	T	T
beta	T	T
treatment	T	T
for	O	O
multiple	D	D
sclerosis	D	D

Ten-year	O	D
disease	O	D
free	O	O
survival	O	O
after	O	O
transperineal	T	O
sonography-guided	T	O
iodine-125	T	O
brachytherapy	T	O
with	O	O
or	O	O
without	O	O
45-Gray	T	O
external	T	O
beam	T	O
irradiation	T	T
in	O	O
the	O	O
treatment	O	O
of	O	O
patients	O	O
with	O	O
clinically	O	O
localized	O	O
,	O	O
low	O	O
to	O	O
high	O	O
Gleason	D	O
grade	D	D
prostate	D	D
carcinoma	D	D

Partial	O	O
or	O	O
near	O	O
total	O	O
pancreatectomy	T	O
for	O	O
persistent	D	D
neonatal	D	D
hyperinsulinaemic	D	D
hypoglycaemia	D	D
:	O	O
the	O	O
pathologist	O	O
's	O	O
role	O	O

Radical	T	O
prostatectomy	T	O
for	O	O
prostate	D	D
cancer	D	D
:	O	O
the	O	O
perineal	O	O
approach	O	O
increases	O	O
the	O	O
risk	O	O
of	O	O
surgically	O	O
induced	O	O
positive	O	O
margins	O	O
and	O	O
capsular	O	O
incisions	O	O

Open	T	O
capsulorrhaphy	T	O
with	T	O
suture	T	O
anchors	T	O
for	O	O
recurrent	D	D
anterior	D	D
dislocation	D	O
of	D	O
the	D	O
shoulder	D	O

Intravenous	T	O
immunoglobulin	T	T
treatment	T	T
in	O	O
multiple	D	D
sclerosis	D	D

Randomised	O	O
trial	O	O
of	O	O
irinotecan	T	O
versus	O	O
fluorouracil	T	O
by	O	O
continuous	O	O
infusion	O	T
after	O	O
fluorouracil	O	O
failure	O	D
in	O	O
patients	O	O
with	O	O
metastatic	D	D
colorectal	D	D
cancer	D	D

The	O	O
effectiveness	O	O
of	O	O
intraocular	T	D
pressure	T	O
reduction	T	O
in	O	O
the	O	O
treatment	O	O
of	O	O
normal-tension	D	O
glaucoma	D	O

Perceived	O	O
contraindications	O	O
to	O	O
thrombolytic	T	T
treatment	T	T
in	O	O
acute	D	D
myocardial	D	D
infarction	D	D

Lignocaine	T	O
or	O	O
bupivacaine	T	O
for	O	O
digital	D	O
ring	D	O
block	D	O

Steroids	T	O
in	O	O
lateral	D	O
epicondylitis	D	O

Steroids	T	O
in	O	O
De	D	O
Quervain	D	O
's	D	O
tenosynovitis	D	O

Antibiotics	T	T
after	O	O
dog	D	O
bite	D	O

Immobilisation	T	O
after	O	O
first	O	O
anterior	O	O
shoulder	D	O
dislocation	D	O

Stereotactic	T	O
radiosurgery	T	O
for	O	O
acoustic	D	O
neuroma	D	O
:	O	O
a	O	O
Canadian	O	O
perspective	O	O

Anticytokine	T	T
therapy	T	T
--	O	O
a	O	O
new	O	O
era	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
rheumatoid	D	D
arthritis	D	D
?	O	O

Control	O	O
of	O	O
the	O	O
malignant	D	D
hyperpyrexic	D	D
syndrome	D	D
in	O	O
MHS	O	O
swine	O	O
by	O	O
dantrolene	T	O
sodium	T	O

Hematopoietic	T	O
stem-cell	T	T
transplantation	T	T
for	O	O
the	O	O
treatment	O	O
of	O	O
severe	D	D
combined	D	D
immunodeficiency	D	D

Low-dose	T	T
clozapine	T	O
for	O	O
the	O	O
treatment	O	O
of	O	O
drug-induced	D	D
psychosis	D	D
in	D	D
Parkinson	D	D
's	D	D
disease	D	D

Comparing	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
fluoxetine	T	O
and	O	O
venlafaxine	T	O
in	O	O
outpatient	D	O
depression	D	D

Cost-effectiveness	O	O
of	O	O
interferon	T	T
treatment	T	T
for	O	O
hepatitis	D	D
C	D	O

Hyperbaric	T	O
oxygen	T	T
therapy	T	T
for	O	O
children	O	O
with	O	O
cerebral	D	D
palsy	D	D

Peripheral	T	O
retinal	T	O
cryotherapy	T	O
for	O	O
postvitrectomy	D	D
diabetic	D	D
vitreous	D	D
hemorrhage	D	D
in	O	O
phakic	O	O
patients	O	O

Hyperbaric	T	O
or	T	O
normobaric	T	O
oxygen	T	O
for	O	O
acute	D	D
carbon	D	O
monoxide	D	O
poisoning	D	O
:	O	O
a	O	O
randomised	O	O
controlled	O	O
clinical	O	O
trial	O	O

Multicentre	O	O
clinical	O	O
evaluation	O	O
of	O	O
vigabatrin	T	O
(	T	O
Sabril	T	O
)	T	O
in	O	O
mild	D	O
to	D	O
moderate	D	O
partial	D	O
epilepsies	D	O

Matrix	T	O
metalloproteinase	T	O
inhibitors	T	T
in	O	O
the	O	O
treatment	O	O
of	O	O
cancer	D	D

High	O	O
dose	O	O
cyclophosphamide	T	O
with	O	O
carboplatin	T	O
:	O	O
a	O	O
tolerable	O	O
regimen	O	O
suitable	O	O
for	O	O
dose	O	O
intensification	O	O
in	O	O
children	O	O
with	O	O
solid	D	D
tumors	D	D

Microsurgical	T	O
treatment	T	O
of	O	O
supratentorial	D	D
cavernous	D	D
malformations	D	D

Microsurgical	T	O
treatment	T	O
of	O	O
infratentorial	D	D
malformations	D	D

Stereotactic	T	O
radiosurgery	T	O
for	O	O
management	O	O
of	O	O
deep	D	D
brain	D	D
cavernous	D	D
malformations	D	D

Interferon-antibodies	T	O
and	O	O
the	O	O
breakthrough	O	O
phenomenon	O	O
during	O	O
ribavirin/interferon-alpha	T	O
combination	T	T
therapy	T	T
and	O	O
interferon-alpha	T	T
monotherapy	T	T
of	O	O
patients	O	O
with	O	O
chronic	D	D
hepatitis	D	D
C	D	D

Treatment	O	O
of	O	O
Barrett	D	O
esophagus	D	O
with	O	O
argon	T	O
plasma	T	O
coagulation	T	O
with	T	O
acid	T	O
suppression	T	O
--	O	O
a	O	O
prospective	O	O
study	O	O

Meta-analysis	O	O
of	O	O
typhoid	D	O
vaccine	T	O
efficacy	O	O
trials	O	O
showed	O	O
that	O	O
whole	O	O
cell	O	O
vaccines	O	O
are	O	O
more	O	O
effective	O	O
than	O	O
either	O	O
the	O	O
oral	O	O
,	O	O
attenuated	O	O
vaccine	O	O
or	O	O
the	O	O
Vi	O	O
polysaccharide	O	O
vaccine	O	O

Experimental	O	O
vaccination	T	O
against	O	O
Mycoplasma	D	O
agalactiae	D	O
using	O	O
different	O	O
inactivated	O	O
vaccines	O	O

A	O	O
randomized	O	O
,	O	O
controlled	O	O
study	O	O
in	O	O
adults	O	O
of	O	O
the	O	O
immunogenicity	O	O
of	O	O
a	O	O
novel	O	O
hepatitis	D	D
B	D	O
vaccine	T	O
containing	O	O
MF59	O	O
adjuvant	O	O

Immunogenicity	O	O
of	O	O
three	O	O
Haemophilus	D	O
influenzae	D	O
type	D	O
b	D	O
protein	O	O
conjugate	O	O
vaccines	T	O
in	O	O
HIV	O	O
seropositive	O	O
adults	O	O
and	O	O
analysis	O	O
of	O	O
predictors	O	O
of	O	O
vaccine	O	O
response	O	O

Vaccination	T	O
against	O	O
Schistosoma	D	D
mansoni	D	D
infection	D	D
using	O	O
74	O	O
kDa	O	O
Schistosoma	O	O
protein	O	O
antigen	O	O

Phase	O	O
1	O	O
safety	O	O
and	O	O
immune	O	O
response	O	O
studies	O	O
of	O	O
a	O	O
DNA	T	O
vaccine	T	O
encoding	O	O
hepatitis	D	D
B	D	O
surface	O	O
antigen	O	O
delivered	O	O
by	O	O
a	O	O
gene	O	O
delivery	O	O
device	O	O

Protection	O	O
of	O	O
swine	O	O
from	O	O
foot-and-mouth	D	D
disease	D	D
with	O	O
one	O	O
dose	O	O
of	O	O
an	O	O
all-D	T	O
retro	T	O
peptide	T	O

Intranasal	T	O
immunization	T	O
with	O	O
Chlamydia	D	D
trachomatis	D	D
,	D	O
serovar	D	O
E	D	O
,	O	O
protects	O	O
from	O	O
a	O	O
subsequent	O	O
vaginal	O	O
challenge	O	O
with	O	O
the	O	O
homologous	O	O
serovar	O	O

Mutants	O	O
of	O	O
cholera	O	O
toxin	O	O
as	O	O
an	O	O
effective	O	O
and	O	O
safe	O	O
adjuvant	O	O
for	O	O
nasal	D	D
influenza	D	D
vaccine	T	D

Field	O	O
evaluation	O	O
of	O	O
the	O	O
clinical	O	O
effectiveness	O	O
of	O	O
vaccines	T	O
against	O	O
pertussis	D	O
,	D	O
measles	D	O
,	D	O
rubella	D	O
and	D	O
mumps	D	O
:	O	O
comments	O	O

Transmural	T	O
drainage	T	O
of	O	O
pancreatic	D	D
fluid	D	O
collections	D	O
without	O	O
electrocautery	O	O
using	O	O
the	O	O
Seldinger	O	O
technique	O	O

Echocardiography-guided	T	O
ethanol	T	O
septal	T	O
reduction	T	O
for	O	O
hypertrophic	D	D
obstructive	D	D
cardiomyopathy	D	D

Alterations	O	O
of	O	O
monocyte	O	O
function	O	O
in	O	O
patients	O	O
with	O	O
growth	D	O
hormone	D	T
(	D	O
GH	D	O
)	D	O
deficiency	D	O
:	O	O
effect	O	O
of	O	O
substitutive	O	O
GH	T	T
therapy	T	T

Comparison	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
salmeterol	T	O
and	O	O
ipratropium	T	O
bromide	T	O
on	O	O
exercise	O	O
performance	O	O
and	O	O
breathlessness	O	O
in	O	O
patients	O	O
with	O	O
stable	D	D
chronic	D	D
obstructive	D	D
pulmonary	D	D
disease	D	D
.	O	O

<	O	O
TO_SEE	O	O
>	O	O
Safety	O	O
trial	O	O
with	O	O
the	O	O
5HT1B/1D	T	O
agonist	T	O
avitriptan	T	O
(	O	O
BMS-180048	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
migraine	D	O
who	O	O
have	O	O
experienced	O	O
pressure	D	O
,	D	O
tightness	D	O
,	D	O
and/or	D	O
pain	D	D
in	O	O
the	O	O
chest	O	O
,	O	O
neck	O	O
,	O	O
and/or	O	O
throat	O	D
following	O	O
sumatriptan	T	T

Double	O	O
blind	O	O
,	O	O
cluster	O	O
randomised	O	O
trial	O	O
of	O	O
low	O	O
dose	O	O
supplementation	O	O
with	O	O
vitamin	T	O
A	T	O
or	O	O
beta	T	O
carotene	T	O
on	O	O
mortality	D	O
related	D	O
to	D	O
pregnancy	D	O
in	O	O
Nepal	O	O
.	O	O

Medical	T	O
treatments	T	O
for	O	O
balding	D	O
in	O	O
men	O	O

Carbon	D	O
monoxide	D	O
poisoning	D	O
treated	O	O
with	O	O
hyperbaric	T	O
oxygen	T	O
:	O	O
metabolic	O	O
acidosis	O	O
as	O	O
a	O	O
predictor	O	O
of	O	O
treatment	O	O
requirements	O	O

Medication	T	O
received	O	O
by	O	O
patients	O	O
with	O	O
depression	D	D
following	O	O
the	O	O
acute	O	D
episode	O	O
:	O	O
adequacy	O	O
and	O	O
relation	O	O
to	O	O
outcome	O	O

<	O	O
TO_SEE	O	O
>	O	O
Reduced	D	O
bone	D	O
density	D	O
at	O	O
completion	O	O
of	O	O
chemotherapy	T	T
for	O	O
a	O	O
malignancy	D	O

<	O	O
TO_SEE	O	O
>	O	O
Surgical-site	D	D
complications	D	D
associated	O	O
with	O	O
a	O	O
morphine	T	O
nerve	T	T
paste	T	T
used	O	O
for	O	O
postoperative	D	D
pain	D	D
control	D	O
after	D	O
laminectomy	D	O

Splenectomy	T	O
during	O	O
pregnancy	O	O
:	O	O
an	O	O
option	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
autoimmune	D	D
thrombocytopenic	D	D
purpura	D	D

Melatonin	T	O
treatment	T	O
of	O	O
sleep-wake	D	D
cycle	D	O
disorders	D	D
in	O	O
children	O	O
and	O	O
adolescents	O	O

Randomized	O	O
phase	O	O
II	O	O
study	O	O
of	O	O
the	O	O
neurokinin	T	O
1	T	O
receptor	T	O
antagonist	T	O
CJ-11	T	O
,	T	O
974	T	O
in	O	O
the	O	O
control	O	O
of	O	O
cisplatin-induced	D	O
emesis	D	O

Cataract	D	T
surgery	T	T
and	O	O
its	O	O
effect	O	O
on	O	O
intraocular	O	O
pressure	O	O

The	O	O
outcome	O	O
of	O	O
arthroscopic	T	O
treatment	T	O
of	O	O
temporomandibular	D	O
joint	D	O
arthropathy	D	O

Neostigmine	T	O
for	O	O
acute	D	D
colonic	D	D
pseudo-obstruction	D	D

New	O	O
vaccine	T	O
targets	O	O
childhood	D	O
pneumonia	D	O

A	O	O
comparison	O	O
of	O	O
botulinum	T	O
toxin	T	O
and	O	O
nitroglycerin	T	O
ointment	T	O
for	O	O
chronic	D	D
anal	D	D
fissure	D	D

<	O	O
TO_SEE	O	O
>	O	O
The	O	O
effect	O	O
of	O	O
bisoprolol	T	O
on	O	O
perioperative	D	O
mortality	D	O
and	O	O
myocardial	D	D
infarction	D	D
in	O	O
high-risk	O	O
patients	O	O
undergoing	O	T
vascular	T	T
surgery	T	T

Surgical	T	O
management	T	O
of	O	O
severe	D	D
secondary	D	D
peritonitis	D	D

Early	T	O
surgical	T	T
treatment	T	T
for	O	O
supratentorial	D	D
intracerebral	D	D
hemorrhage	D	D
:	O	O
a	O	O
randomized	O	O
feasibility	O	O
study	O	O

Evaluation	O	O
of	O	O
clomipramine	T	O
as	O	O
an	O	O
adjunct	O	O
to	O	O
behavioural	T	O
therapy	T	T
in	O	O
the	O	O
treatment	O	O
of	O	O
separation-related	D	O
problems	D	O
in	O	O
dogs	O	O

NICE	O	O
to	O	O
rule	O	O
on	O	O
influenza	D	O
flu	D	O
drug	O	O
zanamivir	T	O

<	O	O
TO_SEE	O	O
>	O	O
Longitudinal	D	O
melanonychia	D	O
associated	O	O
with	O	O
hydroxyurea	T	T
therapy	T	T
in	O	O
a	O	O
patient	O	O
with	O	O
essential	D	O
thrombocytosis	D	O

Biologic	O	O
markers	O	O
as	O	O
predictors	O	O
of	O	O
clinical	O	O
outcome	O	O
from	O	O
systemic	T	O
therapy	T	T
for	O	O
primary	O	D
operable	O	D
breast	D	D
cancer	D	D

Treatment	O	O
of	O	O
hypertension	D	D
with	O	O
ascorbic	T	O
acid	T	O

Postoperative	D	D
peritonitis	D	O
originating	O	O
from	O	O
the	O	O
duodenum	O	O
:	O	O
operative	O	O
management	O	O
by	O	O
intubation	T	O
and	T	O
continuous	T	O
intraluminal	T	O
irrigation	T	O

Efficacy	O	O
of	O	O
open-bite	D	O
treatment	O	O
with	O	O
the	O	O
Thera-spoon	T	O

<	O	O
TO_SEE	O	O
>	O	O
Pompholyx	D	O
(	D	O
vesicular	D	O
eczema	D	O
)	D	O
after	O	O
i.v	T	O
.	T	O
immunoglobulin	T	T
therapy	T	T
for	O	O
neurologic	D	D
disease	D	D

Mitomycin	T	O
,	T	O
ifosfamide	T	O
,	T	O
and	T	O
cisplatin	T	O
in	O	O
unresectable	D	D
non-small-cell	D	D
lung	D	D
cancer	D	D
:	O	O
effects	O	O
on	O	O
survival	O	O
and	O	O
quality	O	O
of	O	O
life	O	O
.	O	O

Hepatic	O	D
arterial	O	D
infusion	O	T
of	O	O
chemotherapy	T	T
after	O	O
resection	T	O
of	O	O
hepatic	D	D
metastases	D	D
from	O	O
colorectal	D	D
cancer	D	D

Waiting	O	O
for	O	O
the	O	O
definitive	O	O
trial	O	O
of	O	O
hepatic	T	D
arterial	T	D
chemotherapy	T	T
for	O	O
colorectal	D	D
cancer	D	D

Phase	O	O
III	O	O
randomized	O	O
study	O	O
of	O	O
cisplatin	T	O
versus	O	O
paclitaxel	T	O
versus	O	O
cisplatin	T	O
and	T	O
paclitaxel	T	O
in	O	O
patients	O	O
with	O	O
suboptimal	O	O
stage	O	O
III	O	O
or	O	O
IV	O	D
ovarian	D	D
cancer	D	D
:	O	O
a	O	O
gynecologic	O	O
oncology	O	O
group	O	O
study	O	O

Evidence	O	O
for	O	O
double	O	O
resistance	O	O
to	O	O
permethrin	T	O
and	T	O
malathion	T	O
in	O	O
head	D	O
lice	D	O

Urgent	O	O
colonoscopy	T	O
for	O	O
the	O	O
diagnosis	O	O
and	O	O
treatment	O	O
of	O	O
severe	D	D
diverticular	D	D
hemorrhage	D	D

Treatment	O	O
of	O	O
Parkinson	D	D
's	D	D
disease	D	D
should	O	O
begin	O	O
with	O	O
a	O	O
dopamine	T	O
agonist	T	O

<	O	O
TO_SEE	O	O
>	O	O
Ulceration	D	O
in	O	O
an	O	O
ileocolic	D	O
anastomosis	D	O
treated	O	O
with	O	O
ranitidin	T	O

Low-molecular-weight	T	O
heparin	T	T
vs	O	O
heparin	T	T
in	O	O
the	O	O
treatment	O	O
of	O	O
patients	O	O
with	O	D
pulmonary	D	D
embolism	D	D

Radiotherapy	T	T
in	O	O
breast-conserving	T	O
treatment	T	T
for	O	O
ductal	D	D
carcinoma	D	D
in	O	O
situ	O	O
:	O	O
first	O	O
results	O	O
of	O	O
the	O	O
EORTC	O	O
randomised	O	O
phase	O	O
III	O	O
trial	O	O
10853	O	O

Methadone	T	O
maintenance	T	O
vs	O	O
180-day	O	O
psychosocially	O	O
enriched	O	T
detoxification	T	T
for	O	O
treatment	O	O
of	O	O
opioid	D	O
dependence	D	O
:	O	O
a	O	O
randomized	O	O
controlled	O	O
trial	O	O

Cryogen	O	O
spray	O	O
cooling	O	O
during	O	O
Nd	T	O
:	T	O
YAG	T	T
laser	T	T
treatment	T	T
of	O	O
hemangiomas	D	O

Effects	O	O
of	O	O
tolcapone	T	O
,	T	O
a	T	O
catechol-O-methyltransferase	T	O
inhibitor	T	O
,	O	O
on	O	O
motor	O	O
symptoms	O	D
and	O	O
pharmacokinetics	O	O
of	O	O
levodopa	T	O
in	O	O
patients	O	O
with	O	O
Parkinson	D	D
's	D	D
disease	D	D
.	O	O

Gene	T	O
therapy	T	T
for	O	O
cancer	D	D

Therapeutic	O	O
effects	O	O
of	O	O
LDL	T	O
apheresis	T	O
in	O	O
the	O	O
prevention	O	O
of	O	O
atherosclerosis	D	O

Dry	T	O
powdered	T	O
formoterol	T	O
,	O	O
twice	O	O
a	O	O
day	O	O
versus	O	O
aerosolized	T	O
salbutamol	T	O
,	O	O
four	O	O
times	O	O
a	O	O
day	O	O
,	O	O
in	O	O
patients	O	O
with	O	O
stable	D	O
asthma	D	D

Cell-based	T	O
vaccination	T	O
against	O	O
melanoma	D	O
--	O	O
background	O	O
,	O	O
preliminary	O	O
results	O	O
,	O	O
and	O	O
perspective	O	O

Celecoxib	T	O
for	O	O
arthritis	D	D

Poliomyelitis	D	O
prevention	O	O
:	O	O
revised	O	O
recommendations	O	O
for	O	O
use	O	O
of	O	O
inactivated	O	O
and	O	O
live	O	O
oral	O	O
poliovirus	D	O
vaccines	T	O

Mesh	O	O
plug	O	O
repair	O	O
and	O	O
groin	D	O
hernia	D	T
surgery	T	T

Brimonidine	T	O
tartrate	T	O
0.2	O	O
%	O	O
twice	O	O
daily	O	O
vs	O	O
timolol	T	O
0.5	O	O
%	O	O
twice	O	O
daily	O	O
:	O	O
1-year	O	O
results	O	O
in	O	O
glaucoma	D	O
patients	O	O

Ticarcillin/clavulanate	T	O
versus	O	O
imipenem/cilistatin	T	O
for	O	O
the	O	O
treatment	O	O
of	O	O
infections	D	D
associated	D	O
with	D	O
gangrenous	D	O
and	D	O
perforated	D	O
appendicitis	D	O

Is	O	O
zero	O	O
dose	O	O
oral	O	T
polio	D	O
vaccine	T	O
effective	O	O
in	O	O
preterm	O	O
babies	O	O
?	O	O

An	O	O
economic	O	O
analysis	O	O
of	O	O
different	O	O
strategies	O	O
of	O	O
immunization	T	D
against	O	O
hepatitis	D	D
A	D	O
virus	D	O
in	O	O
developed	O	O
countries	O	O

Issues	O	O
and	O	O
challenges	O	O
with	O	O
antithrombotic	T	T
therapy	T	T
in	O	O
diabetic	O	D
patients	O	O
with	O	O
acute	D	D
coronary	D	D
syndromes	D	D

Global	O	O
risk	O	O
assessment	O	O
for	O	O
lipid	T	T
therapy	T	T
to	O	O
prevent	O	D
coronary	D	D
heart	D	D
disease	D	D

The	O	O
role	O	O
of	O	O
fibric	T	O
acid	T	O
derivatives	T	O
in	O	O
the	O	O
secondary	O	O
prevention	O	O
of	O	O
coronary	D	D
heart	D	D
disease	D	D

Epoetin	T	O
:	O	O
a	O	O
pharmacoeconomic	O	O
review	O	O
of	O	O
its	O	O
use	O	O
in	O	O
chronic	D	D
renal	D	D
failure	D	D
and	O	O
its	O	O
effects	O	O
on	O	O
quality	O	O
of	O	O
life	O	O

Rationale	O	O
for	O	O
the	O	O
use	O	O
of	O	O
antiplatelet	T	O
drugs	T	T
in	O	O
patients	O	O
with	O	O
peripheral	D	D
vascular	D	D
disease	D	D

The	O	O
fluoroquinolones	T	O
for	O	O
urinary	D	D
tract	D	D
infections	D	D
:	O	O
a	O	O
review	O	O

Reduction	O	O
of	O	O
vasoreactivity	D	O
and	O	O
thrombogenicity	D	O
with	O	O
laser-thermal	T	O
angioplasty	T	O
:	O	O
comparison	O	O
with	O	O
balloon	T	O
angioplasty	T	O

Effects	O	O
of	O	O
ultrasound	T	O
energy	T	O
on	O	O
total	D	O
peripheral	D	O
artery	D	D
occlusions	D	O
:	O	O
initial	O	O
angiographic	O	O
and	O	O
angioscopic	O	O
results	O	O
.	O	O

High-dose	T	T
chemotherapy	T	T
with	T	O
autologous	T	O
stem-cell	T	O
support	T	O
for	O	O
epithelial	D	D
ovarian	D	D
cancer	D	D

Pelvic	T	O
floor	T	O
stimulation	T	O
in	O	O
the	O	O
treatment	O	O
of	O	O
adult	D	D
urinary	D	D
incontinence	D	D

Chronic	T	D
vagus	T	D
nerve	T	T
stimulation	T	T
for	O	O
treatment	O	O
of	O	O
seizures	D	D

``	T	O
Tandem	T	O
''	T	O
high-dose	T	O
chemoradiotherapy	T	O
with	T	O
autologous	T	O
stem-cell	T	O
support	T	O
in	O	O
the	O	O
treatment	O	O
of	O	O
newly	O	O
diagnosed	O	D
or	O	O
responsive	O	O
multiple	D	O
myeloma	D	O

Special	O	O
report	O	O
:	O	O
comparative	O	O
efficacy	O	O
of	O	O
different	O	O
types	O	O
of	O	O
pneumatic	T	O
compression	T	O
pumps	T	O
for	O	O
the	O	O
treatment	O	O
of	O	O
lymphedema	D	O

Special	O	O
report	O	O
:	O	O
pressure-reducing	T	O
support	T	O
surfaces	T	O
in	O	O
the	O	O
prevention	O	O
and	O	O
treatment	O	O
of	O	O
pressure	D	O
ulcers	D	O
:	O	O
group	O	O
1	O	O
technologies	O	O

Intravenous	T	D
immune	T	D
globulin	T	O
for	O	O
recurrent	D	D
spontaneous	D	D
abortion	D	D

External	T	O
counterpulsation	T	O
for	O	O
treatment	O	O
of	O	O
chronic	D	D
stable	D	D
angina	D	D
pectoris	D	D

Intra-articular	T	O
hyaluronan	T	O
injections	T	O
for	O	O
treatment	O	O
of	O	O
osteoarthritis	D	O
of	O	O
the	O	O
knee	O	O

Pneumococcal	D	O
vaccine	T	O
:	O	O
a	O	O
second	O	O
look	O	O

